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1 Introduction 
1.1 Pancreatic cancer 
1.1.1 Epidemiology 
Pancreatic cancer, although in total numbers an infrequent tumor entity, repre-
sents the tumor disease with the worst prognosis of patient survival. In Germany, 
pancreatic cancer mainly occurs in the elderly population with a median age of 
diagnosis of 71 among men and 75 among women (1). In 2012, according to the 
German cancer statistic approx. 16700 newly diagnosed cases of pancreatic can-
cer were reported (1), making it the tenth most common tumor entity among men 
and the sixth most common among women in terms of incidence (Figure 1). Glob-
ally, incidence rates of pancreatic cancer are both higher among men and in de-
veloped countries (2). 
 
 
 
 
 
 
Figure 1 Most frequent tumor sites as a percentage of all new cases in Germany 2012 (not including non-
melanoma skin cancer). Taken and modified from the German cancer statistic 2011/2012 (1). 
 
Despite intensive research on more effective treatment modalities the therapy 
outcome of pancreatic cancer remains very poor. In Germany, 5 years after initial 
diagnosis only 7 % of the patients remain alive, representing the lowest rate of 
patient survival among all types of cancer. In total numbers, in 2012 approx. 
16100 deaths were caused by this fatal tumor disease accounting for 6.6 % and 
8.1 % of cancer-related death among men and women respectively (1). Thus, 
pancreatic cancer is the fourth leading cause of cancer-related mortality both in 
Germany (Figure 2) and the US (3). Globally seen it is estimated to be the sev-
enth leading cancer-related cause of death in both men and women (2). 
[%] [%] 
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Figure 2 Most frequent tumor sites when cancer was the cause of death in Germany 2012. Taken and 
modified from the German cancer statistic 2011/2012 (1). 
 
Generally speaking the term ‘pancreatic cancer’ refers to exocrine tumors of the 
pancreas, mainly represented by the pancreatic ductal adenocarcinoma (PDA).  
1.1.2 Therapeutic guidelines 
As in the treatment of other tumor entities, therapy of pancreatic cancer depends 
on the localization and dimension of the primary tumor (T) as well as on potential 
metastatic lesions in lymph nodes (N) or secondary organs (M), the so-called 
TNM stadium. The currently valid S3-guideline for the treatment of pancreatic 
ductal adenocarcinoma (4) has just been updated in 2013 to align clinical practice 
to recent findings (5). 
To date, surgical resection still represents the only potentially curative treatment 
method for pancreatic cancer. Thereby, it is broadly agreed that a resection mar-
gin within healthy tissue without any tumorous cells (R0 resection) is associated 
with a better treatment outcome and prognosis of the patients, compared to sur-
gery in which not all tumor tissue could be resected and the resection margin 
includes tumorous cells (R1 resection) (6). However, real survival benefit even 
after R0 resection was shown to be associated with a histopathologically meas-
ured distance of tumor cells from the resection margin greater than 1 mm (median 
survival ranging from 35 to 16 to 14 months after R0-wide, R0 or R1 resection, 
respectively) (7). Accordingly, surgical treatment is only indicated for patients with 
[%] [%] 
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a high chance for R0 resection and an acceptable risk profile of perioperative 
morbidity and mortality. Possibility of surgical removal is therefore decided on a 
case by case basis and depends on the respective tumor localization, distant 
metastases and the involvement of local vasculature (Figure 3) (8). In case of a 
non-metastatic but unresectable tumor, individually depending on the tumor lo-
calization and health status of the patient, a neoadjuvant (radio-)chemotherapy 
can be performed in the hope of reaching resectability and therefore a better 
prognosis. By all means surgery should be followed by an adjuvant chemother-
apy with 5-fluorouracil (5-FU) or gemcitabine in monotherapy for 6 months (4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Anatomy and surgical resectability of pancreatic cancer. Pancreatic cancers are categorized 
on a continuum from resectable to unresectable according to the involvement of adjacent structures 
and the presence of distant metastases. Taken from Ryan et al. (8). 
 
In case of unresectable or metastatic pancreatic cancer only palliative treatment 
modalities remain, aiming at improving the health-related quality of life as well as 
potentially prolonging the survival of the individual patient. Currently, for this indi-
cation different first-line chemotherapy protocols are available. Due to its favora-
ble toxicity profile and feasibility the preferred and today most commonly per-
formed chemotherapy is a monotherapeutic treatment with gemcitabine. How-
ever, clinical data have proven that under certain conditions combinations with 
other chemotherapeutic agents result in a superior treatment outcome and higher 
patient survival (Table 1) (9). Results of a phase III trial combining gemcitabine 
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with the epithelial growth factor receptor (EGFR) targeting tyrosine kinase inhibi-
tor erlotinib have demonstrated a significant increase of overall survival com-
pared to gemcitabine monotherapy (10). However, therapeutic benefit of this reg-
imen was linked to the appearance of a skin rash, a typical side-effect of anti-
EGFR treatment, within 8 weeks after initiation of treatment (Table 1). Another 
combination, the so-called FOLFIRINOX regimen (a combination of folinic acid 
(leucovorin), 5-FU, irinotecan and oxaliplatin) represents a highly tumoricidal but 
likewise (hemato-)toxic chemotherapy protocol for advanced pancreatic cancer. 
Therefore, although significantly prolonging overall survival compared to gem-
citabine monotherapy (11), it should only be applied in a subgroup of patients 
below the age of 75 with a good performance status.  
Besides these protocols and the dual chemotherapy nab-paclitaxel + gemcitabine, 
so far, no further combinations of chemotherapeutic agents or targeted therapies 
are approved or recommended as first-line treatment for advanced pancreatic 
cancer. In case of disease progression under first-line monotherapy with gem-
citabine, the combination 5-FU + oxaliplatin should be given as second-line treat-
ment. If the FOLFIRINOX regimen fails, a second-line monotherapy with gem-
citabine can be performed. 
 
 
Treatment regimen N Progression-free  
survival 
Overall  
survival 
1-year survival rate EBM grade 
Erlotinib + gemcitabine  
versus gemcitabine (10) 
569 3.75 versus 3.55 months 
(HR 0.77, p = 0.004) 
6.24 versus 5.91 months 
(HR 0.82, p = 0.038)* 
23 % versus 17 %  
(p= 0.023)* 
Ib 
FOLFIRINOX 
versus gemcitabine (11) 
342 6.4 versus 3.3 months 
(HR 0.47, p < 0.001) 
11.1 versus 6.8 months 
(HR 0.57, p < 0.001) 
48 % versus 21 %  
(p < 0.001) 
Ib 
Nab-paclitaxel + gemcitabine 
versus gemcitabine (12) 
861 5.5 versus 3.7 months 
(HR 0.69, p < 0.001) 
8.5 versus 6.7 months 
(HR 0.72, p < 0.001) 
35 % versus 22 % 
(p < 0.001) 
Ib 
 
* In the subgroup analysis of overall survival for patients with rash ≥ grade 2: Overall survival 10.5 months (HR 0.74, p = 0.037) and 1-
year overall survival 43 % (p < 0.001). EBM, evidence based medicine; HR, hazard ratio. Taken and modified from Seufferlein et al. (5). 
 
Recent data from a randomized multicenter phase III trial demonstrated the su-
perior response of patients with metastatic pancreatic cancer to the dual chemo-
therapy nab-paclitaxel + gemcitabine compared to gemcitabine monotherapy 
(12). Thereby, the outcome of the dual chemotherapy was not quite as beneficial 
as the combination of gemcitabine with erlotinib or after application of the FOLFI-
RINOX regimen, in which more potent increases of overall survival were seen in 
Table 1 Recent randomized and controlled trials on combination chemotherapy for advanced pancreatic 
cancer showing a survival advantage over gemcitabine monotherapy in the palliative setting.
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the individual patient subgroups compared to gemcitabine monotherapy (Table 
1). However, the rate of serious adverse effects in patients receiving the combi-
nation nab-paclitaxel + gemcitabine was comparable to gemcitabine monother-
apy, although reversible side effects like myelosuppression and peripheral neu-
ropathy occurred slightly more often in the combination group (12).  
These results led to clinical approval of Abraxane® (nab-paclitaxel) + gemcitabine 
by the US Food and Drug Administration (FDA) and European Medicines Agency 
(EMA) as first-line treatment protocol for metastatic pancreatic cancer in 2013 
(13). Since treatment outcome of this combination so far isn’t known to be linked 
to any patient or tumor characteristics, in this indication it might even replace 
gemcitabine monotherapy as standard of care first-line chemotherapy protocol. 
1.1.3 Rationale for the development of new treatment protocols 
Reasons for the poor outcome of pancreatic cancer mainly originate from its un-
favorable tumor biology (recently reviewed by Hidalgo (14)). Due to the central 
retroperitoneal localization of the pancreas, symptoms of the tumor disease are 
mostly unspecific and mimic diseases of other abdominal organs. In addition, they 
often manifest only in an advanced tumor stage. If not detected accidentally in 
the context of otherwise performed imaging of the abdomen, this often leads to a 
late diagnosis of the tumor disease when the primary tumor can no longer be 
surgically resected and/or has already spread to other parts of the body. Unfor-
tunately, pancreatic cancer spreads early to lymph nodes and secondary organs 
(mainly liver, lung and bone marrow), excluding surgical treatment modalities and 
leaving only options of palliative care. 
Although various palliative treatment protocols exist, their influence on the prog-
nosis of PDA in matters of long-term survival so far is strongly limited by its com-
plex and heterogeneous tumor microenvironment (Figure 4). PDA formation is 
characterized by a desmoplastic reaction in which pancreatic tissue is reor-
ganized to a dense and highly fibrotic stroma. This stromal reconstruction, asso-
ciated with an abnormal vasculature and the creation of an immunosuppressive 
microenvironment locally restraining antitumor immunity (14), seems to be in-
volved with enhanced tumor progression and early metastasis (15). Progression 
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of other tumor diseases in the majority of cases depends upon an extensive tumor 
vascularization, supplying tumor growth with therefore required nutrients. In case 
of PDA, tumor cell survival and growth are adapted to its specific hypovascular 
and hypoxic microenvironment, rendering it mostly insensitive to antiangiogenic 
agents (16). Taken together, both desmoplastic stroma and poor vascularization 
of PDA form a substantial barrier for the effective delivery of any systemically 
applied cytotoxic agent. 
 
 
 
 
 
 
 
 
 
Figure 4 Microenvironment of pancreatic 
adenocarcinoma. Taken and modified from 
Ryan et al. (8). 
 
PDA formation is known to be linked to a successive accumulation of gene mu-
tations in an early stage of tumor development (17). Similar to the adenoma-to-
carcinoma sequence in colon cancer, PDA typically derives from distinct precur-
sor lesions such as Pancreatic Intraepithelial Neoplasia (PANIN) (8). Recurring 
intrinsic genetic mutations within the premalignant lesion ultimately result in the 
formation of PDA. The rapid progression of PDA is thereby based on its highly 
instable genome, leading to a constant process of ever-evolving tumor cell sub-
populations not only in the primary but secondary tumor lesions as well. Key mu-
tations, originating from the primary tumor and present in every tumor cell inde-
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pendently of its respective localization, are paralleled by further genomic rear-
rangements creating a complex inter- and intratumoral genomic heterogeneity. 
De-novo-mutations in metastatic lesions not only render them genetically differ-
ent from the primary tumor but also adapt their cellular metabolism to the tissue-
specific microenvironment of the newly-affected organ. The individual tumor cell 
subpopulations thereby differ in their susceptibility to cytotoxic agents, leading to 
a natural selection of tumor cells with primary or secondary acquired resistance 
mechanisms in the course of antitumor treatment. Moreover, tumor cells with 
stem cell-like features for self-renewal and cell migration have been found to play 
an important role in tumor invasion and metastasis while exhibiting considerable 
primary resistance against standard chemotherapy protocols (18).  
It seems logical that any attempt of complete tumor eradication without relapse 
of the tumor disease has to address the specific but highly heterogeneous tumor 
biology of pancreatic cancer. Current regimens of cytotoxic treatment (mainly rep-
resented by single or combined chemotherapeutic agents) so far fail in this regard 
and are therefore unable to effectively stabilize the tumor disease. Considering 
the devastating prognosis and depressing survival of patients with pancreatic 
cancer, new treatment protocols incorporating novel agents with distinct modes 
of action are desperately needed. 
1.2 Oncolytic virotherapy 
1.2.1 Basic principles 
Oncolytic virotherapy represents one of the currently most promising novel treat-
ment regimens, utilizing wild-type or genetically modified viruses for targeted an-
titumor therapy (19). Oncolytic viruses (OVs), as stated in the so-called oncolytic 
virotherapy paradigm (20), specifically target and infect tumor cells followed by 
exploitation of the host cell metabolism for efficient viral replication (Figure 5) (21). 
This process ultimately leads to massive tumor cell lysis (so-called oncolysis) and 
the release of progeny virus particles able to infect yet uninfected neighboring or 
distant tumor cells. Subsequent oncolytic cycles promote cumulative tumor erad-
ication until no further tumor cells exist. Concomitantly the release of both viral 
as well as tumor antigens results in the induction of innate and adaptive immune 
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responses directed against the tumor cells even if they aren’t infected by the OV. 
For this reason oncolytic virotherapy is believed not only to result in a potent tu-
mor eradication in the short-term (within weeks or months) but also in the long-
term immunotherapeutic process of arousing antitumor immunity and creating a 
lasting antitumor memory (22). 
Figure 5 Oncolytic virotherapy - Mechanism of action. Taken and modified 
from Xu et al. (21). 
 
To assure the specific targeting of tumor cells has been (and still is) one of the 
field’s major challenges. Generally speaking tumor cells generate a local immu-
nosuppressive microenvironment to circumvent tumor-directed immune re-
sponses. One of such mechanisms is the downregulation of interferon-dependent 
pathways, normally inducing a response of the innate and adaptive immune sys-
tem. Since the interferon pathway also plays a key role in the defense of virus-
infected cells, in return, such conditions facilitate viral infection and render tumor 
cells a favorable host for the viral life cycle (23).  
Some naturally occurring viruses such as Reolysin® (Reovirus type 3 Dearing 
strain, ReoT3D) (recently reviewed by Clements et al. (24)) have an intrinsically 
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strong tropism for tumor cells. Others, such as adeno-, herpes-, measles- or vac-
cinia viruses have to be genetically modified to prevent infection and oncolysis of 
healthy tissues, the prerequisite for their safe clinical application with minimal tox-
icity. Basic strategies include the deletion of virus encoded virulence genes such 
as the E1B 55-kDa protein in the adenoviral mutants ONYX-015 (25) and H101 
(26), their translational development marking an important milestone in the more 
recent history of oncolytic virotherapy.  
In the course of adenoviral infection, the viral E1B protein prevents infected cells 
from undergoing apoptosis (a well-known mechanism of the antiviral host re-
sponse) by inhibition of p53-regulated genes normally activating pro-apoptotic 
signaling pathways. Since in many tumor cells p53 is mutated, leading to aberrant 
and dysfunctional apoptotic pathways, E1B-deleted adenoviral mutants unable to 
overcome such physiologic countermeasures are constricted to the tumor micro-
environment for their viral life cycle to take place. However, whether viral replica-
tion of ONYX-015 depends on the status of p53 exclusively remains controversial 
(27). Other strategies focus on the deletion of virus encoded enzymes such as 
herpes- or vaccinia virus encoded thymidine kinase needed to enlarge the intra-
cellular nucleotide pool for sufficient viral replication (28,29). Rapidly proliferating 
tumor cells, which also require an adequate environment for excessive DNA rep-
lication, possess their own enzymatic facilities (often overexpressed cellular hom-
ologues of the virus encoded proteins) to satisfy their need for genetic raw mate-
rial.  
Those mechanisms were among the first to be developed and are exemplary for 
the understanding of how viruses can be modified to achieve tumor selectivity. 
Over the years many more strategies have been developed such as inserting 
foreign gene expression cassettes in nonessential gene loci (30) or placing the 
expression of essential viral genes under the control of tumor-specific promoter 
regions (31). Often different strategies have been combined to generate an even 
more tumor/replication-restricted OV. Generally speaking such modified OVs are 
not intrinsically selective for tumor cells but their ability to efficiently replicate in 
healthy tissues has been severely restrained.  
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But while safety concerns regarding the replication restriction of OVs have to be 
addressed in the process of successfully bringing oncolytic virotherapy from the 
bench to the bedside, the manipulation of genes essential for the viral life cycle 
may have its downside. Since the genetic backbone of naturally occurring viruses 
is adjusted for efficient replication while simultaneously circumventing antiviral 
host responses, along with the engineering of the viral genome to accomplish 
optimal tumor selectivity comes the attenuation of viral replication not only in nor-
mal but in tumor cells as well. Thus, achieving optimal efficacy of a selected viral 
vector is a process of delicate balance between reaching adequate tumor selec-
tivity (dampening upcoming safety concerns) without attenuating viral replication 
as key element determining its oncolytic and immunotherapeutic potency (30). 
1.2.2 History and development – What has been learned? 
OVs have been part of clinical investigations for over a century now (32). Alt-
hough knowledge about virus biology was greatly limited in the beginnings of vi-
rotherapeutic research, early case reports of tumor shrinkage in the course of 
natural virus infections promoted further investigations. Over the years, this led 
to ever evolving insights not only in the proceeding of OVs but also in basic char-
acteristics of the human immune response and tumor biology itself. However, due 
to a lack of proper understanding and overambitious efforts disregarding vital 
safety concerns, at times this process was overshadowed by severe incidents, 
some of them flawing the faith in oncolytic virotherapy to this very day. Neverthe-
less, overwhelming progress has been made and groundbreaking achievements 
on genetic research in the 1990s have marked the beginning of a new era of 
virotherapeutic research, resulting for example in the construction of the very first 
recombinant OVs encoding marker and/or therapeutic transgenes. 
Case reports of tumor remission during naturally occurring virus infections (the 
first dating back to the 19th century) mostly included patients with hematological 
malignancies. One of the most recent (from 1971) refers to the complete tumor 
regression of an 8-year old boy with Burkitt’s lymphoma while showing clinical 
signs of a concomitant measles virus infection (33). In a follow-up examination 4 
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months after virus infection the boy remained tumor-free which exceeded previ-
ous reports of only short-lived tumor remissions (1-2 months). Ultimately, such 
reports led to the conclusion that some naturally occurring viruses possess intrin-
sic antitumor activity (especially in immunocompromised patients as is the case 
in patients suffering from hematological malignancies) and established the re-
search on oncolytic virotherapy. 
Though few clinical applications of naturally occurring viruses were already per-
formed in the beginnings of the 20th century, back then basic knowledge about 
virus and tumor biology was almost nonexistent and their setup was rather highly 
experimental than science-based. For first groundbreaking achievements, the 
field had to wait until the 1950s when ex vivo culturing of human cells and rodent 
cancer models had just been developed. The first proof of principle of oncolytic 
virotherapy as a novel treatment regimen was thereby contributed by Alice Moore 
in 1949 when she was able to demonstrate that treatment of mouse sarcoma 180 
with Russian Far East encephalitis virus led to complete tumor regression in 
some animals, if the viral agent had been given in sufficiently high enough doses 
(34,35).  
More than 20 years later Teruo Asada successfully used non-attenuated mumps 
virus to treat a variety of tumor entities (36). Of 90 terminal cancer patients 37 
were reported to respond drastically with complete or extensive tumor regression 
while observing only minimal toxicity. However, since established experimental 
models for high-dose virus production were still missing at that time, the used 
strains of mumps virus were obtained from several sources and unfortunately 
have been lost after the work was discontinued (20). 
In the 1970s and 1980s the field of virotherapeutic research became rather quiet 
until being reignited by the development of recombinant DNA techniques in the 
1990s, now enabling to address emerging safety concerns by focusing on the 
construction of attenuated and more tumor-selective OVs (32). The new technol-
ogy also allowed the development of standardized cell culture systems from 
which the newly-constructed OVs could be obtained in much higher doses than 
before. Since then, the safety of OVs in the human host has been successfully 
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ascertained by a multitude of clinical trials employing OVs for the treatment of 
almost every tumor entity (37).  
Among the first virus strains to be genetically ‘optimized’ were adeno- and her-
pesviruses, eventually culminating in the construction of ONYX-015 and its deri-
vative variant H101, both being E1B 55-kDa deleted adenoviruses (the im-
portance of the E1B protein during adenoviral infection has already been illus-
trated in section 1.2.1, p. 7). ONYX-015 soon reached phase III status but partly 
due to monetary reasons further clinical development of this agent was stopped 
in 2003. However, in 2005 the combination of H101 with the chemotherapeutic 
agents cisplatin and 5-fluorouracil (5-FU) received approval for the treatment of 
patients with head and neck cancer in the People’s Republic of China (38) after 
previous phase II/III trials (39,40) had demonstrated an enhanced tumor re-
sponse to the combination compared to standard chemotherapy with cisplatin 
and 5-FU alone. But as gratifying this development was for the field of oncolytic 
virotherapy, approval for this protocol in the western hemisphere still failed due 
to methodological flaws in collecting evidence for clinical benefit and enhanced 
overall survival (38).  
1.2.3 Current state of virotherapeutic research – Present challenges and 
strategies 
Over the last 30 years, due to enormous achievements in genetic recombination 
techniques the design of ever more refined OVs has been facilitated. Today, aim-
ing at maximizing their oncolytic and immunotherapeutic potential while generat-
ing tumor/replication-restricted OVs, viral genomes can be sequenced and ma-
nipulated more easily than ever before. Nonetheless, clinical trials applying OVs 
in monotherapy in the majority of cases only have been able to report single case 
success (41) and after the initial approval of H101 in combination with cisplatin 
and 5-FU in the People’s Republic of China for a long time no further virothera-
peutic has found its way into clinical routine. Only now, as the first of its kind the 
GM-CSF expressing HSV mutant talimogene laherparepvec (T-VEC, IMLYGICTM) 
(42), has been approved by the FDA and the EMA for the treatment of metastatic 
melanoma (43). It is now up to this particular agent to prove therapeutic benefit 
of oncolytic immunotherapy in clinical routine, to dampen still prevailing safety 
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concerns and to pave the way for further oncolytic agents. Much work has yet to 
be done to ultimately establish oncolytic virotherapy at the bedside and to accom-
plish the lofty goal of finding a virotherapeutic cure for the masses of different 
tumor entities. As in the development and subsequent (pre-)clinical testing phase 
of any therapeutic agent, many emerging challenges had to and yet have to be 
faced, an ongoing process not only consuming enormous resources but also re-
quiring a vast quantity of time. 
Being biologic agents with a complex mode of action, the efficacy of oncolytic 
viruses depends on a multitude of parameters (Figure 6). Key factors especially 
determining the success of oncolytic virotherapy are believed to be the successful 
virus delivery to the tumor and highly efficient inter- and intratumoral spread after 
primary infection. Both issues have been addressed by the development of many 
strategies circumventing restraining host factors such as initially unfavorable an-
tiviral innate and adaptive immune responses (the latter following vaccinations in 
the youth), virus sequestration in liver and spleen, neutralization by serum factors, 
deficient virus extravasation or a dense tumor stroma by arming OVs with cost-
imulatory molecules, shielding them by using virus-infected cell carriers or apply-
ing them in combination with other drugs, e.g. chemotherapeutic compounds or 
novel checkpoint inhibitors (20). Additionally, high-throughput screenings have 
been conducted, aiming at finding new therapeutic targets, circumvent host cell 
response mechanisms and in consequence further refine oncolytic viruses, 
boosting their oncolytic potency (44).  
Figure 6 Key factors affecting oncolytic virus therapeutic efficacy. Taken from Allan et 
al (44). 
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However, oncolysis-mediated tumor debulking has proven to be insufficient in 
creating a lasting tumor response and significant benefit for patient survival. Ac-
cordingly, in recent years the focus has been broadened to likewise promote the 
aspect of oncolytic immunotherapy effectively inducing tumor-directed innate and, 
more importantly, adaptive immune responses. Recent results from OPTiM, a 
phase III trial of T-VEC, have revealed the immunological properties of oncolytic 
virotherapy for the first time in a larger patient cohort (n=291) (45). The intrale-
sional application of T-VEC to patients with injectable advanced-stage melanoma 
(≥ stage IIIb) thereby resulted in durable responses (≥ 6 months) both in injected 
and uninjected lesions. Patients ‘only’ receiving subcutaneous GM-CSF served 
as comparison group in this trial.  
Since i) T-VEC expresses the immunostimulatory molecule GM-CSF, ii) mela-
noma is known to be highly susceptible to immunotherapy and iii) durable re-
sponses were seen in uninjected lesions as well, it is highly probable that the 
therapeutic success of T-VEC depends on the successful activation of antitumor 
immunity. Of especial interest are also the facts that response rates were greater 
in patients receiving T-VEC as first-line therapy and that differences in overall 
survival between both treatment groups were higher in patients with skin, subcu-
taneous, or nodal disease only than in patients with metastases in the lung or 
other visceral organs.  
Assured by these data, T-VEC has finally achieved FDA and EMA approval for 
the treatment of metastatic melanoma on October 27 and December 17, 2015, 
respectively (43). But although such results greatly encourage boosting the im-
munological properties of OVs to achieve a lasting immune-mediated tumor re-
sponse in the long-term, an initially strong antiviral host response might impede 
primary viral infection and replication, the key for (immuno-)therapeutic success. 
OVs are biological agents constantly changing their dose after primary infection. 
In the context of evaluating their safety as well as their infection and replication 
efficacy (especially under the influence of the host immune system) it has become 
instrumental to monitor viral spread after primary application by inserting different 
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reporter genes into their genetic backbone. Strategies thereby include virus en-
coded serum markers (46), the construction of light-emitting viruses (47,48) or 
radiologic strategies such as viral expression of the thyroidal sodium iodide sym-
porter (hNIS) enabling the tumor-specific uptake of radioisotopes (49). Such tu-
mor-imaging OVs represent both promising therapeutic agents which additionally 
can be used as a diagnostic tool not only in the beginnings after initiation of the 
virotherapeutic treatment but also in a more advanced state of cancer therapy. 
Therefore these OVs belong to a group of agents typically referred to as 
‘theranostics’ (50).  
Detecting virus particles after their systemic administration also seems to be cru-
cial in consideration of reaching sufficient doses for efficient delivery to their site 
of action. Recent results from a phase I trial intravenously infusing the vaccinia 
virus JX-594 (Pexa-Vec) demonstrated that, similar to other systemic agents, 
successful viral extravasation and migration to the tumor is a dose-dependent 
process (51). In tumor biopsies collected 8-10 days after virotherapeutic treat-
ment, intravenously infused JX-594 was only detectable when applied in doses 
of 109 infectious units or higher. This led to the conclusion that doses of system-
ically applied virotherapeutic agents have to exceed a ‘viremic threshold’ to suc-
cessfully reach the tumor site.  
High-dose applications of many OVs are primarily limited by so far insufficient 
manufacturing procedures being unable to yield extra high viral titers in most of 
the currently used virotherapeutic systems. However, since the field is progress-
ing and more efficient fabrication processes are likely to be developed, reemerg-
ing safety issues have to be considered. Although the clinical tolerability of novel 
tumor/replication-restricted OVs has been ensured, extensively higher doses of 
a therapeutic agent are also supposed to result in a less favorable toxicity profile. 
Adverse effects typically seen shortly after virotherapeutic treatment are low-
grade flu-like symptoms (including fever, chills, myalgia and/or asthenia). In the 
process of administering OVs in higher doses and/or in combination with other 
drugs, safeguard strategies like potent antiviral drugs have to be available to in-
tercept excessive toxicity. 
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One of the biggest challenges of oncolytic virotherapy still remains the choice of 
the ‘right’ virus for distinct tumor indications. Although almost every OV can be 
genetically modified to replicate only in a certain tissue with maximal oncolytic 
efficacy, different virus families are defined by their distinct biological features. 
Based on basic parameters such as particle structure and life cycle, each OV is 
adapted intrinsically to a certain host range in which efficient infection, potent 
replication, strategies counteracting antiviral host responses, oncolysis and virus 
spread operate best. By ‘improving’ their genetic configuration each of these fac-
tors can be influenced, both positively and negatively, implying that for each tu-
mor entity it has to be elucidated which OV may cause the best tumor response.  
For that matter, current preclinical cell or animal models are still highly insufficient. 
Virus-induced immune responses can only be investigated in immunocompetent 
animals which render human tumor xenografts infeasible and therefore so far fail 
to simulate human conditions properly. In addition, some OVs (such as measles 
vaccine virus-based virotherapeutics) are constricted to the human host, making 
their preclinical evaluation only possible in cell culture or human xenografts in 
immunodeficient animals. Clinical trials, early phases I/II primarily designed to 
ensure the agent’s safety, are very time-consuming and costly. Furthermore, at 
the time at which a particular OV has finally reached phase III stadium (after sev-
eral years) often, due to ‘simple’ genetic recombination, another - more promising 
- OV is already on its way. 
Additionally, the importance of the route of administration of the respective viro-
therapeutics still remains obscure (52). Intratumoral injection of OVs probably 
reaches the highest oncolytic efficacy and typically is associated with lower rates 
of systemic toxicity. However, systemic application regimens are generally fa-
vored to also cover microscopic metastatic lesions now being accessible for di-
rect virus-induced destruction. Although intratumorally injected OVs to a lesser 
extent will also spread over the body and a tumor-directed immune response 
might also eradicate distant tumor lesions, the high-dose systemic application of 
OVs promises to be more effective. In addition, only a subset of tumor entities 
can be reached successfully by intralesional injection. However, the efficacy of 
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intravenous spread depends upon different factors and, due to their specific virus 
biology, not all virus families may equally be suited for systemic infusion (53). 
Other possible application routes include intraperitoneal/intrapleural administra-
tion in case of peritoneal/pleural tumor spread or intrathecal delivery to achieve 
higher treatment doses for tumors of the central nervous system. To profit from 
the benefits of different administration routes combinations thereof also might be 
justified.  
In conclusion, todays biggest challenges of oncolytic virotherapy indeed remain 
finding, constructing and further optimizing the ‘right’ viral agent for a distinct tu-
mor indication before applying it via the most effective route of administration. 
Vice versa, in view of personalized medicine and complex immunologic hetero-
geneity in the human population, it may be of even more importance to select the 
OV on the basis of human host factors such as the ‘right’ genetic tumor cell and 
immune cell setting or a sufficient and therefore promising initial tumor response. 
However, despite intensive research over the last decades, mostly only limited 
(mono-)virotherapeutic success has been achieved so far. Supported by recent 
trial data it has become evident that new protocols such as combining OVs with 
other treatment regimens have to be developed to overcome their to date only 
limited clinical efficacy, finally aiding oncolytic virotherapy to unfold its whole po-
tential of targeted antitumor therapy. 
1.2.4 Chemovirotherapy 
Usually the efficacy of monotherapeutic regimens is limited by an insufficient tu-
mor response and the induction of resistance mechanisms against the applied 
agent (as illustrated more detailed for the case of pancreatic cancer in section 
1.1.3, p. 5). Therefore, the combination of agents with distinct mechanisms of 
action promises to be highly effective not only in eradicating the initial tumor mass 
but also in preventing the induction of resistance mechanisms. Accordingly, the 
combination of OVs with chemotherapeutic agents (so-called chemovirotherapy) 
is of major interest. But before successfully applying theory into praxis, several 
parameters have to be considered in order to fully assess both possible benefits 
and threats of such a combined, i.e. chemovirotherapeutic, treatment. 
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Untargeted cytostatics, such as most of the currently clinically applied chemo-
therapeutic agents, affect every proliferating cell of the human body inde-
pendently of their malignant potential. Since this mode of action is rather unspe-
cific, the main barrier for their high-dose clinical application is their unfavorable 
toxicity profile. Based on the general idea that tumor cells naturally proliferate 
more strongly than their physiological counterparts, they are supposed to also be 
more affected by systemically applied chemotherapeutics. But while higher doses 
may result in a more profound response of the tumor cells, other fast proliferating 
cell populations such as mucous membranes and hematopoietic stem cells will 
be affected as well. Adverse effects such as anemia, leukopenia and mucositis 
are therefore typical consequences in the course of chemotherapeutic treatment 
regimens. Therefore, the important lesson was learned that individualized anti-
cancer treatment not only includes choosing the ‘right’ agents but also to carefully 
balance their risk-benefit profile towards a more effective antitumor response 
while preserving an acceptable health-related quality of life. 
Moreover, the cytotoxic effect of chemotherapy depends nearly entirely on oper-
ating cell death mechanisms such as apoptosis. By interfering with key functions 
of cellular metabolism, chemotherapeutics shift the delicate balance from anti- to 
pro-apoptotic signaling pathways ultimately leading to apoptotic cell death. But in 
the process of tumorigenesis, tumor cells, whose process of accumulating ge-
netic alterations naturally constitutes a potent pro-apoptotic stimulus, often cir-
cumvent physiologic signaling pathways by overexpressing anti- and downregu-
lating pro-apoptotic gene products. This severely impedes the success of chemo-
therapeutic treatment regimens and often makes is necessary to (i) apply high-
dose chemotherapy (also involving high toxicity), (ii) combine different chemo-
therapeutic agents (mostly with overlapping toxicity profiles) or (iii) apply them in 
combination with other antitumor agents with different sites of action. 
Replication-restricted OVs in contrast are engineered for their viral life cycle to 
take place in tumor cells only while impeding viral replication in healthy tissues. 
Shortly after viral infection, tumor cells are actively killed by oncolysis to release 
the progeny virus particles independently of physiologic cell death mechanisms. 
Ch. 1 Introduction Dissertation Eike Hendrik Binz 
19 
 
In addition, the combination of immunogenic OVs and tumor antigen release is 
proposed to stimulate antitumor immunity. This kind of antitumor treatment there-
fore mostly faces immunologic resistance mechanisms such as interferon-medi-
ated host cell responses (23) or immune cell-based resistance mechanisms such 
as tumor-associated granulocytic myeloid-derived suppressor cells (G-MDSCs) 
which induce a immunosuppressive tumor cell phenotype thereby limiting the de-
sired immunotherapeutic effect (54). Tumor cells may also be intrinsically re-
sistant against virotherapeutic treatment if the OVs can’t properly infect and ex-
ploit their cellular metabolism for efficient replication. However, innate immune 
responses are supposed to be a more prominent primary resistance mechanism 
against oncolytic virotherapy which has to be overcome to reach sufficient virus 
doses at the tumor site. Adaptive immune responses on the other hand will be 
triggered in response to primary (and any subsequent) infection with the oncolytic 
agent. Though utilizing this response for arousing antitumor immunity is greatly 
desired, a too strong preliminary viral clearance may prevent tumor cell infection 
and viral spread and pose a highly potent acquired resistance mechanism, espe-
cially in the long-term of oncolytic virotherapy and particularly when the viral agent 
is applied at multiple times. 
The mechanisms of action and resistance profiles of these two approaches 
chemo- and virotherapy are therefore entirely different, in fact considerably more 
dissimilar than those of different chemotherapeutics (whereupon multimodal 
chemotherapy protocols are widely used in the clinic). Additionally, due to the 
virus-mediated induction of antiviral host responses such as apoptosis, infected 
tumor cells even with dysfunctional cell death pathways are likely to be more 
prone to chemotherapy-induced cell death.  
Virotherapy typically leads to flu-like symptoms (as illustrated previously in sec-
tion 1.2.3, p. 12) whereas chemotherapy typically results in anemia, leucopenia 
and mucositis (as illustrated above). The condition that the toxicity profiles of both 
approaches don’t overlap is therefore of utmost importance. This matter is further 
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affirmed by the fact that potential synergistic interactions between distinct thera-
peutic approaches not only would result in a more potent tumor response but also 
permit dose reductions of the applied agents to a less toxic degree. 
Moreover, although virus-mediated oncolysis can result in a significant tumor re-
duction, the main effect of oncolytic virotherapy is believed to be a tumor-directed 
response of the innate and more importantly the adaptive immune system. How-
ever, this process requires time that cancer patients, being mostly diagnosed in 
advanced stages of the tumor disease, usually don’t have. Harnessing the immu-
notherapeutic potential of oncolytic virotherapy therefore depends on an effective 
stabilization of the tumor disease in the first place. For most tumor entities chem-
otherapy represents the standard of care (both in the (neo-)adjuvant as well as in 
the palliative setting) and therefore provides the opportunity to gain the time re-
quired for slower, but long-lasting antitumor effects such as profound immune 
responses. Furthermore, curbing tumor cell growth in the short-term will likely be 
more successful when combining the cytotoxic effect of chemotherapeutics with 
the oncolytic effect of OVs. 
Preclinical evidence for potential clinical benefit of the chemovirotherapeutic ap-
proach is overwhelming (55). OVs have been combined with a multitude of differ-
ent chemotherapeutic agents and synergistic interactions with each of the mainly 
used virus families adenovirus (56), herpes simplex virus (57), reovirus (24) and 
vaccinia virus (58) (and other virus families as well) have been found. However, 
every genetic modification of a given oncolytic vector may profoundly influence 
its biology and for this reason also its interaction with chemotherapeutic agents. 
Therefore, every chemovirotherapeutic protocol, even if incorporating only a 
slightly dissimilar OV, has to be tested and its potential clinical benefit evaluated. 
Since with today’s facilities the engineering of a new viral vector is a rather easy 
procedure, this poses a Sisyphus work and (pre-)clinical testing of all potential 
combinations will not be possible. Further understanding of the complex interac-
tions between OVs and chemotherapeutic agents is therefore desperately 
needed. 
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The fact that chemotherapy represents the standard of care for many tumor enti-
ties also opens up new possibilities in the clinical setting. Given that replication-
restricted OVs primarily had to ease upcoming safety concerns, trials so far 
mostly included patients at their end-stage of the disease (after all other treatment 
modalities had failed to achieve the desired tumor response). Accordingly, it has 
to be assumed that this subset of patients exhibits rather unfavorable conditions 
for oncolytic virotherapy to unfold its whole potential. Tumor cells having survived 
treatment with a plurality of different anticancer agents, have to be regarded as 
highly resistant, capable of evading cell death via a multitude of different mecha-
nisms. Although OVs operate in a completely different manner than chemother-
apeutics, it seems unlikely that such highly aberrant cells will be killed before they 
become resistant anew, this time against the applied OV as well. More im-
portantly, the immune system of palliative cancer patients is likely to be enfeebled 
and might not have the ability to mount a strong immune response. Future clinical 
applications of OVs in combination with chemotherapeutic agents therefore pro-
vide the opportunity to address earlier tumor stages as well, i.e. in the setting of 
first-line chemovirotherapeutic regimens. 
Based on the promising preclinical data an array of clinical trials incorporating 
chemovirotherapeutic protocols has already been started (59). The few clinical 
data which so far have been published thereby identified no enhanced toxicity 
after chemovirotherapeutic treatment (even when the agents were given concom-
itantly) and therefore validated the safety of the combinatorial approach. The cur-
rently most advanced OV in monotherapy, the herpes virus-based T-VEC, has 
recently also been combined with the checkpoint inhibitor ipilimumab. Preliminary 
results from a phase Ib trial in patients with advanced melanoma thereby have 
demonstrated an even stronger response to the chemovirotherapeutic combina-
tion than to either agent alone (60) (results from the phase III trial in monotherapy 
have been illustrated in section 1.2.3, p.12). The phase II part of this trial is cur-
rently ongoing (NCT01740297) and its results are eagerly awaited.  
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The first chemovirotherapeutic protocols which lately have reached phase III test-
ing incorporated the naturally occurring reovirus Reolysin® and the GM-CSF ex-
pressing vaccinia virus JX-594. The combination of intravenously administered 
Reolysin® with carboplatin and paclitaxel in patients with head and neck cancer 
has recently been completed and was able to demonstrate a significant improve-
ment of overall survival by the chemovirotherapeutic combination compared to 
the dual chemotherapy alone (61). However, published data of this study (desig-
nated as REO 018) are still awaited. The phase II combination of JX-594 with the 
oral multiple kinase inhibitor sorafenib in treatment-refractory patients with hepa-
tocellular carcinoma (HCC) not only was found to be safe but also enhanced the 
therapeutic effect (62). These data led to the recent design of a phase III trial this 
time employing the chemovirotherapeutic combination as first-line treatment for 
patients with advanced HCC (NCT02562755) (63). 
Combining OVs with established chemotherapeutic agents, preferably in a first-
line chemovirotherapeutic treatment scenario, is therefore based on various good 
reasons. Not only has been proven that the two different approaches can interact 
synergistically in eradicating the tumor disease, but they might also provide 
enough time for a strong response of the adaptive immune system. Since chemo-
therapeutics already represent the standard of care in first- and second-line treat-
ment protocols, their combination with OVs might finally establish oncolytic viro-
therapy at the clinical bedside and improve current treatment outcomes. 
1.3 Virotherapy with the oncolytic vaccinia virus GLV-1h68 
1.3.1 Structure and life cycle of vaccinia viruses 
Vaccinia virus belongs to the family of poxviruses (Poxviridae). Due to its inter-
twined history with the smallpox causing variola virus during smallpox eradication, 
it is also its most extensively investigated representative (64). Accordingly, to-
day’s understandings about poxvirus biology are mainly based on the research 
on vaccinia virus. 
The viral particle (virion) of vaccinia virus consists of a linear double-stranded 
DNA molecule enveloped by different numbers of lipid bilayer membranes (Figure 
7). Its entire life cycle takes place in the host cell’s cytoplasm and thereby mostly 
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relies on its own encoded proteins. Along with many other mechanisms, the re-
sulting minimal interaction with proteins of the host cell enables vaccinia virus to 
infect a wide range of tissues while simultaneously avoiding antiviral host re-
sponses. Unlike variola virus, vaccinia virus is not restricted to the human host 
but can also infect some animals.  
Figure 7 Virion structure of vaccinia virus (a) schematic and (b) microscopic. Taken and modified 
from Harrison et al. (64) 
The exact process of how vaccinia virus enters the host cell still is not well under-
stood. For cell entry vaccinia virus thereby seems to exploit endocytotic mecha-
nisms of its target cells (65). However, in contrast to adenovirus or measles virus 
which, if not specifically engineered otherwise, utilize receptors such as CAR 
(coxsackie and adenovirus receptor) or CD46 for their cell entry, no such receptor 
has yet been found for vaccinia virus. Further understanding is additionally hin-
dered by the fact that vaccinia virus produces three forms of infectious particles: 
intracellular mature virus (IMV), cell-associated enveloped virus (CEV) and ex-
tracellular enveloped virus (EEV).  
Newly produced virions first form IMV particles (depicted in Figure 7a) which 
mainly remain in the host cell until lysis. However, a subset of IMVs dissociate 
from their host cell into the local vasculature now spreading as EEVs over the 
body. CEVs in contrast penetrate surrounding cells and enable direct cell-to-cell 
spread of vaccinia virus. In the process of exiting the host cell both CEVs and 
EEVs acquire an additional lipoprotein bilayer that surrounds the IMV particle. In 
a b 
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case of EEV this outer envelope is equipped with complement control proteins 
protecting the EEV from complement activation (66).  
Those three forms, IMV, CEV and EEV, not only are constructed differently but 
also fulfill different tasks in the strategy of vaccinia virus to reach maximal viral 
spread. IMVs represent by far the majority of formed virions but are only released 
in the final stage of virus infection when the host cell undergoes virus-induced 
lysis. CEVs and EEVs are released much earlier and are therefore essential for 
rapid short- and long-range virus spread. Although EEVs constitute only a minor 
fraction of formed virus particles (< 10 %), vaccinia mutants unable to produce 
them in sufficient numbers were shown to be significantly attenuated by inefficient 
virus dissemination (67).  
1.3.2 Discovery of vaccinia virus and its role during smallpox eradication 
Vaccinia virus also represents the virus with the longest history of clinical use in 
humans (68). In 1798, the English doctor Edward Jenner was able to show that 
people who had previously suffered from cowpox were resistant to the similar but 
significantly worse smallpox disease with a lethal outcome of up to 40 %. In his 
case study describing the first successful vaccination, Jenner gathered pus from 
a cowpox infected milkmaid and injected it into the arm of an 8-year old boy who 
subsequently developed light symptoms of the disease (69). After a second in-
jection 1.5 months later, this time with pus from a smallpox patient, the boy re-
mained healthy even when being rechallenged with smallpox several months 
later. With this experiment, Jenner unknowingly was able to show for the first time 
that infection with a similar but less virulent pathogen can immunize against the 
more virulent disease and create a lasting immunological memory. Appropriately 
the term ‘vaccination’ originates from ‘vacca’ the latin word for cow. Edward Jen-
ner and Louis Pasteur who later described the underlying mechanisms of this 
process are therefore often recognized as the ‘fathers of immunology’ (70). 
Word about vaccination spread fast in the Western hemisphere which led to its 
frequent use during the next century (68). However, in the beginnings of the 20th 
century when basic knowledge about virus biology just had started to emerge, it 
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was noticed that the virus strain used at that time differed from the original cow-
pox virus. Due to its favorably milder vaccination reaction this now called ‘vaccinia 
virus’ was further used for subsequent smallpox vaccination though its exact 
origin remains obscure. In the following years, owing to the global usage of vac-
cinia virus in smallpox vaccination and laboratory research, different new virus 
strains evolved ‘locally’ such as the Western Reserve, Wyeth, Copenhagen or 
Lister strains.  
Clinical use of vaccinia virus finally culminated in the global Smallpox Eradication 
Program (SEP) (71). Lasting from 1966 to 1980 the program addressed espe-
cially regions in Africa and Asia where smallpox was still endemic at that time. At 
its end in 1980 the World Health Organization (WHO) declared smallpox finally 
being eradicated globally. Today stocks of variola virus still remain in the US and 
Russia, though - unknowingly - further stocks might be stashed elsewhere (64). 
1.3.3 Rationale for using vaccinia virus in oncolytic virotherapy 
Primarily used as potent vaccine, in recent years the application range of vaccinia 
virus has broadened. Being extensively studied, vaccinia virus exhibits several 
unique features that make it a promising virotherapeutic agent (72).  
For starters vaccinia virus is known for its wide host range not only in humans but 
animals as well. Being able to infect almost every tissue allows for a wide-spread 
clinical use against many tumor entities and suggests efficacy across tumor cell 
subpopulations with distinct genetic configurations. It also facilitates indispensa-
ble preclinical testing since established animal models can be easily used without 
viral constraint to the human host. Moreover, compared to other OVs vaccinia 
virus infection has the advantage of being independent of the cellular expression 
of viral entry receptors.  
Secondly, replication and viral spread of vaccinia virus are performed both rapidly 
and highly efficiently. The entire viral life cycle, from the moment of infecting the 
host cell until its lysis, lasts only 24 hours und culminates in the release of a vast 
amount of infectious particles. Viral spread is maximized by the formation of 3 
different infectious particles that spread and enter host cells differently. CEV and 
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EEV, responsible for efficient short- and long-range spread, are released even 
earlier than IMV approximately 6 hours after infection and additionally accelerate 
virus dissemination (68). 
Another favorable property of vaccinia virus is its large genome of approx. 192 
kb that can additionally accommodate foreign DNA sequences of at least 25 kb 
(73). By comparison, other OVs such as oncolytic adenoviruses can accommo-
date considerably less foreign DNA. This renders vaccinia virus a suitable gene 
vector for the insertion of reporter genes, tumor-associated antigens, therapeutic 
transgenes or immunomodulatory molecules. As a result, many vaccinia-based 
gene vector systems encoding a multitude of transgenes have been developed 
(58).  
Since vaccinia virus encodes its own enzymatic facilities, no integration of the 
viral genome into the host cell’s genome takes place. Moreover, viral replication 
is localized in cytosolic ‘virus factories’ independent of the host cell’s nucleus (64). 
Vaccinia virus therefore not only represents a potent stand-alone virotherapeutic 
but also interacts minimally with the host cell genome, both being preferable pre-
requisites for its safe clinical application. 
Due to its successful use as vaccine against smallpox, vaccinia virus is also 
known to be highly immunogenic (74). It would be even more so if it did not en-
code several proteins to circumvent antiviral host responses (75,76). The deletion 
of virulence genes in the quest of engineering a tumor-selective vaccinia-based 
agent therefore might also augment its immunological potential. Since OVs are 
mainly believed to be immunotherapeutics in nature, using vaccinia virus for the 
treatment of cancer is of great interest (58). Thus, it is hardly surprising that the 
currently clinically most advanced vaccinia virus JX-594, a derivative of the Wy-
eth strain, encodes the proinflammatory cytokine GM-CSF (77). 
Only recently a phase II trial employing JX-594 to patients with advanced hepa-
tocellular carcinoma (HCC) was completed (results from another phase II trial of 
JX-594 in combination with sorafenib have been illustrated in section 1.2.4, p. 17). 
Intralesionally infused JX-594 thereby was shown to induce a polyclonal humoral 
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immune response leading to antibody-mediated complement-dependent cytotox-
icity (78). Moreover, tumor responses were seen both in injected and non-injected 
distant tumor lesions. Additionally, the baseline presence/absence of neutralizing 
antibodies against vaccinia virus (possibly impeding viral replication and spread) 
did not correlate with therapeutic efficacy. The most crucial parameter determin-
ing therapeutic benefit was rather the applied viral dose of JX-594, overall survival 
thereby ranging from 13.6 months (high-dose group) to 4.3 months (low-dose 
group). 
In terms of safety no other virus has been longer in clinical use or more exten-
sively been studied than vaccinia virus (68). Adverse effects following vaccination 
were typically mild and included local pain at the injection site as well as mild flu-
like symptoms such as headache, myalgia, chills, nausea and fatigue (79). Mod-
erate or severe complications were extremely rare (1-250 / million primary vac-
cinations) and included eczema vaccinatum, generalized or progressive vaccinia, 
myopericarditis or encephalitis. For this reason, application of vaccinia virus in 
humans so far has been remarkably safe. Furthermore, for the unlikely case of 
uncontrolled virus infection a number of different antiviral agents have already 
been developed (64). Currently the only approved agent is intravenous vaccinia 
immune globuline (VIGIV) (80) while the nucleotide analogue cidofovir (81) is re-
served for second-line anti-vaccinia therapy. Other agents such as the egress 
inhibitor tecovirimat (aka ST-246) (82) and certain tyrosine kinase inhibitors (83) 
are indeed rather experimental but have shown their efficacy against vaccinia 
virus. Of note, this includes the inhibitory effect of sorafenib on the replication of 
vaccinia viruses leading to the necessity for a sequential application of first soraf-
enib and then (after a 14 day pause) the onset of vaccinia virotherapy (84). 
In summary vaccinia virus is not only able to infect almost any cell type but also 
to transport and express large amounts of foreign genetic material while being 
independent of host cell nuclear transcription processes. Extensive clinical expe-
rience has certified its safe application and for the rare case of excessive toxicity 
potent antivirals are ready to hand. Future clinical applications of vaccinia virus 
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should mainly focus on harnessing its oncolytic but even more its immunothera-
peutic potential to prove real benefit of this agent in anticancer therapy. 
1.3.4 Construction of GLV-1h68 
The oncolytic vaccinia virus GLV-1h68 (aka GL-ONC1) used as virotherapeutic 
agent in this thesis has previously been constructed by insertion of three expres-
sion cassettes in nonessential gene loci of the parental Lister strain vaccinia virus 
(Figure 8) (46): 
 
 
Figure 8 Genetic construct of GLV-1h68. Taken and modified from Zhang et al. (46). 
▪ F14.5L locus →  expression cassette encoding Renilla luciferase-Ae-
quorea green fluorescent protein fusion (GFP) [ruc-gfp] 
▪ J2R locus (encoding viral thymidine kinase) → expression cassette encod-
ing β-galactosidase (β-gal) [lacZ] 
▪ A56R locus (encoding viral hemagglutinin) → expression cassette encod-
ing β-glucuronidase (β-gluc) [gusA] 
Inactivation of the well-known genes for thymidine kinase (its importance during 
viral infection has already been illustrated in section 1.2.1, p. 7) and hemaggluti-
nin as well as the less studied F14.5L gene product led to considerable viral at-
tenuation in breast tumor-bearing nude mice whereas virus colonization was 
largely restricted to tumor tissues. In comparison to the parental Lister strain virus 
and single- or double-mutant derivatives, not only the level of attenuation in-
creased with each gene inactivation (30) but also its oncolytic potency (46). Ad-
ditionally, it was assumed that, due to a higher translational burden, the insertion 
of foreign gene expression cassettes into nonessential gene loci attenuated the 
OV even more than simply disrupting the corresponding virulence genes (85). 
Infection with GLV-1h68 in vivo also led to a latent upregulation of genes mostly 
matching functions of the innate immune response (46). It was therefore hypoth-
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esized that this GLV-1h68-mediated activation of the immune system is a re-
sponse to potent viral replication, steadily cumulating oncolysis and the concur-
rent release of proinflammatory molecules. 
Due to the expression of serum and tissue markers (β-gluc, β-gal) as well as its 
capability of luminescent and fluorescent light emission (GFP), GLV-1h68 unifies 
both therapeutic and diagnostic properties enabling real-time monitoring of its 
therapeutic efficacy (86) (more detailed information about ‘theranostics’ are spec-
ified in section 1.2.3, p. 12). Initial treatment with GLV-1h68 was highly efficient 
and led to complete tumor elimination in over 95 % of breast tumor-bearing nude 
mice which was linked to 100 % survival at the end of the study (130 days post 
infection) (46). In addition, tumor regression was paralleled by gradual extinction 
of GFP fluorescence and decreasing β-galactosidase activity, as shown by im-
munohistochemical staining of tumor sections. 56 days after virus injection, along 
with complete tumor remission in most of the mice, neither GFP expression nor 
β-galactosidase could be detected. 
1.3.5 Virotherapeutic research with GLV-1h68 
Based on these promising initial results a multitude of further investigations on 
GLV-1h68 and its potential role in future virotherapeutic application regimens has 
been conducted. Screening the NCI-60 cancer cell lines for their susceptibility to 
GLV-1h68 infection has shown that GLV-1h68 is able to efficiently infect and rep-
licate within a wide range of tumor tissues (87). Generally, viral infection seemed 
to be favored by overexpression of cellular components involved in cell move-
ment and adhesion as well as the tumor cell-mediated suppression of the innate 
immune response. GFP expression of GLV-1h68 correlated positively with viral 
replication and was not tumor- but rather cell line-dependent. Furthermore, GLV-
1h68 application has been confirmed to be safe and highly effective in different 
animal models of human cancer (46,85,88-105). 
Continuing research on GLV-1h68 also gave further insights into the mechanisms 
determining therapeutic success of this particular agent. Although GLV-1h68 ex-
hibits anti-vascular (89) and proinflammatory properties (90-92,106), a strong vi-
ral replication of GLV-1h68 seems to be the most crucial predictive marker for 
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potent antitumor efficacy (46,85,89,90,92-94,107). However, the degree to which 
the different interactions contribute to the oncolytic potency of GLV-1h68 was 
demonstrated to depend on the particular tumor microenvironment (89).  
Strong viral replication of GLV-1h68 was also shown to be essential for the acti-
vation of the innate immune system. In nude mice GLV-1h68 shifted the chronic 
inflammation process of rejecting the human xenograft to an acute and destruc-
tive one (92). In another immunocompromised model tumor remission after intra-
venous injection of the viral agent was accompanied by high numbers of macro-
phages and NK cells at the tumor site (90). GLV-1h68 induced intratumoral infil-
tration of myeloid cells could also be detected by 19F-magnetic resonance imag-
ing (MRI) (108).  
However, responses of the innate immune system are mostly unspecific and, in 
one case, were shown to be directed against GLV-1h68 and not against the tumor 
tissue (93). Since the adaptive immune system also possesses antiviral proper-
ties and modulates the activity of innate immune responses, it is likely to affect 
replication and spread of GLV-1h68 as well. Nevertheless, proof for its beneficial 
or detrimental effect on the therapeutic efficacy of GLV-1h68 from human patients 
or immunocompetent animal models is still missing. 
Additionally, GLV-1h68 was shown to be able to eradicate tumor cells with stem-
cell like features (95) as well as preferentially colonizing lymph node metastases 
in a prostate cancer model in nude mice (96). The latter has been contributed to 
an increased vascular permeability and a higher number of immune cells in lymph 
node metastases in comparison to the primary tumor. Successful tracking of 
lymph node metastases by GLV-1h68 has also been shown in an immunocom-
petent animal model (97). In this regard, localized virus-mediated GFP expres-
sion not only is of essential prognostic relevance but also enables real-time de-
tection of affected lymph nodes during surgery. To enhance viral delivery, GLV-
1h68 has been shielded with silk-elastin-like protein polymers (SELPs) in a 
mouse model of incomplete tumor resection (98). Shielding of the viral particles 
resulted in an enhanced transgene expression and increased tumor shrinkage of 
the residual tumor cells. Therefore, the administration of GLV-1h68 to the 
Ch. 1 Introduction Dissertation Eike Hendrik Binz 
31 
 
postsurgical resection bed was shown to be another potential use of this viral 
agent. 
In vitro, markers of early gene expression like β-gal, luciferase and GFP expres-
sion correlated well with the susceptibility of different tumor cell lines to GLV-1h68 
mediated oncolysis (99,106). This may be of significant prognostic value for pre-
dicting its therapeutic potency in vivo. But whether high susceptibility to GLV-
1h68 in vitro is associated with high oncolytic efficacy in animal models or human 
patients remains controversial. Ex vivo assays measuring early gene products of 
GLV-1h68 indeed have been proposed as being useful in predicting the thera-
peutic success in an animal model (100). Additionally, the comparison of GLV-
1h68 with some less-attenuated and therefore more strongly replicating deriva-
tives has demonstrated a clear correlation between enhanced viral replication in 
vitro and more rapid tumor shrinkage in vivo (85). However, although the less-
attenuated derivatives caused an increased tumor response, in some of the 
cases this came at the price of higher toxicity and lesser survival of the mice. In 
another study two pancreatic cell lines differing in their susceptibility to GLV-1h68 
mediated oncolysis in vitro were found to respond similarly in vivo (101). On the 
contrary, some well responding cell lines in vitro demonstrated less therapeutic 
efficacy in vivo which was associated with lower viral titers (92). In summary, 
these data clearly suggest that in vivo additional factors beyond the baseline ge-
netic configuration of tumor cells influence viral replication and treatment out-
come.  
Human genes possibly predicting the effective viral replication of vaccinia-based 
agents in the human host have already been found (109). However, in view of 
future ‘personalized’ clinical applications of GLV-1h68 it would not only be essen-
tial to include tumor patients with the ‘right’ genetic setting but also to evaluate as 
early as possible whether the virotherapeutic treatment is beneficial and results 
in the desired tumor response. In this regard, the monitoring of viral replication 
and therapeutic efficacy by measuring viral expression of β-gal, β-gluc, lumines-
cence and fluorescence seems to be crucial to distinguish responders from non-
responders. 
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To refine its therapeutic and diagnostic properties GLV-1h68 has also served as 
parental virus for the development of new vaccinia virus constructs. Similarly to 
the previously constructed measles virus encoding the human sodium iodide 
symporter (MV-NIS) (49) the oncolytic vaccinia virus GLV-1h153 has been con-
structed by replacing the β-glucuronidase encoding gusA cassette of GLV-1h68 
with a hNIS gene cassette (110). Likewise, another derivative, GLV-1h99, was 
constructed by replacing the ruc-gfp gene cassette with a gene cassette contain-
ing the human norepinephrine transporter gene (hNET) (111). Due to the tumor-
specific uptake of different radiotracers, detectable by imaging modalities such 
as positron emission tomography, both GLV-1h99 and GLV-1h153 enable deep-
tissue-imaging of tumors while monitoring viral spread and therapeutic efficacy 
(112,113). Other constructs encoding the anti-VEGF single chain antibody 
GLAF-1 (114) or the essential cell cycle protein Cdc6 (115) have demonstrated 
the therapeutic benefit of inserting therapeutic transgenes. Moreover, the hyper-
IL-6 expressing GLV-1h90 was able to additionally reduce chemotherapy-in-
duced thrombocytopenia in nude mice while remaining as potent as its parental 
virus GLV-1h68 (116).  
GLV-1h68 has also been successfully combined with other treatment regimens. 
Radiation has been shown to sensitize tumor cells for subsequent GLV-1h68 
treatment in human melanoma and glioma xenografts in nude mice (94,102) as 
well as enhancing the levels of apoptotic cell death in sarcoma cell lines when 
given adjuvantly (117). Combination of GLV-1h68 with cyclophosphamide re-
sulted in an enhanced tumor growth inhibition compared to treatment with either 
agent alone (118). Utilizing GLV-1h68 mediated expression of β-galactosidase to 
convert a prodrug seco-analogue of the cytotoxic antibiotic duocarmycin SA to its 
toxic compound led to the induction of apoptosis and enhanced oncolysis (119). 
Moreover, GLV-1h68 has been combined successfully with chemotherapy ap-
plied via isolated limb perfusion, radiation and surgery in a orthotopic model of 
advanced extremity sarcoma (120). 
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Of particular importance for this thesis was the combination of GLV-1h68 with the 
chemotherapeutic agents cisplatin or gemcitabine in 2 different cell lines of hu-
man pancreatic adenocarcinoma in vitro and in vivo (101). Both combination pro-
tocols resulted in an acceleration of tumor shrinkage and increased therapeutic 
efficacy, though treatment with GLV-1h68 alone was able to cause the same tu-
mor response as the gemcitabine combination group when only given sufficient 
time.  
Based on these data, few clinical trials incorporating GLV-1h68 (referred to as 
GL-ONC1 when used in clinical trials) have been performed. In patients with per-
itoneal carcinomatosis intraperitoneal infusion of GLV-1h68 not only was shown 
to be safe and well tolerated but to result in a dramatic decline of tumor cells in 
the ascitic fluid (121). Another phase I trial investigating the combination of GLV-
1h68 with the platinum compound cisplatin and radiation in patients with locore-
gional advanced head and neck cancer has recently been completed. According 
to preliminary data the triple combination was found to be safe and a follow-up 
phase II trial is planned (122). Final data of this study are still pending. Currently, 
clinical trials employing GLV-1h68 in patients with ovarian cancer (NCT02759588) 
or malignant pleural effusion (NCT01766739) and its combination with the com-
plement inhibitor eculizumab (NCT02714374) are under way. 
In conclusion, GLV-1h68 application in humans or tumor-bearing animals so far 
has been safe and highly efficient while viral replication was constrained to tumor 
tissues. Therapeutic efficacy could be measured non-invasively and correlated 
well with the decrease of the inserted reporter genes. However, (pre-)clinical re-
sults from combination protocols with chemotherapy and/or radiation have al-
ready indicated the additional therapeutic value of combining GLV-1h68 with 
other treatment regimens. 
1.4 Objectives 
Due to its unfavorable tumor biology, pancreatic adenocarcinoma is one of the 
deadliest types of cancer. Unfortunately, pancreatic ductal adenocarcinoma 
(PDA) is mostly diagnosed in a locally advanced or metastatic stage when cura-
tive surgical treatment is no longer possible and current treatment regimens in 
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form of multimodal chemotherapy protocols can’t effectively stabilize the tumor 
disease. Key determinants that contribute to its considerable primary and sec-
ondary resistance against chemotherapeutic treatment are mostly its i) genetic 
instability (generating a manifold of genetically different tumor cell subpopula-
tions), ii) desmoplastic stroma (impeding any systemic treatment modalities) and 
iii) local immunosuppressive microenvironment. 
Oncolytic virotherapy on the other side is assumed to benefit from such conditions. 
Tumor cells with highly aberrant and dysfunctional cell-death pathways are suit-
able host cells for oncolytic viruses (OVs) that are engineered for being unable to 
overcome physiologic antiviral host responses. Furthermore, tumor-mediated im-
munosuppression not only favors initial viral infection and intratumoral spread but 
also represents a therapeutic target that might finally be overridden by the immu-
notherapeutic properties of oncolytic virotherapy.  
Accordingly, pancreatic cancer has been the focus of many (pre-)clinical investi-
gations, most thereof employing monovirotherapeutic regimens (21,123). Since 
recent data indicated therapeutic benefit of chemovirotherapy, oncolytic virother-
apy preferably being an add-on component to already established treatment mo-
dalities, pancreatic cancer has also been treated with different (mainly gemcita-
bine-based) combination protocols in the preclinical setting (101,124-137). How-
ever, current chemovirotherapeutic trials only incorporate adeno- or reovirus-
based regimens (59). 
Here, in this thesis, the oncolytic vaccinia virus GLV-1h68 was tested in combi-
nation with various chemotherapeutic compounds on 4 well-characterized cell 
lines of pancreatic adenocarcinoma. This in vitro investigation aimed at providing 
a first preclinical basis for future chemovirotherapeutic regimens putatively im-
proving the treatment outcome of PDA. 
Initially, it had to be evaluated whether the pancreatic cancer cell lines differ in 
their susceptibility to different chemotherapeutic agents (such as standard of care 
gemcitabine and others) or the virotherapeutic agent GLV-1h68 in monotherapy 
and to which degree resistance is already preexistent.  
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Based on these data distinct chemovirotherapeutic protocols had to be devised 
in which the different agents were administered in tumor cell line-adjusted sub-
therapeutic doses. Primary aim of these protocols was to overcome any therapy-
impeding resistance and achieve therapeutic benefit by inducing a more potent 
antitumor response. Of especial interest were so far uninvestigated chemoviro-
therapeutic combinations such as GLV-1h68 applied together with the recently 
approved dual chemotherapy nab-paclitaxel + gemcitabine.  
Since it was speculated that success of any combination therapy not only de-
pends on the applied agents but also their dose and administration sequence, 
the influence of these parameters on the particular chemovirotherapeutic proto-
cols and their therapeutic benefit had to be assessed as well. Thus, the combi-
nation partners had to be administered either concurrently or one of the agents 
had to be applied first while the other was delayed. In line with this consideration 
it was of interest whether a specific application setting could be identified which 
would lead to an enhanced cytotoxicity in all of the tested tumor cell lines. 
Additionally, it was assumed that a potent viral replication would constitute an 
important prerequisite for a strong immunotherapeutic effect. Since chemothera-
peutics are known to potentially influence the viral life cycle, potential chemother-
apy-mediated reductions of viral replication had to be investigated in any che-
movirotherapeutic protocol. Accordingly, the monitoring of viral titers and of viral 
gene expression under the influence of chemotherapy constituted another vital 
part of this investigation. 
In the end, these investigations aimed at developing novel highly potent GLV-
1h68-based chemovirotherapeutic protocols which then had to be tested in fur-
ther work in animal models as well as later on in clinical trials.  
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2 Material and Methods 
2.1 Material 
2.1.1 Consumables 
Cell scrapers Corning Inc. 
CELLSTAR® Conical-bottom tube 15 ml Greiner Bio One 
CELLSTAR® Conical-bottom tube 50 ml Greiner Bio One 
Combitips 2.5 ml, 12.5 ml Eppendorf 
Cryotubes 1ml Corning Inc. 
Pasteur pipettes, 230 mm long size WU Mainz 
Pipettes 5 ml, 10 ml, 25 ml, 50 ml Corning Inc. 
Pipette tips 10 µl, 100 µl, 200 µl, 1000 µl Biozym / Peqlab 
Reaction tubes 1.5 ml, 2.0 ml Eppendorf  
Reaction tubes 1.5 ml, 2.0 ml (amber) Eppendorf 
Tissue culture flask 75 cm2 Greiner Bio One 
Tissue culture plate 24 well TPP 
Tissue culture plate 96 well TPP / Corning Inc. 
2.1.2 Chemicals 
5-fluorouracil (stored light-protected) Pharmaceutical Department,  
 University Hospital Tübingen 
Acetic Acid Merck KGaA 
CellTiter-Blue® (CTB) Reagent Promega 
CMC Sigma-Aldrich 
Crystal violet Carl Roth 
Descosept Dr. Schuhmacher GmbH 
DMSO AppliChem 
Erlotinib ChemieTek 
Gemcitabine LC Laboratories 
Hydrochloric Acid Merck KGaA 
Hydrochloric Acid (fuming) Merck KGaA 
Irinotecan Sigma-Aldrich 
Isopropanol (70 %) SAV Liquid Production 
Nab-paclitaxel Pharmaceutical Department,  
 University Hospital Tübingen 
Oxaliplatin Sigma-Aldrich 
Sekusept® Extra N ECOLAB Healthcare 
Sulforhodamine B (SRB) Sigma-Aldrich 
Thyazolyl BlueTetrazolium Bromide Sigma-Aldrich 
(MTT) 
Trichloroacetic acid Carl Roth 
TRIS Carl Roth 
Trypan blue Sigma-Aldrich 
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2.1.3 Media, Sera and Buffer 
DMEM Biochrom 
DMEM (colorless) Biochrom 
Gibco® Antibiotic-Antimycotic Life Technologies 
(penicillin, streptomycin, amphotericin B) 
Gibco® Fetal Calf Serum Life Technologies 
PBS (cell culture use) PAA Laboratories 
RPMI 1640 (colorless) PAA Laboratories 
Trypsin/EDTA Lonza 
Self-prepared solutions: 
CMC solution DMEM 500 ml 
 FCS 25 ml 
 CMC 7.5 g 
 AB/AM 5 ml 
DMEM + 2 % FCS (infection medium) DMEM 500 ml 
 FCS 10 ml 
DMEM + 10 % FCS (growth medium) DMEM 500 ml 
 FCS 50 ml 
MTT dye (stored light-protected) MTT 2.5 mg/ml  
  (1.25 g) 
 RPMI (colorless) 500 ml 
MTT Solubilization/Stop Solution HCl (37 %) 10 ml 
 Isopropanol 90 ml 
PBS (non cell culture use) NaCl 137 mM (8 g) 
 KCl 2.7 mM (0.2 g) 
 Na2HPO4 10 mM (1.44 g) 
 KH2PO4 1.8 mM (0.24 g) 
 H2Odd  filled up to 1 l 
SRB dye (0.4 % in 1 % acetic acid) SRB 4 g 
 Acetic acid 10 ml 
 H2Odd  filled up to 1 l 
TCA solution (10 %) TCA 100 g 
 H2Odd  filled up to 1 l 
Tris base TRIS  10 mM (1.21 g) 
 H2Odd  filled up to 1 l 
 pH 10.5 
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2.1.4 Cell lines 
AsPc-1 Human pancreatic adenocarcinoma cells. 
 Taken from the ascites of a 62-year-old woman with 
metastatic adenocarcinoma in the head of the pan-
creas. Producing both abundant mucin and carcino-
embryonic antigen (CEA). 
 Purchased from Sigma-Aldrich. 
BxPc-3 Human pancreatic adenocarcinoma cells. 
 Taken directly from the primary tumor of a 61-year-old 
woman with adenocarcinoma in the body of the pan-
creas. Producing CEA, human pancreas cancer-asso-
ciated antigen (PCAA), human pancreas-specific an-
tigen and traces of mucin. 
Purchased from ATCC. 
MIA PaCa-2 Human pancreatic adenocarcinoma cells. 
 Taken directly from the primary tumor of a 65-year-old 
man with adenocarcinoma in the body and tail of the 
pancreas infiltrating the periaortic area. 
Purchased from ATCC. 
Panc-1 Human pancreatic adenocarcinoma cells. 
 Taken directly from the primary tumor of a 56-year-old 
man with a metastatic adenocarcinoma in the head of 
the pancreas invading the duodenal wall. 
Purchased from Sigma-Aldrich. 
CV-1 African green monkey kidney cells. 
 CV-1 cells were provided by the Genelux Corp.  
2.1.5 Oncolytic virus 
GLV-1h68 (aka GL-ONC1) Genelux Corp. 
2.1.6 Laboratory Equipment 
Assistent® Hemocytometer Glaswarenfabrik Karl Hecht 
Autoclave 3850 EL Systec 
Branson Sonifier S-450A analog ultrasonic  Emerson Electric Company 
cell disruptor 
Centrifuge Eppendorf / Heraeus 
CK40 phase contrast inverted microscope Olympus 
F-View II FireWire fluorescence camera Soft Imaging System 
Fluorescence microscope IX50 Olympus 
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Freezer (-20 °C, -80 °C, -145 °C) Liebherr 
GENios Plus Multifunction Fluorescence Tecan 
Microplate Reader 
HandyStep® S Brand 
Incubator Heraeus / INTEGRA / Memmert 
HERAsafe® Laminar Flow Workbench Thermo Electron Corp. 
Multichannel pipette Eppendorf 
Multitemp II Thermostatic Circulator 2219 LKB Bromma 
Pipette Boy INTEGRA 
Pipettes BIOHIT HealthCare / Eppendorf 
Rotational Vacuum Concentrator Christ  
Synergy HT Multi-Mode Microplate Reader BioTek 
Vortexer IKA® Werke 
Water bath 3042 (37 °C) Köttermann 
2.2 Methods 
2.2.1 Safety 
The laboratory, in which this research took place, is certified as Biosafety Level 
2 according to the Directive 2000/54/EC – biological agents at work released by 
the European Parliament in 2000 (138). Therefore, all experiments imbedding 
(potentially or actually) infectious or hazardous substances were performed un-
der a laminar flow workbench. Additionally, if any experiments were performed 
on substances containing highly infectious poxvirus, protective glasses were 
worn. Afterwards, all materials were disinfected accurately, irradiated with UV-
light for at least 15 minutes and ultimately autoclaved. 
2.2.2 Microscopy 
To guarantee sterile and proper conditions as well as to assess the performance 
of cell culture or after treatment, the cells were continuously examined under the 
CK40 phase contrast inverted microscope from Olympus. If any fluorescence had 
to be detected or visualized, the fluorescence microscope IX50 from Olympus 
was used. 
2.2.3 Cell culture 
2.2.3.1 General cell culture 
All 4 pancreatic adenocarcinoma cell lines, both immortalized and adherent, were 
cultivated in growth medium (DMEM + 10 % FCS) in tissue culture flasks with 
filter screw caps. The flasks and tissue culture plates, in which the tumor cells 
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were seeded for treatment, were incubated at 37 °C in a humid atmosphere con-
taining 5 % CO2. All treatment steps were performed under sterile conditions in a 
laminar flow workbench. Media and PBS were prewarmed to 37 °C before use. 
2.2.3.2 Passaging cells 
In order to split or harvest the tumor cells, they were washed first with warm PBS 
and then detached by adding trypsin/EDTA. BxPc-3 cells were treated twice with 
trypsin, due to their high level of adherence to the flask’s surface. Detached tumor 
cells were diluted in fresh growth medium, inactivating trypsin by its supplemen-
tation with FCS, while single cell suspensions were generated by gently resus-
pending the tumor cell suspension a few times with a pipette. Afterwards, the 
suspension was split and spread in new culture flasks or stored temporarily in 15 
or 50 ml tubes to be counted and later seeded in tissue culture plates for further 
treatment (see section 2.2.3.3, p. 40). 
2.2.3.3 Cell counting and seeding 
Before the tumor cells could be seeded in tissue culture plates, their number per 
ml tumor cell suspension had to be determined using an improved Neubauer he-
mocytometer.  
To distinguish between viable and dead cells, cells were stained with trypan blue 
before counting. Viable cells don’t absorb trypan blue whereas it can pass the 
cell membrane of dead cells, staining the cellular proteins. Unstained viable cells, 
appearing brighter than their surroundings, now could be counted using a micro-
scope with a 10x objective. 
The counting chamber of the improved Neubauer hemocytometer is defined by 
the actual hemocytometer, a thick glass microscope slide with rectangular inden-
tations parceled out by squares of different size (Figure 9a), and its cover glass. 
For counting, the 4 outer squares, each subdivided into 16 lesser squares, were 
used. The dimensions of the outer squares are 1 x 1 mm, while the distance 
between the microscope slide and the properly fixed cover glass is 0.1 mm. This 
results in a total capacity of 100 nl per outer square.  
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First, the counting chamber was prepared by rubbing the cover glass carefully 
along two elevated glass edges on the microscope slide, until so-called Newton 
rings appeared, indicating the proper fixation. Subsequently, stained tumor cell 
suspension was administered to the margin of the cover glass, utilizing the capil-
lary force to soak it into the counting chamber. Viable cells in all 4 outer squares 
were counted and their mean value was multiplied with 104 to calculate the num-
ber of cells per ml stained solution. Considering the thinning caused by staining 
with trypan blue the actual number of cells per ml cell suspension was calculated 
accurately (Figure 9b).  
For treatment, tumor cells were seeded in 24-well plates at a density of 4 x 104 
(BxPc-3, MIA PaCa-2, Panc-1) or 5 x 104 (AsPc-1) cells per well. The chosen 
densities resulted from the prior observation of approx. 90 - 100 % confluence 
after 24 hours incubation, at which time the tumor cells should be treated. 
2.2.3.4 Cryopreservation and thawing 
To stock the tumor cells for a longer time period, they were cryopreserved in a 
freezing cabinet at -145 °C. Tumor cells were first harvested (see section 2.2.3.2, 
p. 40) and transferred into 15 ml tubes. The cell suspension then was centrifuged 
for 3 minutes at 1200 rpm (rounds per minute) and room temperature. After re-
moving the supernatant, the remaining tumor cell pellet was gently resuspended 
in cryo medium (90 % (DMEM + 20 % FCS), 10 % DMSO). One ml aliquots were 
transferred into cryotubes, which were packed in an isopropanol bath to be cooled 
Figure 9 Functionality of an improved Neubauer hemocytometer. (a) Schematics of the counting 
grid. (b) Calculation of cell concentration. 
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down slowly to -80 °C overnight. The next day, the frozen cryotubes were relo-
cated to a freezing cabinet with -145 °C. 
To recultivate the stocked tumor cells, the cryotubes were thawed in a water bath 
at 37 °C. In order to prevent DMSO from killing the tumor cells, the solution was 
diluted immediately in 5 ml growth medium and transferred into a 15 ml tube to 
be centrifuged as described above. The supernatant was removed and the cell 
pellet was gently resuspended in growth medium. The generated single cell sus-
pension ultimately was cultivated in a new tissue culture flask. On the following 
day, the medium was replaced with new growth medium to finally remove any 
remnants of DMSO. 
2.2.4 Virotherapeutic treatment 
2.2.4.1 (Mono-)virotherapy 
On the day of infection, previous to the actual virotherapeutic treatment, the GLV-
1h68 solution was prepared. Frozen virus solution was thawed carefully and soni-
cated for 30 s at 4°C. Depending on the needed virus dose (MOI, multiplicity of 
infection), the dispersed viral particles then were diluted in DMEM supplemented 
with 2 % FCS (infection medium).  
Figure 10 Setting (mono-)virotherapy. hpi, hours post infection. 
Schematics for 72 h incubation after infection published in (139).  
Approx. 24 hours after seeding, tumor cells were washed with warm PBS and 
250 µl infection medium, containing different MOIs of infectious GLV-1h68, were 
administered into each well (Figure 10). During the following hour, plates were 
swayed every 15 – 20 minutes to ensure that all tumor cells were exposed to the 
infectious viral particles and therefore had a chance of being infected successfully. 
At 1 hour post infection (hpi), the infection medium was replaced with 500 µl 
growth medium. Tumor cells were further incubated at 37 °C. At 72 and 96 hpi, 
Time after treatment (hours) 
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the remaining tumor cell mass after virotherapy was measured by SRB assay 
(see section 2.2.7.1, p. 48). 
2.2.4.2 Virus growth curves 
To assess the influence of the chemotherapeutics nab-paclitaxel and/or gemcita-
bine on the viral replication of GLV-1h68, virus growth curves were generated, 
comparing the viral replication of GLV-1h68 in cells that were treated with one, 
both or without the combination partners.  
Tumor cells were seeded in 24-well plates and, on the following day, infected with 
GLV-1h68 according to the normal virotherapy scheme (as described above in 
section 2.2.4.1, p. 42). The following treatment steps belong to the chemoviro-
therapeutic triple-therapy and are described more detailed in section 2.2.6.4. At 
1 hpi, the infection medium of the tumor cells which were treated with the combi-
nation therapy was replaced with nab-paclitaxel-containing growth medium. Half 
an hour later (1.5 hpi), gemcitabine-containing growth medium was added. If only 
nab-paclitaxel or gemcitabine was given, instead of the other agent normal 
growth medium was added. Tumor cells which were treated solely with GLV-1h68 
received MOCK treatment by replacing the infection medium with normal growth 
medium and later adding more growth medium. Tumor cells were further incu-
bated at 37 °C. 
Samples of 4 wells per treatment group were taken at different time points after 
the primary infection (1.5 hpi, 24 hpi, 48 hpi, 72 hpi, 96 hpi). First, the tumor cells 
were scraped from the bottom into the medium, after which the suspension was 
resuspended thoroughly. Then, the cell suspensions of each 4 wells were pooled 
in test tubes and frozen at -80 °C without adding anti-freezing agent. Thus, the 
tumor cells burst, releasing the intracellular GLV-1h68 particles. 
For the following virus titration a virus plaque assay was performed. CV-1 cells 
were seeded in 24-well plates and, by reaching 100 % confluence, infected with 
the collected virus samples. Therefore, the test tubes were thawed in a water 
bath at 37 °C and sonicated as described above (see section 2.2.4.1, p. 42). 
Thereafter, a 1:10 serial dilution of the virus samples (10-1 to 10-6) was generated 
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by adding 100 µl virus sample to 900 µl infection medium, subsequently transfer-
ring 100 µl of the resulting dilution to another 900 µl infection medium and repeat-
ing this transfer 4 more times. Each generated solution was vortexed thoroughly 
before the next degree of dilution was produced. Two wells of the seeded CV-1 
cells then were infected with 250 µl of the respective dilutions and incubated at 
37 °C. After swaying the plates every 20 minutes, at 1 hpi, each well was overlaid 
with 1 ml CMC solution. Finally, the plates were incubated for 2 days at 37 °C. 
To visualize the virus plaques, cells were stained by adding 250 µl crystal violet 
to each well. Subsequently, the plates were incubated for 4 hours at room tem-
perature, after which the supernatants were removed. Tumor cells were washed 
2 times with tap water and the plates were irradiated with UV-light for at least 15 
minutes. Stained virus plaques of each well were counted after which the corre-
sponding virus titers [PFU/ml, plaque forming units per ml] of each treatment 
group were calculated accurately in consideration of the particular dilution factors 
and the amount of infection medium administered in the plaque assay (Figure 11). 
2.2.5 Chemotherapeutic treatment 
2.2.5.1 Monochemotherapy 
Approx. 24 hours after tumor cell seeding, medium was removed and 500 µl 
growth medium containing different concentrations of the respective chemother-
apeutic agent were administered (Figure 12). Treatment with the light sensitive 
agent 5-FU was performed under dimmed light. Tumor cells were further incu-
bated at 37 °C. At 48 and 72 hours post treatment (hpt), the remaining tumor cell 
mass was measured by SRB assay (see section 2.2.7.1, p. 48). 
ݒ𝑖𝑟𝑎𝑙 ݐ𝑖ݐ݁𝑟 = ௠௘௔௡ ௩௔௟௨௘ ௢௙ ௧ℎ௘ ௗ௨௣௟𝑖௖௔௧௘௦଴.ଶହ ௠௟ ሺ𝑖௡௙௘௖௧𝑖௢௡ ௩௢௟௨௠௘ሻ  𝑥 ݀𝑖𝑙ݑݐ𝑖݋݊ ݂𝑎ܿݐ݋𝑟  
Figure 11 Virus plaque assay - Calculation of the virus titer. 
 
Time after treatment (hours) 
Figure 12 Setting chemotherapy. hpt, hours post treatment. 
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2.2.5.2 Dual chemotherapy 
Approx. 24 hours after tumor cell seeding, medium was removed and 500 µl 
growth medium containing different concentrations of combined nab-paclitaxel 
and gemcitabine were administered. The concentrations of both chemotherapeu-
tic agents were based on the respective treatment doses for combinatorial treat-
ment, resulting alone in a remaining tumor cell mass of ≈ 75 % at 72 hours post 
treatment (designated as a so-called 25 % lethal dose, ‘LD25 dose’). After 72 
hours of dual chemotherapy the remaining tumor cell mass was measured by 
SRB assay (see section 2.2.7.1, p. 48). 3 treatment groups with distinct dose 
variations were differentiated: 
1. Ratio of combined nab-paclitaxel and gemcitabine remained constant but two-
fold dilutions were generated (Table 2).  
2. Treatment doses of nab-paclitaxel remained constant at 50 % of the LD25 dose 
while the doses of gemcitabine were varied (Table 3).  
3. Treatment doses of gemcitabine remained constant at 50 % of the LD25 dose 
while the doses of nab-paclitaxel were varied (Table 4).  
Agents Doses 
nab-PTX LD25 
0.5 x 
LD25 
0.25 x 
LD25 
0.125 x 
LD25 
0.0625 x 
LD25 
0.03125 x 
LD 25 
0.015625 x 
LD25 
Gem LD25 
0.5 x 
LD25 
0.25 x 
LD25 
0.125 x 
LD25 
0.0625 x 
LD25 
0.03125 x 
LD 25 
0.015625 x 
LD25 
 
  
        
        
Table 2 Dual chemotherapy - Constant ratio of combined nab-paclitaxel + gemcitabine 
Abbreviations: Gem, gemcitabine; LD25, 25 % lethal dose; nab-PTX, nab-paclitaxel. 
 
Agents Doses 
nab-PTX 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x  
LD25 
Gem LD25 
0.75 x 
LD25 
0.5 x 
LD25 
0.25 x 
LD25 
0.1 x 
LD25 
0.075 x  
LD 25 
0.05 x 
LD25 
 
  
        
        
Table 3 Dual chemotherapy - Variation of the gemcitabine doses 
Abbreviations: Gem, gemcitabine; LD25, 25 % lethal dose; nab-PTX, nab-paclitaxel. 
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2.2.6 Chemovirotherapeutic treatment 
2.2.6.1 Chemotherapy 1 hour post infection 
Approx. 24 hours after seeding, tumor cells were infected with GLV-1h68 accord-
ing to the normal virotherapy scheme (specified in section 2.2.4.1, p. 42). At 1 hpi, 
the infection medium was replaced with 500 µl growth medium containing the 
LD25 dose of the respective chemotherapeutic agent given in combination (Fig-
ure 13). Tumor cells were further incubated at 37 °C. At 72 hpi, the remaining 
tumor cell mass after combinatorial treatment was measured by SRB assay (see 
section 2.2.7.1, p. 48).  
Figure 13 Setting chemovirotherapy 1 hpi (hour(s) post infection). 
Figure published in (139). 
 
2.2.6.2 Chemotherapy 24 hours post infection 
Approx. 24 hours after seeding, tumor cells were infected with GLV-1h68 accord-
ing to the normal virotherapy scheme (see section 2.2.4.1, p. 42). At 24 hpi, the 
normal growth medium was replaced with 500 µl growth medium which contained 
the LD25 dose of the respective chemotherapeutic agent given in combination 
(Figure 14). Tumor cells were further incubated at 37 °C. At 72 hpi, the remaining 
tumor cell mass after combinatorial treatment was measured by SRB assay (see 
section 2.2.7.1, p. 48). 
Time after treatment (hours) 
Agents Doses 
nab-PTX LD25 
0.75 x 
LD25 
0.5 x 
LD25 
0.25 x 
LD25 
0.1 x 
LD25 
0.075 x  
LD 25 
0.05 x 
LD25 
Gem 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x 
LD25 
0.5 x 
LD25 
 Abbreviations: Gem, gemcitabine; LD25, 25 % lethal dose; nab-PTX, nab-paclitaxel. 
Table 4 Dual chemotherapy - Variation of the nab-paclitaxel doses 
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Figure 14 Setting chemovirotherapy 24 hpi (hour(s) post infection). 
Figure published in (139). 
 
2.2.6.3 Chemotherapy 24 / 48 hours prior to infection 
Approx. 24 hours after tumor cell seeding, medium was replaced with 500 µl 
growth medium containing the LD25 dose of the respective chemotherapeutic 
agent given in combination (Figure 15). 24 or 48 hours later, the tumor cells were 
infected with GLV-1h68 according to the normal virotherapy scheme (see section 
2.2.4.1, p. 42) and further incubated at 37 °C. Because the tumor cells were 
seeded more than 24 hours prior to the virotherapeutic treatment, samples of 
each treatment group were counted before virotherapy in order to calculate the 
proper MOI. At 72 hpi, the remaining tumor cell mass after combinatorial treat-
ment was measured by SRB assay (see section 2.2.7.1, p. 48).  
2.2.6.4 Chemovirotherapeutic triple-therapy 
Approx. 24 hours after seeding, tumor cells were infected with GLV-1h68 accord-
ing to the normal virotherapy scheme (see section 2.2.4.1, p. 42). At 1 hpi, the 
infection medium was replaced with 490 µl nab-paclitaxel-containing growth me-
dium (Figure 16). Half an hour later (1.5 hpi), 10 µl gemcitabine-containing growth 
medium were added. The concentrations of nab-paclitaxel (in 490 µl growth me-
dium) and gemcitabine (in 10 µl growth medium) were calculated to result in the 
proper (for triple-therapy adjusted) LD25 doses of both agents in 500 µl growth 
medium. Tumor cells were further incubated at 37 °C. At 72 hpi, both remaining  
Time after treatment (hours) 
Figure 15 Settings chemovirotherapy -24 / -48 hpi (hour(s) post infection). (a) Setting chemovirotherapy -24 
hpi. (b) Setting chemovirotherapy -48 hpi. 
Time after treatment (hours) 
b 
Time after treatment (hours) 
a 
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Figure 16 Setting chemovirotherapeutic triple-therapy. 
hpi, hour(s) post infection. Figure published in (139). 
 
cell mass and cell viability after combinatorial treatment were measured by SRB, 
CellTiter-Blue® and MTT assays (see sections 2.2.7.1 - 2.2.7.3, p. 48 - 50), re-
spectively. 
2.2.7 Cell viability assays 
2.2.7.1 Sulforhodamine B Assay 
The sulforhodamine B (SRB) assay was the primary assay performed to quantify 
the remaining tumor cell mass after treatment in relation to the untreated control 
(MOCK). Basic principle of this colorimetric assay is the unspecific conjugation of 
SRB dye to protein components of cells, directly proportional to the cell mass 
(140). By solubilizing the protein-bound dye the resulting absorbance can be 
measured with a photospectrometer. 
First, tumor cells were seeded in 24-well plates. 24 hours later the respective 
chemo- and/or virotherapeutic treatment was performed. After a defined incuba-
tion time, depending on the respective treatment setting, tumor cells were washed 
with cold PBS and fixated by administrating 250 µl of cold 10 % TCA solution to 
each well. After 30 minutes incubation at + 4 °C, TCA was removed and cells 
were washed 3 times with tap water. In case of being treated with GLV-1h68, 
cells were additionally irradiated with UV-light for at least 15 minutes to ensure 
all infectious viral particles being inactivated. Finally, the plates were dried in a 
drying chamber at 40 °C.  
Cell protein staining was performed by adding SRB dye for 10 minutes. Excess 
dye then was washed out with 1 % acetic acid several times until all unbound dye 
was removed. Afterwards, the plates were dried another time.  
Time after treatment (hours) 
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To quantify the protein-bound dye per well, it was solubilized in 10 mM Tris base. 
Depending on the staining intensity 1-2 ml Tris base were administered. 160 µl 
solution of each well then were spread equally in 2 wells of a 96-well plate (pipet 
control, 2 x 80 µl). Thereafter, the optical density (OD) of the solutions was meas-
ured at a wave length of 550 nm using the GENios Plus Multifunction Fluores-
cence Microplate Reader (Tecan). If the OD values of the pipet control differed 
more than 0.1, the respective samples had to be transferred and analyzed again.  
Individual OD values of each treatment group were correlated with the mean 
value of the untreated control (MOCK), which was set at 100 % of remaining 
tumor cell mass.  
2.2.7.2 CellTiter-Blue® Assay 
The CellTiter-Blue® (CTB) assay, measuring the metabolic capacity of cells as 
indicator for cell viability, was performed to confirm the data obtained with the 
SRB assay, thereby validating the effectivity of antitumor treatment with the triple-
therapy. It is based on the potency of viable cells to reduce the dark-blue dye 
resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide), which possesses only lit-
tle intrinsic fluorescent activity, to the pink and highly fluorescent compound 
resorufin (7-Hydroxy-3H-phenoxazin-3-one). The resulting change of fluores-
cence and absorbance, directly proportional to the number of viable cells, can be 
measured with a fluorometer or photospectrometer respectively.  
Since seeding and treatment conditions of the tumor cells remained the same as 
for the SRB assay (specified in section 2.2.7.1, p. 48), the manufacturer’s protocol 
(141) had to be slightly adapted to 24-well plates. At 72 hpi, 100 µl medium of 
each well were replaced with the same amount of CTB Reagent. Tumor cells 
were further incubated at 37 °C for 1 up to 4 hours, the particular time period was 
empirically determined depending on the individual metabolic rate of each cell 
line. End-point fluorescence was quantified at an excitation wavelength of 550 
nm by measuring the resulting emission at 595 nm with the GENios Plus Multi-
function Fluorescence Microplate Reader (Tecan). 
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Individual fluorescence values of each treatment group were correlated with the 
mean value of the untreated control (MOCK), which was set at 100 % of cell 
viability.  
2.2.7.3 MTT Assay 
To verify the collected data of treating pancreatic adenocarcinoma cells with the 
triple-therapy, the MTT assay, another colorimetric assay measuring the meta-
bolic capacity of cells, was performed (142). Viable cells retain their potency to 
reduce the light sensitive tetrazolium dye MTT to the insoluble agent formazan, 
which accumulates as a precipitate inside the cells. By solubilizing the intracellu-
lar formazan the resulting absorbance, directly proportional to the number of via-
ble cells, can be measured with a photospectrometer.  
Seeding and treatment conditions of the tumor cells remained the same as for 
the SRB assay (specified in section 2.2.7.1, p. 48). At 72 hpi, the tumor cells were 
washed with 500 µl warm PBS, after which 250 µl MTT dye were added to each 
well under dimmed light. In succession, the plates were incubated for 2 hours at 
37 °C.  
To quantify the metabolized MTT, the excess dye then was replaced with 1 ml 
solubilization/stop solution (10 % HCl in isopropanol). The plates were swayed 
another 10 minutes, resulting in a yellow dilution of solubilized formazan. 200 µl 
of each well were transferred to a 96-well plate and their OD values were meas-
ured at the wave length of 570 nm using the Synergy HT Multi-Mode Microplate 
Reader (BioTek). 
Individual OD values of each treatment group were correlated with the mean 
value of the untreated control (MOCK), which was set at 100 % of cell viability.  
2.2.8 Software 
The GENios Plus Multifunction Fluorescence Microplate Reader (Tecan) and the 
Synergy HT Multi-Mode Microplate Reader (BioTek) were run with the XFluor4 
and Gen5 software, respectively. Microscopic images were taken with analySIS 
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V3.2 (Soft Imaging System). Basic calculations were executed with Microsoft Ex-
cel 2013. Visualization and further statistical evaluation of the data were per-
formed with GraphPad Prism V6 (GraphPad Software). 
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3 Results 
In order to establish a novel chemovirotherapeutic combination therapy poten-
tially improving the treatment outcome of pancreatic adenocarcinoma, a combi-
natorial treatment of 4 established and well-characterized pancreatic adenocar-
cinoma cells lines with the genetically modified vaccinia virus GLV-1h68 and var-
ious chemotherapeutic agents was investigated in vitro.  
Preliminary to the actual chemovirotherapy, the treatment doses of the individual 
chemo- and virotherapeutic agents had to be determined under monotherapeutic 
conditions in a case-by-case approach. For this purpose, pancreatic adenocarci-
noma cells were treated first with ascending concentrations of each agent in mon-
otherapy (shown in section 3.1). After analyzing the cytotoxic effect of the individ-
ual mono(viro-/chemo-)therapies, ‘adjusted’ doses of each and every single 
agent were determined for subsequent combination therapy approaches. Here, 
the proper concentration of each combination partner when used alone (i.e., un-
der monotherapeutic conditions) should result in a remaining tumor cell mass of 
≈ 75 % after 72 hours of treatment (designated as a so-called 25 % lethal dose, 
‘LD25 dose’). Higher cytotoxicity might disguise any additional effect otherwise 
seen after combinatorial treatment when cytotoxicities would sum up too close to 
100 % of tumor cell destruction thereby hindering any read-out of putative com-
binatorial effects. 
Secondly, the actual chemovirotherapy, combining the vaccinia virus GLV-1h68 
with each of the chosen chemotherapeutic agents separately, was performed and 
its cytotoxicity analyzed (shown in section 3.2). Since in combination therapy all 
combination partners interact with each other, the concentrations of the single 
agents are not the only important factor determining the best possible treatment 
outcome. Hence, the influence of different application sequences (i.e., the order 
of which compound was given first, followed by a defined schedule of the other 
combinatorial partners) was the main focus of these experiments. 
Thirdly, based on the already collected data, pancreatic adenocarcinoma cells 
were treated with the chemovirotherapeutic triple-therapy, a combination of the 
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vaccinia virus GLV-1h68 with the approved dual chemotherapy nab-paclitaxel + 
gemcitabine (shown in section 3.3). After analyzing its cytotoxic effect, the influ-
ence of the dual chemotherapy and the respective chemotherapeutic agents on 
viral gene expression and replication of GLV-1h68 was investigated with the vis-
ualization of viral GFP expression and generation of virus growth curves, respec-
tively. 
3.1 Mono(viro-/chemo-)therapy – Dose-finding for combination therapy 
3.1.1 Virotherapy with the oncolytic vaccinia virus GLV-1h68 
To determine proper doses of GLV-1h68 for chemovirotherapy, as well as to an-
alyze their susceptibility to viral infection and oncolysis, each of the 4 pancreatic 
adenocarcinoma cell lines was infected with individually ascending virus concen-
trations. The MOI (multiplicity of infection) thereby represents the ratio of infec-
tious virus particles per tumor cell (a MOI of 0.1 accordingly describes a propor 
Figure 17 Virotherapy with ascending doses of GLV-1h68 in four different human pancreatic tumor cell 
lines for 72 h (depicted in black bars) or 96 h (depicted in orange bars) in vitro. Tumor cells were first 
infected with the oncolytic vaccinia virus GLV-1h68. One hour post infection (hpi) the inoculum was re-
moved and normal growth medium was added. Remaining tumor cell mass was analyzed by sulforho-
damine B (SRB) assay (n ≥ 3, mean and standard deviation are shown). MOCK, untreated control. MOI, 
multiplicity of infection. Figure of 72 hpi values published in (139). 
 
MOI 
BxPc-3 
MOI 
MIA PaCa-2 
MOI 
AsPc-1 Panc-1 
MOI 
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tion of 1 infectious virus particle per 10 tumor cells). Tumor cells were further 
incubated for 72 or 96 hours, after which the remaining cell masses were ana-
lyzed by SRB assay (Figure 17). Additionally, dose-dependent GFP expression 
was visualized in Panc-1 cells (Figure 18). 
It could be shown that the 4 tumor cell lines varied considerably in their response 
to the virotherapeutic treatment with the oncolytic vaccinia virus GLV-1h68. 
Though GLV-1h68 demonstrated a dose-dependent oncolytic effect in all 4 tumor 
cell lines, proving the feasibility of virotherapy in general, the viral doses of GLV-
1h68 needed for potent tumor cell killing differed greatly. Compared to the un-
treated control (MOCK), especially the tumor cell line BxPc-3 showed an en-
hanced response to lower concentrations of GLV-1h68. Moreover, comparing the 
remaining cell masses at 72 and 96 hours post infection (hpi), a longer incubation 
time with GLV-1h68 after primary infection also resulted in an enhanced tumor 
cell killing. In conclusion, the therapeutic response to virotherapeutic treatment 
with GLV-1h68 not only depended on the administered virus dose, but also on 
the treated tumor cell line and the duration of virotherapy.  
Based on the remaining cell masses at 72 hpi, the following MOIs of GLV-1h68 
were selected for chemovirotherapeutic treatment in the particular tumor cell lines 
(Table 5). 
The dose-dependent character of viral infection was similarly illustrated by visu-
alization of viral GFP expression in Panc-1 cells (Figure 18). At the lowest MOI 
of 0.01 only single cell clusters showed signs of viral infection. With ascending 
Tumor cell lines Partial doses 
AsPc-1 MOI 0.1 
BxPc-3 MOI 0.01 
MIA PaCa-2 MOI 0.5 
Panc-1 MOI 0.1 
 
  
  
  
  
  
Table 5 Partial (‘adjusted’) doses of GLV-
1h68 chosen for chemovirotherapy 
Abbreviations: MOI, multiplicity of infection. 
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phase contrast 
 phase contrast GFP  GFP overlay  overlay MOCK 
 
MOCK MOI 0.01 
 
MOI 0.01 MOI 0.05 
 
MOI 0.05 MOI 0.1 
 
MOI 0.1 MOI 0.5 
 
MOI 0.5 MOI 1 
Figure 18 Visualization of GLV-1h68 infection in Panc-1 cells at 72 hpi. Tumor cells were infected with 
ascending doses (MOIs) of GLV-1h68. At 1 hpi, the medium was changed. Expression of green fluores-
cent protein (GFP) indicating viral infection (central panels), corresponding phase contrast pictures (left 
panels) and the respective overlay images (right panels) are shown (scale 1:200). hpi, hour(s) post infec-
tion. MOCK, untreated control. MOI, multiplicity of infection. 
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MOIs, i.e. rising ratios of infectious virus particles per tumor cell, also fluores-
cence levels increased until at the highest MOI of 1 nearly all tumor cells were 
stained by viral GFP expression. These findings were paralleled by a visible de-
crease of the number of tumor cells being remnant at 72 hpi in the phase contrast 
images which additionally demonstrated the character of virus-mediated oncoly-
sis. Viral infection spreading from the primary infection site to neighboring tumor 
cells was followed by likewise outwards spreading oncolysis, leaving tumor-free 
gaps in the cell layer. Accordingly, the seemingly low GFP signal at the MOI of 
0.1 originated from the initial oncolytic effect of GLV-1h68. 
3.1.2 Chemotherapy with the nucleoside analogue 5-fluorouracil (5-FU) 
In order to find a suitable combination partner for GLV-1h68 and to determine its 
proper concentration for chemovirotherapy, pancreatic adenocarcinoma cell lines 
were treated with different chemotherapeutic agents.  
The first agent applied in (mono-)chemotherapy was the nucleoside analogue 5-
fluorouracil (5-FU). In doing so, all 4 pancreatic adenocarcinoma cell lines were 
BxPc-3 
mM 5-FU 
MIA PaCa-2 
mM 5-FU 
mM 5-FU 
AsPc-1 Panc-1 
mM 5-FU 
Figure 19 Chemotherapy with ascending concentrations of the nucleoside analogue 5-fluorouracil (5-
FU) in four different human pancreatic tumor cell lines for 48 h (depicted as black line) or 72 h (depicted 
as blue line) in vitro. Remaining tumor cell mass was analyzed by sulforhodamine B (SRB) assay (n=2, 
mean and standard deviation are shown). hpt, hour(s) post treatment. 
Ch. 3 Results Dissertation Eike Hendrik Binz 
57 
 
treated with ascending concentrations of 5-FU (0.001, 0.01, 0.1, 1 and 10 mM). 
Tumor cells were further incubated for 48 or 72 hours, after which the remaining 
cell masses were analyzed by SRB assay (Figure 19). 
All 4 tumor cell lines responded to the chemotherapy with 5-FU in a dose-de-
pendent fashion while, likewise, indications for different levels of resistance to the 
cytotoxic agent could be observed. At 48 hpt, BxPc-3 and MIA PaCa-2 cells were 
the first showing any considerable response to 5-FU at concentrations of 0.01 
mM and higher. The tumor cell killing seen in the other 2 cell lines (AsPc-1 and 
Panc-1) remained poor even when higher doses of 5-FU were administered. 
When treated for 72 hours 3 of the 4 tumor cell lines (AsPc-1, BxPc-3 and Panc-1) 
demonstrated a considerably enhanced tumor cell killing at the whole range of 
concentrations. MIA PaCA-2 cells, however, didn’t seem to benefit greatly from a 
longer incubation time with 5-FU, being indicated by the lesser gain of cytotoxicity 
at 72 hpt versus 48 hpt. 
Based on the remaining cell masses at 72 hpt, these findings resulted in the se-
lection of the following concentrations of 5-FU for chemovirotherapeutic treatment 
in the particular tumor cell lines (Table 6).  
 
3.1.3 Chemotherapy with the nucleoside analogue gemcitabine 
The second chemotherapeutic agent applied in (mono-)chemotherapy was gem-
citabine, another nucleoside analogue. Thereby, all 4 pancreatic adenocarci-
noma cell lines were treated with ascending concentrations of gemcitabine (0.01, 
0.1, 1, 10 and 100 µM). Tumor cells were further incubated for 48 or 72 hours, 
after which the remaining cell masses were analyzed by SRB assay (Figure 20). 
Tumor cell lines Partial doses 
AsPc-1 1 x 10-2 mM 
BxPc-3 1 x 10-3 mM 
MIA PaCa-2 1 x 10-2 mM 
Panc-1 5 x 10-3 mM 
  
  
  
  
  
Table 6 Partial (‘adjusted’) doses of 5-fluoro-
uracil chosen for chemovirotherapy 
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Figure 20 Chemotherapy with ascending concentrations of the nucleoside analogue gemcitabine in four 
different human pancreatic tumor cell lines for 48 h (depicted as black line) or 72 h (depicted as blue line) 
in vitro. Remaining tumor cell mass was analyzed by sulforhodamine B (SRB) assay (n=3, mean and 
standard deviation are shown). hpt, hour(s) post treatment. Figure of 72 hpt values published in (139). 
 
As a result, all 4 tumor cell lines responded poorly to the chemotherapy with gem-
citabine, indicating resistance to this cytotoxic agent. While in comparison with 
the other 2 tumor cell lines BxPc-3 and MIA PaCa-2 cells already responded to 
lower doses of gemcitabine, the observed tumor cell killing in these cell lines 
seemed to persist when higher doses were administered, a dose increase of 
gemcitabine resulting in no or only a moderate increase of cytotoxicity. However, 
when comparing the remaining cell masses at 48 and 72 hpt an enhanced tumor 
Table 7 Partial (‘adjusted’) doses of gemcita-
bine chosen for chemovirotherapy 
Tumor cell lines Partial doses 
AsPc-1 1 x 10-1 µM 
BxPc-3 2 x 10-2 µM 
MIA PaCa-2 3 x 10-2 µM 
Panc-1 7.5 x 10-2 µM 
 
µM gemcitabine 
BxPc-3 
µM gemcitabine 
MIA PaCa-2 
AsPc-1 
µM gemcitabine µM gemcitabine 
Panc-1 
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cell killing after prolongation of the chemotherapy could be seen in all 4 tumor cell 
lines. 
Based on the remaining cell masses at 72 hpt, these findings resulted in the se-
lection of the following concentrations of gemcitabine for chemovirotherapeutic 
treatment in the particular tumor cell lines (Table 7). 
3.1.4 Chemotherapy with the mitotic inhibitor nab-paclitaxel 
The next chemotherapeutic agent applied in (mono-)chemotherapy was the mi-
totic inhibitor nab-paclitaxel, clinically approved for the treatment of advanced 
pancreatic adenocarcinoma only in combination with gemcitabine. Following the 
scheme of the previously performed experiments, all 4 pancreatic adenocarci-
noma cell lines were treated with ascending concentrations of nab-paclitaxel. Due 
to the lesser experience with this relatively new agent a greater range of concen-
trations (0.0001, 0.001, 0.01, 0.1, 1, 10 and 100 µM) was surveyed. Tumor cells 
were further incubated for 48 or 72 hours, after which the remaining tumor cell 
masses were analyzed by SRB assay (Figure 21). 
Figure 21 Chemotherapy with ascending concentrations of the mitotic inhibitor nab-paclitaxel in four 
different human pancreatic tumor cell lines for 48 h (depicted as black line) or 72 h (depicted as blue line) 
in vitro. Remaining tumor cell mass was analyzed by sulforhodamine B (SRB) assay (n ≥ 3, mean and 
standard deviation are shown). hpt, hour(s) post treatment. Figure of 72 hpt values published in (139). 
µM nab-paclitaxel 
BxPc-3 
µM nab-paclitaxel 
MIA PaCa-2 
µM nab-paclitaxel 
AsPc-1 
µM nab-paclitaxel 
Panc-1 
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All 4 tumor cell lines responded similarly to the chemotherapy with nab-paclitaxel. 
0.01 µM nab-paclitaxel thereby seemed to be a critical concentration at which all 
4 tumor cell lines first showed a considerable response to the chemotherapeutic 
agent. Yet, when higher doses than 0.1 µM nab-paclitaxel were applied, most 
notably in AsPc-1 and Panc-1 cells, no further reduction of tumor cell mass was 
seen, an effect only overcome after administration of 100 µM nab-paclitaxel, the 
highest concentration administered in this setting. This condition was apparent 
independently of the duration of treatment, although in all 4 tumor cell lines a 
longer treatment with nab-paclitaxel also resulted in a slightly enhanced tumor 
cell killing. 
Based on the remaining cell masses at 72 hpt, these findings resulted in the se-
lection of the following concentrations of nab-paclitaxel for chemovirotherapeutic 
treatment in the particular tumor cell lines (Table 8). 
 
3.1.5 Chemotherapy with the platinum compound oxaliplatin 
Other chemotherapeutic agents, usually not part of monochemotherapeutic first-
line protocols in the treatment of advanced pancreatic adenocarcinoma, were 
surveyed in the preliminary testing phase as well. After nab-paclitaxel the second 
of this group of chemotherapeutic agents was the platinum compound oxaliplatin, 
clinically used only as part of the FOLFIRINOX regimen (folinic acid (leucovorin) 
+ 5-fluorouracil + irinotecan + oxaliplatin) (first-line) or in combination with gem-
citabine (second-line). Pursuing the schematics of the already performed 
(mono-)chemotherapies all 4 pancreatic adenocarcinoma cell lines were treated 
with ascending concentrations of oxaliplatin (0.01, 0.1, 1, 10 and 100 µM). Tumor 
Tumor cell lines Partial doses 
AsPc-1 1 x 10-2 µM 
BxPc-3 1 x 10-2 µM 
MIA PaCa-2 5 x 10-3 µM 
Panc-1 5 x 10-3 µM 
  
  
  
  
  
Table 8 Partial (‘adjusted’) doses of nab-pacli-
taxel chosen for chemovirotherapy 
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cells were further incubated for 48 or 72 hours, after which the remaining cell 
masses were analyzed by SRB assay (Figure 22).  
As can be seen, all 4 tumor cell lines showed only poor response rates to the 
chemotherapy with oxaliplatin at the applied range of concentrations. 
MIA PaCa-2 cells, in comparison with the other 3 tumor cell lines, indeed re-
sponded best, but considerable tumor cell killing was seen only at concentrations 
of 10 µM oxaliplatin and higher. However, in none of the 4 tumor cell lines a sub-
stantial difference between the treatment outcomes after 48 or 72 hours chemo-
therapy could be seen. These findings clearly indicate resistance to oxaliplatin, 
all 4 tumor cell lines responding only after high concentrations of the chemother-
apeutic agent were administered, finally overcoming cellular resistance mecha-
nisms. 
Based on the remaining cell masses at 72 hpt, these findings resulted in the se-
lection of the following concentrations of oxaliplatin for chemovirotherapeutic 
treatment in the particular tumor cell lines (Table 9): 
BxPc-3 
µM oxaliplatin 
MIA PaCa-2 
µM oxaliplatin 
AsPc-1 Panc-1 
µM oxaliplatin µM oxaliplatin 
Figure 22 Chemotherapy with ascending concentrations of the platinum compound oxaliplatin in four 
different human pancreatic tumor cell lines for 48 h (depicted as black line) or 72 h (depicted as blue 
line) in vitro. Remaining tumor cell mass was analyzed by sulforhodamine B (SRB) assay (n ≥ 1, mean 
and standard deviation are shown). hpt, hour(s) post treatment. 
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3.1.6 Chemotherapy with the topoisomerase I inhibitor irinotecan 
Another chemotherapeutic agent usually not applied in monochemotherapy for 
the treatment of advanced pancreatic adenocarcinoma is the topoisomerase I 
inhibitor irinotecan, representing another component of the FOLFIRINOX regi-
men (folinic acid (leucovorin) + 5-fluorouracil + irinotecan + oxaliplatin). Thereby, 
all 4 pancreatic adenocarcinoma cell lines were treated with ascending concen-
trations of irinotecan (0.01, 0.1, 1, 10 and 100 µM). Tumor cells were further in-
cubated for 48 or 72 hours, after which the remaining cell masses were analyzed 
by SRB assay (Figure 23). 
At the applied range of concentrations, all 4 tumor cell lines demonstrated an 
overall poor response to chemotherapy with irinotecan. Mirroring the results seen 
after chemotherapy with oxaliplatin, in comparison with the other 3 tumor cell lines, 
MIA PaCa-2 cells responded best, but only when concentrations of 10 µM iri-
notecan and higher were administered. Furthermore, comparing the remaining 
cell masses at 48 and 72 hpt, a prolongation of treatment for 24 hours also led to 
a slightly enhanced tumor cell killing, but only at higher concentrations trespass-
ing a critical concentration at which an initial response was seen already after 48 
hours of treatment. 
Based on the fact that irinotecan in the clinic is usually applied only in combination 
with several other chemotherapeutic agents, chemovirotherapeutic protocols in-
corporating irinotecan were not further developed during this investigation. The 
obtained results, however, can be seen as a basis for possible combination reg-
imens in the future. 
Table 9 Partial (‘adjusted’) doses of oxali-
platin chosen for chemovirotherapy 
Tumor cell lines Partial doses 
AsPc-1 1 x 10-2 µM 
BxPc-3 1 x 10-2 µM 
MIA PaCa-2 5 x 10-3 µM 
Panc-1 1 x 10-3 µM 
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3.1.7 Tyrosine kinase inhibitor therapy with EGFR targeting erlotinib 
The last agent surveyed in (mono-)chemotherapy as possible combination part-
ner for GLV-1h168 was the tyrosine kinase inhibitor erlotinib, clinically approved 
for the treatment of advanced pancreatic adenocarcinoma only in combination 
with gemcitabine. As performed in the previous experiments, all 4 pancreatic ad-
enocarcinoma cell lines were treated with ascending concentrations of erlotinib 
(0.01, 0.1, 1, 10 and 100 µM). Tumor cells were further incubated for 48 or 72 
hours, after which the remaining tumor cell masses were analyzed by SRB assay 
(Figure 24).  
As could be shown, all 4 tumor cell lines responded poorly to the tyrosine kinase 
inhibitor therapy with erlotinib, though to a varying extent. While AsPc-1 and 
BxPc-3 cells responded to dose increases of erlotinib with an enhanced tumor 
cell killing at the whole range of concentrations, Panc-1 cells showed only a very 
µM irinotecan µM irinotecan 
µM irinotecan µM irinotecan 
BxPc-3 MIA PaCa-2 
Panc-1 AsPc-1 
Figure 23 Chemotherapy with ascending concentrations of the topoisomerase I inhibitor irinotecan in 
four different human pancreatic tumor cell lines for 48 h (depicted as black line) or 72 h (depicted as 
blue line) in vitro. Remaining tumor cell mass was analyzed by sulforhodamine B (SRB) assay (n ≥ 1, 
mean and standard deviation are shown). hpt, hour(s) post treatment. 
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moderate response even at the highest concentrations administered in this set-
ting. MIA PaCa-2 cells only responded to concentrations of 10 µM erlotinib and 
higher. Comparing the remaining cell masses after 48 and 72 hours of tyrosine 
kinase inhibitor therapy, the better responding cell lines AsPc-1 and BxPc-2 
showed at least a moderately increased tumor cell killing, whereas MIA PaCa-2 
and Panc-1 cells didn’t seem to respond better after a prolongation of treatment 
for 24 hours at all. 
Due to the fact that erlotinib is only approved in combination with gemcitabine for 
the treatment of advanced pancreatic adenocarcinoma and only in case the pa-
tients show an initial dermatologic response to the combination therapy, no che-
movirotherapeutic protocol imbedding erlotinib was developed during this inves-
tigation. Similar to the results obtained after chemotherapy with irinotecan, these 
data can be seen as a basis for possible combination regimens in the future. 
  
BxPc-3 
µM erlotinib 
AsPc-1 
µM erlotinib 
MIA PaCa-2 
µM erlotinib 
µM erlotinib 
Panc-1 
Figure 24 Therapy with ascending concentrations of the tyrosine kinase inhibitor erlotinib in four differ-
ent human pancreatic tumor cell lines for 48 h (depicted as black line) or 72 h (depicted as blue line) in 
vitro. Remaining tumor cell mass was analyzed by sulforhodamine B (SRB) assay (n ≥ 1, mean and 
standard deviation are shown). hpt, hour(s) post treatment 
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3.2 Chemovirotherapy – Finding the right combinatorial sequence  
3.2.1 Combination of GLV-1h68 with 5-fluorouracil (5-FU) 
After performing the initial monotherapies and selecting suitable partial ‘adjusted’ 
doses of each agent, the first devised chemovirotherapeutic protocol was the 
combination of GLV-1h68 with the nucleoside analogue 5-FU. 
Not knowing in which way the two agents would interact and in consideration that 
the most feasible administration sequence would be a concomitant application of 
both agents, 5-FU was administered directly after primary infection with GLV-
1h68 at 1 hpi. Both agents were thereby applied in their particular LD25 doses 
(see above). Tumor cells were further incubated until, at 72 hpi, the cytotoxicity 
of the chemovirotherapy was analyzed by SRB assay (Figure 25). 
Figure 25 Chemovirotherapy with GLV-1h68 and 5-fluorouracil (5-FU) in four different human pancre-
atic tumor cell lines in vitro. 5-FU was added after infection with GLV-1h68 at 1 hpi. Remaining tumor 
cell mass was analyzed at 72 hpi by sulforhodamine B (SRB) assay (n=1, mean and standard devia-
tion are shown). hpi, hour(s) post infection. MOCK, untreated control. MOI, multiplicity of infection. 
MIA PaCa-2 
AsPc-1 Panc-1 
BxPc-3 
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To assess the results in the correct manner, by looking at the remaining cell 
masses of both monotherapies it has to be reviewed first if suitable partial doses 
of each agent were chosen. Secondly, to determine if and to which extent an 
enhanced or reduced cytotoxic effect of the chemovirotherapeutic protocol can 
be seen, the remaining cell mass after chemovirotherapeutic treatment has to be 
compared to both of the respective monotherapies separately.  
In doing so, all 4 tumor cell lines responded to both monotherapeutic treatments 
within the acceptable limits of variation from the target value of 75 % remaining 
cell mass after 72 hours of treatment (Figure 25), confirming the previously col-
lected data. However, no substantial difference of cytotoxicity between the che-
movirotherapeutic combination protocol and the respective monotherapies could 
be seen in neither of the 4 tumor cell lines. Tumor cell loss after combination 
therapy within a tumor cell line corresponded at least with the outcome seen after 
single viro- or chemotherapy, initially excluding any potential antagonistic effects. 
3.2.2 Combination of GLV-1h68 with gemcitabine 
To analyze whether the missing additional effect of the previously investigated 
chemovirotherapeutic protocol with 5-FU was linked to its properties as nucleo-
side analogue, GLV-1h68 was combined next with gemcitabine, a different nu-
cleoside analogue of the here screened array of chemotherapeutic agents.  
Going beyond the previous administration setting, additionally, the chronological 
order of the single agents was varied. Gemcitabine not only was administered 
concomitantly (1 hpi), but also 24 hours after (24 hpi) or even 48 hours prior (-48 
hpi) to virotherapeutic treatment with GLV-1h68. Independently of the particular 
administration sequence and the resulting differences in the duration of treatment 
the remaining cell masses were analyzed at 72 hpi by SRB assay (Figure 26).  
When evaluating the results of tumor cell loss with regard to the three different 
administration sequences, additionally to the prior mentioned criteria other varia-
bles have to be considered as well. Although the duration of virotherapy within 
each setting always was the same (72 h), the duration of chemotherapy (CTX)   
varied from 48 (CTX 24 and -48 hpi) to 71 hours (CTX 1 hpi). Moreover, when  
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Figure 26 Chemovirotherapy with GLV-1h68 and gemcitabine (Gem) in four different human pancreatic 
tumor cell lines in vitro. Gem was added either after infection with GLV-1h68 at 1 hpi (depicted in black 
bars) and 24 hpi (depicted in orange bars) or prior to infection at -48 hpi (depicted in green bars). Re-
maining tumor cell mass was analyzed at 72 hpi by sulforhodamine B (SRB) assay (n=1, mean and 
standard deviation are shown). hpi, hour(s) post infection. MOCK, untreated control. MOI, multiplicity of 
infection. Figure of Gem (1 hpi) and Gem (-48 hpi) values published in (139). 
 
the chemotherapeutic agent was administered prior to the virotherapeutic treat-
ment (CTX -48 hpi), after viral infection the tumor cells were incubated for another 
72 hours without addition of any chemotherapeutic agent. Thus, with reference 
to the different durations of treatment, the remaining cell masses after chemo-
therapy within a single tumor cell line have to be correlated with each other. More-
over, and more importantly, when considering the effectivity of chemovirothera-
peutic treatment, not only within a single tumor cell line but also in comparison 
with the others, it has to be checked whether a pattern can be identified in which 
a particular application setting results in an enhanced cytotoxic effect in all or at 
least the majority of treated tumor cell lines.  
Looking at the loss of the tumor cell mass after 71 hours of chemotherapy with 
gemcitabine (Gem 1 hpi) suitable concentrations of gemcitabine were chosen 
BxPc-3 MIA PaCa-2 
AsPc-1 Panc-1 
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(Figure 26). As expected, when compared with the remaining cell masses after 
only 48 hours incubation with gemcitabine (Gem 24 hpi) all 4 tumor cell lines 
responded more strongly to the longer lasting chemotherapy. Interestingly, when 
treated first with gemcitabine (Gem -48 hpi), the initial response of AsPc-1 and 
Panc-1 cells to the monochemotherapy seemed to outweigh the longer incuba-
tion time without gemcitabine. Whether gemcitabine additionally might have in-
duced a persisting growth inhibition couldn’t be determined on the basis of these 
data. In the end, no antagonistic effects of the combination could be seen in nei-
ther of the 4 tumor cell lines but when compared to both respective monothera-
pies no combination protocol led to a considerably enhanced cytotoxic effect nei-
ther. 
3.2.3 Combination of GLV-1h68 with oxaliplatin 
Since chemovirotherapy with nucleoside analogues didn’t result in any notewor-
thy increase of cytotoxicity in the 4 pancreatic adenocarcinoma cell lines, the next 
investigated chemovirotherapeutic protocol should incorporate a chemothera-
peutic agent with a different mode of action. Accordingly, GLV-1h68 was com-
bined with the platinum compound oxaliplatin. Thereby, the administration se-
quence of both agents remained the same. Oxaliplatin was administered either 
concomitantly (1 hpi), 24 hours after (24 hpi) or 48 hours prior (-48 hpi) to primary 
infection with GLV-1h68. At 72 hpi, the remaining cell masses were analyzed by 
SRB assay (Figure 27). 
While in AsPc-1 cells the chemovirotherapeutic treatment with GLV-1h68 and ox-
aliplatin led to a clear increase of cytotoxicity independently of the chronological 
order of the agents, in the other 3 tumor cell lines (BxPc-3, MIA PaCa-2 and 
Panc-1) this effect could only be seen in a few settings and then only to a lesser 
extent. In BxPc-3 cells the response after chemovirotherapy invariably was the 
same as after monochemotherapy with oxaliplatin alone, whereas MIA PaCa-2 
and Panc-1 cells somewhat responded better to the combination when oxaliplatin 
was given 24 hours after infection with GLV-1h68 (Ox 24 hpi). Looking at the 
remaining cell masses of the 71-hour monochemotherapy with oxaliplatin (Ox 1 
hpi) in all 4 tumor cell lines proper concentrations of the chemotherapeutic agent 
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were chosen. Furthermore, when oxaliplatin was applied prior to the virothera-
peutic treatment (Ox -48 hpi) all 4 tumor cell lines, but especially BxPc-3 and 
Panc-1 cells, demonstrated signs of a notable initial tumor cell killing in the mono-
chemotherapeutic treatment arm.  
3.2.4 Combination of GLV-1h68 with nab-paclitaxel 
Encouraged by the results seen after chemovirotherapy with oxaliplatin, another 
chemotherapeutic protocol imbedding the mitotic inhibitor nab-paclitaxel was de-
signed. Moreover, based on published data from Huang et al. (143), in which a 
derivative of the Western Reserve strain of vaccinia virus was combined success-
fully with paclitaxel in vitro, the parameters of the administration sequence were 
altered slightly. Nab-paclitaxel was added either concomitantly (1 hpi), 24 hours 
Figure 27 Chemovirotherapy with GLV-1h68 and oxaliplatin (Ox) in four different human pancreatic tumor 
cell lines in vitro. Ox was added either after infection with GLV-1h68 at 1 hpi (depicted in black bars) and 
24 hpi (depicted in orange bars) or prior to infection at -48 hpi (depicted in green bars). Remaining tumor 
cell mass was analyzed at 72 hpi by sulforhodamine B (SRB) assay (n=3, mean and standard deviation 
are shown). hpi, hour(s) post infection. MOCK, untreated control. MOI, multiplicity of infection. 
 
BxPc-3 MIA PaCa-2 
AsPc-1 Panc-1 
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after (24 hpi) or prior (-24 hpi) to the virotherapeutic treatment. As before, inde-
pendently of the individual duration of treatment, the remaining cell masses were 
analyzed at 72 hpi by SRB assay (Figure 28). 
Figure 28 Chemovirotherapy with GLV-1h68 and nab-paclitaxel (nab-PTX) in four different human pan-
creatic tumor cell lines in vitro. Nab-PTX was added either after infection with GLV-1h68 at 1 hpi (depicted 
in black bars) and 24 hpi (depicted in orange bars) or prior to infection at -24 hpi (depicted in green bars). 
Remaining tumor cell mass was analyzed at 72 hpi by sulforhodamine B (SRB) assay (n=3, mean and 
standard deviation are shown). hpi, hour(s) post infection. MOCK, untreated control. MOI, multiplicity of 
infection. Figure of nab-PTX (1 hpi) and nab-PTX (24 hpi) values published in (139). 
 
In contrast to the previously obtained results, the chemovirotherapeutic combina-
tion of GLV-1h68 with nab-paclitaxel led to a slightly increased tumor cell loss in 
the majority of different combination protocols. However, in MIA PaCa-2 cells an 
antagonistic effect of the combination therapy could be seen when nab-paclitaxel 
was administered 24 hours prior to the virotherapeutic treatment (nab-PTX -24 
hpi). In 3 out of 4 tumor cell lines (AsPc-1, MIA PaCa-2 and Panc-1) proper con-
centrations of nab-paclitaxel were chosen, whereas in BxPc-3 cells the mono-
chemotherapy alone lead to a remaining tumor cell mass below 50%. As seen 
BxPc-3 MIA-PaCa-2 
AsPc-1 Panc-1 
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before, all 4 tumor cell lines responded better to the 24-hour-longer chemother-
apy with nab-paclitaxel while in the monochemotherapeutic pretreatment arm 
(nab-PTX -24 hpi) the observed reductions of tumor cell masses were the result 
of the initial chemotherapy.  
Nonetheless, the increase of therapeutic efficacy seen in AsPc-1 cells was inde-
pendent of the chronological order of the agents. In the other 3 tumor cell lines 
(BxPc-3, MIA PaCa-2 and Panc1) this response was inconsistent across the dif-
ferent settings of administration and then could be seen only to a lesser extent. 
Therefore, no pattern evolved in which a single chemovirotherapeutic protocol 
led to a superior tumor cell loss in all 4 tumor cell lines when compared with the 
respective monotherapies. 
3.3 Chemovirotherapeutic triple-therapy 
Although the most promising results were seen in the chemovirotherapeutic com-
bination of GLV-1h68 with nab-paclitaxel, for the treatment of pancreatic adeno-
carcinoma this chemotherapeutic agent isn’t approved in monotherapy. Ideally, if 
inhibitory effects of GLV-1h68 on its combination partner could be excluded, GLV-
1h68 should be given as add-on to established treatment protocols which already 
have proven their therapeutic value in clinical studies by improving the therapeu-
tic outcome and prolonging patient survival. This consideration resulted in the 
final design of a chemovirotherapeutic protocol incorporating the vaccinia virus 
GLV-1h68 in combination with the approved dual chemotherapy nab-paclitaxel + 
gemcitabine. 
3.3.1 Dual chemotherapy with nab-paclitaxel and gemcitabine 
Given that the former LD25 doses of the chemotherapeutic agents were deter-
mined by their tumor cell killing after monotherapy, previously to the actual triple-
therapy the partial doses of nab-paclitaxel and gemcitabine had to be adjusted to 
prevent the dual chemotherapy alone from resulting in a deceptive high cytotoxi-
city. Accordingly, the dual chemotherapy was conducted by varying the concen-
trations of both agents based on the respective LD25 doses in each tumor cell 
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line. Thereby, 3 different treatment groups with distinct dose variations were dif-
ferentiated (specified in detail in section 2.2.5.2, p. 45). 72 hpt, the remaining cell 
masses were analyzed by SRB assay (Figure 29 and Figure 30). 
When increasing the concentrations of both agents to the same degree, all 4 tu-
mor cells responded dose-dependently to the dual chemotherapy. Thereby, a 
definite concentration threshold had to be trespassed before any cytotoxic effect 
could be seen. This condition was mainly apparent in MIA PaCa-2 cells, in which 
concentrations almost reaching the respective LD25 doses had to administered, 
while AsPc-1, BxPc-3 and Panc-1 cells already responded to lower doses of the 
MIA PaCa-2 BxPc-3 
AsPc-1 Panc-1 
Figure 29 Dual chemotherapy with nab-paclitaxel and gemcitabine in four different human pancreatic 
tumor cell lines in vitro. Starting from their previously determined LD25 doses a constant ratio of the 
cytotoxic agents was maintained by generating twofold dilutions (specified in detail in Table 2, p. 45). 
Remaining tumor cell mass was analyzed at 72 hours post treatment by sulforhodamine B (SRB) 
assay (n=1, mean and standard deviation are shown). Gem, gemcitabine. nab-PTX, nab-paclitaxel. 
MOCK, untreated control. 
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dual chemotherapy, although the initial response was poor. Interestingly, in AsPc-
1 and Panc-1 cells the application of both agents in the full LD25 doses merely 
led to a tumor cell killing comparable to the results seen after monotherapy alone, 
whereas BxPc-3 and MIA PaCa-2 cells responded more strongly when both 
agents were combined in their respective LD25 doses. Yet, as concluded before, 
in BxPc-3 cells the LD25 dose of nab-paclitaxel may have been too high, there-
fore potentially mistaking the apparently strong response as additional effect of 
the dual chemotherapy. Eventually, in reference to the results after monotherapy, 
1 out of 4 tumor cell lines demonstrated a definitely enhanced cytotoxic effect of 
the dual chemotherapy with nab-paclitaxel and gemcitabine. 
Based on these results the following concentrations of nab-paclitaxel and gem-
citabine were chosen for the chemovirotherapeutic triple-therapy (Table 10). 
In the other 2 treatment groups, in which the concentrations of one chemothera-
peutic agent were varied while the other was administered constantly at 50% of 
its LD25 dose, differences in the influence of nab-paclitaxel and gemcitabine on 
the tumor cell lines could be seen (Figure 30). Panc-1 cells indeed responded 
dose-dependently to gemcitabine but already in 50% of the LD25 dose gemcita-
bine led to a considerable tumor cell killing virtually independent of any further 
dose increases of nab-paclitaxel. In MIA PaCa-2 cells constant doses of nab-
paclitaxel and gemcitabine both were sufficient to induce a primary response to 
the dual chemotherapy which could be further enhanced by increasing the dose 
of the combination partner. Thereby, dose increases of nab-paclitaxel resulted in 
an enhanced tumor cell killing at the whole range of concentrations, while the 
Tumor cell lines    Partial doses 
AsPc-1   nab-PTX: 10 nM     Gem:  100 nM 
BxPc-3   nab-PTX:  2.5 nM   Gem:  5 nM 
MIA PaCa-2   nab-PTX: 2.5 nM   Gem:  15 nM 
Panc-1   nab-PTX: 2.5 nM   Gem:  37.5 nM 
 
  
   
   
   
   
Table 10 Partial (‘adjusted’) doses of nab-paclitaxel and gemcitabine 
for the triple-therapy 
Abbreviations: Gem, gemcitabine; nab-PTX, nab-paclitaxel. 
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BxPc-3 
MIA PaCa-2 
AsPc-1 
Panc-1 
Dose variation of 
nab-paclitaxel gemcitabine 
Figure 30 Dose variations of the dual chemotherapy in four different human pancreatic tumor cell lines in 
vitro. Treatment doses of gemcitabine (left panel) or nab-paclitaxel (right panel) were varied while the com-
bination partner was constantly applied in 50 % of its previously determined LD25 dose (specified in detail 
in Table 3, p. 45 and Table 4, p. 46 respectively). Remaining tumor cell mass was analyzed at 72 hours 
post treatment by sulforhodamine B (SRB) assay (n=1, mean and standard deviation are shown). Gem, 
gemcitabine. nab-PTX, nab-paclitaxel. MOCK, untreated control. 
 
Ch. 3 Results Dissertation Eike Hendrik Binz 
75 
 
dose of gemcitabine had to trespass a certain concentration threshold. A similar 
primary response also was seen in BxPc-3 cells but only when the gemcitabine 
concentration remained constant. In the other treatment group, the application of 
constant doses of nab-paclitaxel resulted in a considerable tumor cell loss inde-
pendently of the concentration of gemcitabine. However, as concluded before, 
the chosen LD25 doses of nab-paclitaxel might have been too high and therefore 
might have disguised an additional effect of gemcitabine. AsPc-1 cells responded 
similarly to both variation settings, demonstrating a primary response which could 
be slightly enhanced by dose increases of the combination partner.  
Although in these experiments, by varying the concentration of the combined 
agents and analyzing their effect on different tumor cell lines, only two parameters 
of combination therapy were investigated, it has to be reasoned clearly that even 
in case of only two agents being combined rather complex interactions can be 
observed. 
3.3.2 Combination of GLV-1h68 with the dual chemotherapy 
After reviewing and considering the results of the previously performed combina-
tion therapies, a final chemovirotherapeutic protocol imbedding GLV-1h68 in 
combination with nab-paclitaxel + gemcitabine was devised.  
Since in the previous settings no application sequence was found to result in a 
superior or inferior cytotoxicity, the dual chemotherapy was administered con-
comitantly to the virotherapeutic treatment. Thereby, adapting the approved and 
actually performed clinical protocol of the dual chemotherapy, nab-paclitaxel was 
applied first (1 hpi) while gemcitabine was added half an hour later (1.5 hpi). 
Moreover, after reviewing the obtained results after monovirotherapy, GLV-1h68 
was administered in three different virus doses (MOIs), one being the previously 
determined LD25 dose whereas the other two resembled similar virus doses. At 
72 hpi, the remaining cell masses and cell viabilities were analyzed by SRB, CTB 
and MTT assay respectively (Figure 31). 
Additionally to the previously applied evaluation criteria, it now had to be verified 
whether the results of the 3 different assays were consistent or whether various  
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Figure 31 Triple-therapy with GLV-1h68 and the dual chemotherapy nab-PTX (added at 1 hpi) + Gem 
(added at 1.5 hpi) in four different pancreatic tumor cell lines. Remaining cell mass and cell viability after 
72 h treatment at increasing doses of GLV-1h68 were analyzed by the sulforhodamine (SRB) assay 
(depicted in red bars), the CellTiter-Blue® (CTB) assay (depicted in blue bars) and the MTT assay (de-
picted in yellow bars), respectively (n ≥ 3, mean and standard deviation are shown). nab-PTX, nab-
paclitaxel. Gem, gemcitabine. hpi, hour(s) post infection. MOCK, untreated control. MOI, multiplicity of 
infection. VV, vaccinia virus GLV-1h68. Figure of SRB and CTB values published in (139). 
BxPc-3 
MIA PaCa-2 
AsPc-1 
Panc-1 
Ch. 3 Results Dissertation Eike Hendrik Binz 
77 
 
conclusions could be drawn from the individual testing method. In doing so, all 3 
assays agreed that in BxPc-3 and MIA PaCa-2 cells the response after chemovi-
rotherapy was clearly enhanced compared to the respective monotherapies. In 
the same 2 tumor cell lines, an increase of the virus dose also led to an increase 
of tumor cell killing, not only in the monotherapeutic but in the chemovirothera-
peutic treatment arm as well. On the contrary this condition was barely apparent 
in AsPc-1 and Panc-1 cells. Considering the remaining cell masses of the partic-
ular ‘monotherapies’ in all 4 tumor cell lines suitable concentrations of the chemo- 
and virotherapeutic agents were chosen.  
Compared to the untreated control (MOCK), in AsPc-1 cells the CTB assay even 
demonstrated an increased cell viability after monovirotherapeutic treatment, 
which could be strongly reduced in combination with the dual chemotherapy. 
These data disagree with the otherwise measured cell viability in the MTT assay 
which demonstrated that virotherapy with GLV-1h68 didn’t increase the cell me-
tabolism of AsPc-1 cells. Whether this condition in AsPc-1 cells was restricted to 
the metabolism of resazurin to resorufin only (similar metabolic pathways might 
be involved as well), or whether cell metabolism was enhanced in general while 
the metabolism of MTT to formazan remained unaffected by virotherapeutic treat-
ment with GLV-1h68, can’t be determined on the basis of the current data. 
On the contrary, although the MTT assay validated the results in the better re-
sponding BxPc-3 and MIA-Paca-2 cells, in Panc-1 cells an antagonistic response 
of the triple-therapy was seen. With the exception of one setting (GLV-1h68 + 
nab-PTX -24 hpi), all of the previous results had indicated that the outcome after 
combination therapy at least resembled the better outcome seen after single viro- 
or chemotherapy. Now, Panc-1 cells indeed responded dose-dependently to the 
monovirotherapeutic treatment with GLV-1h68 but in combination with the dual 
chemotherapy cell viability rose again to the inferior outcome seen after dual 
chemotherapy alone. Considering the results obtained with the SRB assay, in 
which the dual chemotherapy alone as well as in combination with GLV-1h68 led 
to a substantial decrease of tumor cell mass, these data suggest an enhanced 
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cell metabolism of the remaining tumor cells, at least with regard to the metabo-
lism of MTT to formazan.  
Along with the previously illustrated response of AsPc-1 cells to virotherapeutic 
treatment, these data clearly disagree with the values of cell viability measured 
in the CTB assay. In these 2 tumor cell lines this fact therefore indicates a diver-
sified influence of viro- and/or chemotherapeutic treatment on varying domains 
of cellular activity and not on cell metabolism in general.  
Regardless of these differences, compared to the outcome after chemo- or viro-
therapy alone, all 3 assays agree on the central finding that in BxPc-3 and MIA 
PaCa-2 cells the triple-therapy was beneficial whereas in the other 2 cell lines it 
was not. Moreover, the combination of GLV-1h68 with nab-paclitaxel and gem-
citabine caused the greatest increase of therapeutic efficacy seen during this in-
vestigation. 
3.3.3 Influence of the dual chemotherapy on the replication of GLV-1h68 
With regard to parameters potentially constraining the outcome of chemovirother-
apy it has to be considered that any chemotherapeutic agent might interfere with 
the replication of the viral agent given in combination. Independently of long-term 
consequences this initially would lead to a considerable repression of virus-me-
diated oncolysis. Signs of detrimental interactions between the agents were 
thereby first seen in a cell line-dependent reduction of viral GFP expression after 
adding the dual chemotherapy (Figure 32). Interestingly, this was only the case 
in AsPc-1 and Panc-1 cells in which the triple-therapy had caused no further cy-
totoxicity compared to the respective monotherapies. In the superior responding 
BxPc-3 and MIA PaCa-2 cells viral GFP expression remained strong.   
To fully assess the influence of the dual chemotherapy nab-paclitaxel + gemcita-
bine on viral replication of GLV-1h68, virus growth curves were generated. Given 
that an actual beneficial response after treatment with the triple-therapy was seen 
only in 2 of the 4 tumor cell lines it was of especial interest whether this condition 
was linked to an altered viral replication of GLV-1h68. Therefore, according to the 
schedule of the triple-therapy, GLV-1h68 was administered with or without the 
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dual chemotherapy. At certain time points post infection (1.5 hpi, 24 hpi, 48 hpi, 
72 hpi and 96 hpi) the corresponding virus titer was quantified by virus titration 
(Figure 33). Tumor cells thereby were infected with the highest virus doses ad-
ministered previously. 
As a matter of fact, among the 4 tumor cell lines notable differences regarding 
the viral replication were seen. Considering the substantial increase of virus titer 
over time in the monovirotherapeutic treatment arm, potent viral replication was 
seen in all 4 tumor cell lines, proving that each tumor cell line could be success-
fully infected with GLV-1h68. Yet, in AsPc-1 and Panc-1 cells the addition of nab- 
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Figure 32 Viral GFP expression after the triple-therapy at 72 hpi in BxPc-3 and AsPc-1 cells infected 
with the medium viral dose previously administered in the triple-therapy setting (Figure 31). Expression 
of green fluorescent protein (GFP) indicating viral infection (central panels), corresponding phase con-
trast pictures (left panels) and the respective overlay images (right panels) are shown (scale 1:190). 
hpi, hour(s) post infection. MOI, multiplicity of infection. VV, vaccinia virus GLV-1h68. 
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Figure 33 Effect of the dual chemotherapy nab-paclitaxel + gemcitabine on the viral replication of GLV-
1h68 in four different pancreatic tumor cell lines. Tumor cells were treated according to the previously 
described combination setting with the highest used MOI in either cell line (Figure 31). At five given time 
points (1.5, 24, 48, 72, 96 hpi) tumor cells were harvested, followed by virus titer determination [PFU - 
plaque forming units] (n=3, mean and standard deviation are shown). nab-PTX, nab-paclitaxel. Gem, 
gemcitabine. hpi, hour(s) post infection. MOI, multiplicity of infection. Figure modified from this version 
published in (139). 
 
paclitaxel + gemcitabine led to a considerable reduction of viral replication paral-
leling the previously observed decrease of viral GFP expression. On the contrary, 
in BxPc-3 and MIA PaCa-2 cells, viral replication of GLV-1h68 remained potent 
and resembled the virus titers after monovirotherapy. Therefore, the negative in-
fluence of the dual chemotherapy on viral replication of GLV-1h68 was found to 
be directly linked to a loss of therapeutic benefit otherwise seen after the triple-
therapy. 
In conclusion, although no definite statement can be made without further 
knowledge of other parameters potentially determining success or failure of the 
triple-therapy, these data suggest that an unhindered virus replication represents 
a mandatory requirement for a possible success of this chemovirotherapeutic 
protocol. 
hpi 
BxPc-3 
hpi 
MIA PaCa-2 
hpi 
AsPc-1 
hpi 
Panc-1 
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3.3.4 Influence of nab-paclitaxel on viral replication of GLV-1h68 
It was assumed that the observed reduction of viral titers in AsPc-1 and Panc-1 
cells was the result of overdosing one or even both chemotherapeutic agents. To 
assess the influence of each of the chemotherapeutic agents on viral replication 
of GLV-1h68 separately, first, virus growth curves in combination with nab-
paclitaxel were generated. For this investigation, the responsive cell line BxPc-3 
was selected to evaluate whether the unfavorable environment for viral replica-
tion in AsPc-1 and Panc-1 cells could be emulated by administering higher doses 
of the chemotherapeutic agent.  
According to the schedule of the triple-therapy BxPc-3 cells were treated first with 
GLV-1h68 and at 1 hpi with ascending doses of nab-paclitaxel while viral titers 
were determined as previously (Figure 34). Additionally, viral GFP expression in 
the corresponding tumor cells was visualized at 72 hpi (Figure 35). 
Compared to the viral titer seen after GLV-1h68 treatment alone, nab-paclitaxel 
was found not to influence viral replication in BxPc-3 cells, even in the highest 
administered concentration of 25 nM (Figure 34). Since an unchanged viral rep-
lication had previously been found to determine the therapeutic benefit of the tri-
ple-therapy it was hypothesized that nab-paclitaxel didn’t negatively influence the 
outcome in AsPc-1 and Panc-1 cells.  
Figure 34 Viral titers of GLV-1h68 under the influence of nab-paclitaxel (nab-PTX) in the pancre-
atic tumor cell line BxPc-3. Tumor cells were infected with GLV-1h68 (MOI 0.05). At 1 hpi, the 
inoculum was removed and medium containing nab-PTX was added. At five given time points (1.5, 
24, 48, 72, 96 hpi) tumor cells were harvested, followed by virus titer determinations [PFU, plaque 
forming units] (n=3, mean and standard deviation are shown). hpi, hour(s) post infection. 
 
hpi 
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On the contrary in the associated microscopic images it seemed that the levels 
of GFP expression decline when nab-paclitaxel was administered in a concentra-
tion of 25 nM (Figure 35). Moreover, the remaining tumor cell mass in the corre-
sponding phase contrast images appears to increase with ascending doses of 
nab-paclitaxel. However, as visualized previously (Figure 18) virus-mediated on-
colysis kills cells differently than chemotherapeutic agents. OVs spread outwards 
phase contrast GFP 
nab-PTX 0 nM 
nab-PTX 2.5 nM 
nab-PTX 5 nM 
nab-PTX 10 nM 
nab-PTX 25 nM 
Figure 35 Effect of nab-paclitaxel on viral infection in BxPc-3 cells analog to the previously 
measured viral titers at 72 hpi (Figure 34). Expression of green fluorescent protein (GFP) 
indicating viral infection (right panels) and corresponding phase contrast pictures (left pan-
els) are shown (scale 1:190). hpi, hour(s) post infection. nab-PTX, nab-paclitaxel. 
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from the primary infection site leaving only strongly GFP expressing tumor cell 
clusters at the margin whereas chemotherapy kills all tumor cells homogenously. 
The latter results in a thin cell layer of evenly spread tumor cells which only sug-
gests a weak GFP expression. Since viral infection could clearly be detected at 
all administered doses of nab-paclitaxel this clarified a strong viral replication of 
GLV-1h68 in BxPc-3 cells additionally undergoing chemotherapy with nab-
paclitaxel. 
3.3.5 Influence of gemcitabine on viral replication of GLV-1h68 
In a next step, the effect of gemcitabine on viral titers of GLV-1h68 was deter-
mined. Similarly to the previous setting, viral growth curves were generated by 
treating BxPc-3 cells first with GLV-1h68 and at 1.5 hpi with ascending doses of 
gemcitabine (Figure 36). As before, GFP expression of GLV-1h68 was visualized 
in the corresponding tumor cells at 72 hpi (Figure 37).  
This time, higher doses of the chemotherapeutic agent, i.e. gemcitabine concen-
trations ≥ 25 nM, positively correlated with a significant decline of viral titers (Fig-
ure 36). Accordingly, viral replication in BxPc-3 cells could be suppressed to a 
similar level as seen before in AsPc-1 and Panc-1 cells after adding the dual 
chemotherapy. Gemcitabine concentrations of 100 nM even were able to reduce 
hpi 
Figure 36 Viral titers of GLV-1h68 under the influence of gemcitabine (Gem) in the pancreatic 
tumor cell line BxPc-3. Tumor cells were infected with GLV-1h68 (MOI 0.05). At 1 hpi, the inoculum 
was removed and normal growth medium was added. Half an hour later (1.5 hpi), gemcitabine 
was added. At five given time points (1.5, 24, 48, 72, 96 hpi) tumor cells were harvested, followed 
by virus titer determinations [PFU, plaque forming units] (n=3, mean and standard deviation are 
shown). hpi, hour(s) post infection. 
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viral titers below their baseline level at 1.5 hpi. Such high-dose administration of 
gemcitabine therefore nearly completely shut down viral replication.  
These findings were also reflected in a dose-dependent cut-off of viral GFP ex-
pression visualized at 72 hpi (Figure 37). While low doses of gemcitabine (< 25 
nM) neither influenced viral titers nor viral GFP expression, concentrations of 25 
nM and higher significantly decreased viral titers and completely prevented viral 
Gem 0 nM 
Gem 5 nM 
Gem 25 nM 
Gem 50 nM 
Gem 100 nM 
phase contrast GFP 
Figure 37 Effect of gemcitabine on viral infection in BxPc-3 cells analog to the previously 
measured viral titers at 72 hpi (Figure 36). Expression of green fluorescent protein (GFP) 
indicating viral infection (right panels) and corresponding phase contrast pictures (left 
panels) are shown (scale 1:190). hpi, hour(s) post infection. Gem, gemcitabine. 
 
Ch. 3 Results Dissertation Eike Hendrik Binz 
85 
 
GFP expression. The phase contrast images thereby confirm the abrupt loss of 
oncolytic efficacy. Only at higher gemcitabine concentrations the cytotoxic effect 
of the chemotherapy was able to catch up with the oncolytic effect of GLV-1h68.  
In a final step, it was assessed whether a delayed administration of gemcitabine 
would give GLV-1h68 enough time to reach sufficient viral titers able to outweigh 
the poor performance of viral replication. Accordingly, the timing of gemcitabine 
administration was varied (1.5 h or 24 hpi) and its influence on GFP expression 
visualized at 72 hpi (Figure 38). 
Figure 38 Time-dependent effect of gemcitabine on viral infection in BxPc-3 cells at 72 hpi. Tumor cells 
were infected with GLV-1h68. At 1 hpi, the medium was changed while Gem was added either at 1 or 24 
hpi. Expression of green fluorescent protein (GFP) indicating viral infections (right panels) and correspond-
ing phase contrast pictures (left panels) are shown (scale 1:140). Gem, gemcitabine. hpi, hour(s) post in-
fection. 
 
Gem 0 nM phase contrast GFP Gem added at 1 hpi phase contrast GFP Gem added at 24 hpi Gem 5 nM Gem 25 nM Gem 100 nM Gem 50 nM 
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As a result, viral GFP expression was similarly influenced independently of the 
point in time when gemcitabine was administered (1 hpi or 24 hpi). Although the 
cut-off of fluorescence at concentrations of 25 nM wasn’t as evident as before, a 
severe decrease of GFP expression could be seen at this dose in both settings. 
However, when gemcitabine was administered at 24 hpi, fluorescence could be 
visually detected even in high-dose (> 25 nM) regimens. These findings indicate 
that a delayed administration of gemcitabine provides time for viral replication to 
somewhat compensate chemotherapy-related detrimental decreases of the viral 
titer. 
In conclusion, gemcitabine was demonstrated to severely restrain viral replication 
and gene expression of GLV-1h68 in the pancreatic tumor cell line BxPc-3. This 
was not only a dose-dependent effect but was also influenced by the point in time 
when gemcitabine was added. Since concurrent nab-paclitaxel administration 
was demonstrated to leave viral titers unchanged it has to be assumed that in the 
cell lines AsPc-1 and Panc-1 too high doses of gemcitabine were the reason for 
the negative influence on viral replication thereby impeding therapeutic benefit of 
the triple-therapy. 
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4 Discussion 
To date, despite intensive research over the past decades, so far only one single 
virotherapeutic protocol has received approval for oncologic treatment in the 
western hemisphere. As the first of its kind the GM-CSF expressing oncolytic 
herpes virus talimogene laherparepvec (T-VEC, IMLYGICTM) only recently 
achieved FDA and EMA approval for the monotherapeutic treatment of metastatic 
melanoma in 2015 (43). However, both preclinical and clinical data of the last 
decade indicate that only in combination with already approved treatment modal-
ities such as chemotherapy, the true therapeutic potential of oncolytic virotherapy 
may be unlocked. Basic considerations for a possible success of this chemoviro-
therapeutic approach include a more potent initial response of tumor cells to a 
combination therapy, leading to a stabilization or even regression of the tumor 
disease, combined with a virus-mediated induction of a strong antitumor immune 
response in the long-term. 
Prerequisites for a successful combination therapy involve basic parameters 
such as concentrations and the administration sequence of the single agents. 
Possible dose-dependent interactions between the combination partners might 
affect the treatment outcome and therefore the success of combinatorial treat-
ment. In case of chemovirotherapy, while the initial cytotoxic effect of the combi-
nation can be measured and quantified by means of approved testing methods 
both in vitro and in vivo, it is still difficult and nearly impracticable to prove possible 
immune-mediated long-term consequences. This would require not only exten-
sive and time-consuming experiments in immunocompetent animals or human 
patients, but also the design of reliable but so far unfortunately only unstandard-
ized testing methods. In contrast, approaches measuring the viral replication as 
surrogate parameter for potent initial and long-term efficacy of virotherapy have 
been developed and are aiming at giving evidence in this complex matter. 
In this thesis, the chemovirotherapeutic combination of oncolytic vaccinia virus 
GLV-1h68 with various chemotherapeutic agents as a novel treatment option for 
advanced pancreatic adenocarcinoma was investigated in vitro. Based on prom-
ising intermediate results and in accordance with currently valid guidelines for the 
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treatment of locally advanced / metastatic pancreatic cancer, a triple-therapy pro-
tocol incorporating GLV-1h68 and the clinically approved dual chemotherapy 
nab-paclitaxel + gemcitabine was devised. Finally, the influence of the dual chem-
otherapy on viral replication of GLV-1h68 was analyzed. 
4.1 Resistance of pancreatic cancer to chemo- and virotherapy in vitro 
Main issue in developing more effective treatment modalities for pancreatic ductal 
adenocarcinoma (PDA) is the overcoming of primary and (therapy-induced) sec-
ondary resistance mechanisms. In the clinical context, the resistance of PDA to 
chemotherapy is mediated by multiple factors: i) the intrinsic chemoresistance of 
tumor (stem) cells, ii) its hypoxic and highly immunosuppressive desmoplastic 
microenvironment, iii) drug-inhibiting matrix components and iv) a high interstitial 
pressure (144). Unfortunately, in vitro such conditions can’t be reproduced ade-
quately. Analyzing the cytotoxic effect of different agents on long-term cultivated 
cell lines of pancreatic adenocarcinoma therefore mainly focuses on evaluating 
their individual sensitivity/resistance to chemo- and/or virotherapy. 
To clearly differentiate between sensitive and resistant tumor cell lines, it has to 
be elucidated first at which point a tumor cell line has to be regarded as resistant. 
Clinically, treating a cancer patient with a cytotoxic agent the tumor is resistant 
against would result in the same survival outcome as ‘doing nothing specific’ (i.e., 
best supportive care) and unnecessarily expose the patient to drug-induced tox-
icity. However, in vitro even resistant tumor cells will be killed if only the concen-
trations reach levels sufficient enough to outweigh the diverse resistance mech-
anisms. Since high-dose application in the clinic is undeniably paralleled by an 
increase of toxicity, a tumor cell line in vitro could therefore be considered re-
sistant if it doesn’t respond to concentrations that are achievable in vivo (145). 
The fact that even in vitro highly-complex bioinformatic analyses are necessary 
to identify tumor-specific gene profiles and protein signatures that correlate with 
resistance to anticancer agents underlines the difficulty of this matter (146). 
In more complex biologic systems, i.e. in animals or humans, therapeutic agents 
are subject to diverse degradation processes. Accordingly, the effective dose 
which mediates the tumor response at the tumor site will be much lower than the 
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originally applied dose and dose-dependent effects may differ from the in vitro 
results. The assignment of concentrations determined in vitro to the in vivo setting 
and vice versa is therefore a rather imprecise matter. Based on these considera-
tions the monotherapeutic treatment of 4 established and well-characterized cell 
lines of PDA with different cytotoxic/oncolytic agents not only was a means of 
finding suitable doses for chemovirotherapy but also an evaluation of cell line- 
dependent levels of sensitivity/resistance to the respective single agents in vitro.  
In line with previous reports (133), low sensitivity to standard of care gemcitabine 
has been found in Panc-1 cells when compared to the better responding BxPc-3 
and MIA PaCa-2 cells (Figure 20). However, in the latter the increase of gemcita-
bine concentrations to levels higher than 0.1 µM barely enhanced the therapeutic 
effect. In these particular tumor cell lines, high-dose chemotherapy therefore may 
have been unable to further enhance the levels of cell death already induced by 
lower doses of gemcitabine. Prolongation of the chemotherapy on the other hand, 
may have provided the necessary time for more tumor cells to undergo chemo-
therapy-induced cell death independently of the applied concentration of the cy-
totoxic agent. 
Panc-1 cells (and to a lesser extent AsPc-1 cells) were also shown to be among 
the least sensitive cell lines for 5-FU treatment correlating with the expression of 
a drug efflux transporter (147). Here, AsPc-1 cells outmatched the capability of 
Panc-1 cells to withstand high 5-FU concentrations (Figure 19). In this context it 
is of especial interest that AsPc-1 cells originate from a patient who underwent 
5-FU-based chemotherapy previous to the process of tumor material sampling 
and establishment of this tumor cell line (148). Reason for the observed survival 
advantage might therefore be a secondary acquired resistance to 5-FU. 
The collected data also indicate resistance of all 4 tumor cell lines both to the 
platinum compound oxaliplatin and the topoisomerase I inhibitor irinotecan. Initial 
signs of cytotoxicity were seen only at concentrations of 1 µM oxaliplatin whereas 
even higher concentrations of this cytotoxic agent had to be administered to 
achieve considerable therapeutic efficacy (Figure 22). Clinically, although not di-
rectly compared to each other, with an overall survival of 3.4 months the outcome 
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after monotherapy with oxaliplatin (investigated in a rather small number of pa-
tients, n=17) (149) was even worse than after standard of care gemcitabine treat-
ment (ranging from 5.91 to 6.8 months in recent trials) (Table 1). Previous reports 
also confirmed the low sensitivity to irinotecan in vitro, AsPc-1 and Panc-1 cells 
thereby being the least sensitive tumor cell lines (Figure 23) (128). These data 
are further confirmed by the fact that for the first-line treatment of advanced PDA 
both oxaliplatin and irinotecan are only used as part of the multidrug FOLFIRI-
NOX regimen (4).  
Similarly poor results were obtained with the EGFR-targeting tyrosine kinase in-
hibitor erlotinib (Figure 24). Initially, it was unclear whether the observed meager 
therapeutic outcome was the result of a low or missing cellular EGFR expression. 
However, previous investigations had shown that in many tumor cell lines of pan-
creatic cancer the EGF receptor is highly conserved: In Panc-1 cells a mutated 
EGFR gene is expressed whereas AsPc-1 and MIA PaCa-2 cells express the 
receptor in its wildtype form (150,151). Clinically, though, levels of EGFR expres-
sion didn’t correlate with the survival benefit after combination therapy with gem-
citabine and erlotinib (10). Predictive marker for therapeutic benefit was rather 
the development of a skin rash shortly after initiation of treatment. Thus, given 
that more reliable predictive markers are still missing, this therapeutic regimen in 
the clinic so far is performed on a ‘trial and error’ basis and was not further pur-
sued during this investigation. 
 
Nab-paclitaxel has only recently been approved for the treatment of advanced 
pancreatic cancer in combination with gemcitabine, after a phase III trial was able 
to demonstrate increased survival after the dual chemotherapy compared to 
standard of care gemcitabine (12). Moreover, nab-paclitaxel was found to deplete 
the desmoplastic stroma partly contributing to the substantial chemoresistance of 
PDA as well as to increase intratumoral levels of gemcitabine by 2.8-fold in tumor-
bearing mice (152). The latter has been attributed to a nab-paclitaxel-mediated 
decrease of tumoral cytidine deaminase, mainly expressed in tumor epithelial 
cells and degrading gemcitabine into its therapeutically less active metabolites 
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(153). Here, however, such conditions can’t be reproduced adequately with the 
selected array of tumor cell lines in vitro.  
In this investigation, all 4 tumor cell lines responded similarly to a monotherapeu-
tic treatment with nab-paclitaxel with a therapeutic cut-off at concentrations of 
0.01 µM, showing a dramatic decline of remaining tumor cell masses (Figure 21). 
Moreover, in 1 out of 4 tumor cell lines (MIA PaCa-2), its combination with gem-
citabine definitely resulted in an enhanced therapeutic response, whereas in 
BxPc-3 cells this may have been the result of overdosing nab-paclitaxel (Figure 
29). Then again, the responses of the tumor cells to dose variations of one agent 
while administering its combination partner at 50 % of its respective LD25 dose 
were rather inconsistent (Figure 30). Dose increases of one cytotoxic agent either 
directly correlated with an additional reduction of tumor cell masses (MIA PaCa-
2 / Panc-1: Gem ↑; BxPc-3 / MIA PaCa-2: nab-PTX ↑) or caused almost no further 
enhancement of tumor cell killing (BxPc-3 / AsPc-1: Gem ↑; AsPc-1 / Panc-1: 
nab-PTX ↑). Unfortunately, general statements on the particular importance of 
either nab-paclitaxel or gemcitabine on therapeutic success of the dual chemo-
therapy can’t be made on the basis of these data.  
Choosing the vaccinia virus GLV-1h68 for treatment of pancreatic adenocarci-
noma was based on several good reasons. Even though in vitro conditions can’t 
properly address this issue, the importance of the special tumor microenviron-
ment of pancreatic cancer (specified more detailed in section 1.1.3, p. 5) is crucial 
in consideration for further research potential. In PDA, cancer-associated fibro-
blasts, playing an important role in mediating resistance to chemotherapeutic 
agents, are present in high numbers and have been shown to promote oncolytic 
virus infection (154). Speaking in favor of using a Lister strain derivative was the 
fact that, although the hypoxic conditions of PDA represent a considerable barrier 
for efficient virus infection and replication, neither virus protein expression nor 
viral titers of Lister strain derivatives of vaccinia virus were found to be reduced 
under such hypoxic conditions (155).  
Screening the NCI-60 cancer cell lines uncovered different cell line-dependent 
levels of permissivity to GLV-1h68 infection (87). Although the pancreatic cancer 
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cell lines MIA PaCa-2 and Panc-1 were not among the most sensitive tumor cell 
lines for viral infection, therapeutic benefit after virotherapy with GLV-1h68 none-
theless has clearly been proven in such tumor-bearing mice (101). Coincidentally, 
in vitro, different levels of susceptibility to GLV1h68-mediated oncolysis were 
found. In accordance with these data, here, MIA PaCa-2 cells only responded to 
high viral doses while in BxPc-3 cells significantly lower viral doses were sufficient 
to achieve a potent oncolytic effect (AsPc-1 and Panc-1 cells ranging in between) 
(Figure 17). Moreover, since GLV-1h68 represents a biological agent which con-
stantly changes its dose as a result of continuous viral replication and subsequent 
oncolytic cycles, it was hardly surprising that prolongation of the virotherapy led 
to a dramatic decline of tumor cell numbers. GLV-1h68 had more time to amplify 
its viral dose, to lyse its host cells and to spread further to yet uninfected tumor 
cells thereby starting the oncolytic cycle anew. 
In conclusion, the collected evidence confirmed the generally low susceptibility of 
pancreatic cancer cells to cytotoxic agents in vitro. A poor therapeutic outcome 
was seen especially after chemotherapy with oxaliplatin, irinotecan or erlotinib 
which might be caused by an intrinsic resistance of pancreatic adenocarcinoma 
against these agents. Moreover, different tumor cell line dependent levels of sus-
ceptibility to the chemotherapeutic agents 5-FU, nab-paclitaxel and/or gemcita-
bine as well as to the virotherapeutic agent GLV-1h68 were found. Based on 
these data, different (‘dose adjusted’) chemovirotherapeutic protocols were de-
vised, focusing on increasing the so far poor therapeutic outcome while also an-
alyzing the interactions depending on the application sequence of chemo- and 
virotherapeutics. 
4.2 Response of pancreatic cancer to chemovirotherapy 
Initially, after combining GLV-1h68 with the nucleoside analogue 5-FU, oncolysis 
was not substantially changed in neither of the 4 tumor cell lines (Figure 25). 
Although antagonistic effects of this particular setting could therefore be excluded, 
the lack of therapeutic benefit stands in contrast to previous reports of success-
fully treating pancreatic adenocarcinoma with 5-FU and other viral constructs. In 
vitro, the combination of 5-FU with herpes virus-based agents potentiated the 
Ch. 4 Discussion Dissertation Eike Hendrik Binz 
93 
 
antitumor response, which in one case was attributed to an enhanced viral repli-
cation (137), in another to an increase of apoptosis (135). The latter may be of 
especial interest since the deletion of an anti-apoptotic gene in the corresponding 
herpes virus L1BR1 may have partly contributed to the therapeutic effect. Admin-
istration of a parvovirus encoding a prodrug convertase (cytosine deaminase) in 
combination with its prodrug 5-FC two days after inoculation of AsPc-1 cells into 
the peritoneal cavity of nude mice completely prevented peritoneal dissemination 
(125). When administered two weeks after tumor inoculation the combination of 
virus and prodrug decreased CEA levels and significantly increased survival of 
tumor-bearing mice. In vitro, the conversion of 5-FC to its cytotoxic compound 5-
FU caused a strong bystander effect. Interestingly, in vivo the therapeutic benefit 
after combining a conditionally replicating adenovirus with either 5-FU or gem-
citabine wasn’t influenced by the administration sequence although sequence-
dependent synergism and antagonism had been seen in vitro before (131). 
Gemcitabine, another nucleoside analogue, represents the current standard of 
care for advanced pancreatic cancer and has been combined with many viral 
constructs. Its combination with the oncolytic herpes virus AV25CDC in vivo not 
only strongly reduced the tumor weight of subcutaneously established and ortho-
topic tumors in nude mice but also in an immunocompetent Syrian hamster model 
(124). In other immunocompetent models gemcitabine-based combination proto-
cols were shown to prolong tumor growth inhibition (126) and animal survival 
(133), while in the latter synergism of the parvovirus H-1PV and gemcitabine had 
previously been observed in BxPc-3, MIA PaCa-2 and Panc-1 cells in vitro. Clin-
ically, systemic gemcitabine infusion has been successfully combined with intra-
tumorally injected ONYX-15 in a phase I/II trial (156). However, although che-
movirotherapy was found to be well tolerated, the treated cohort of 18 patients 
was too small for the read-out of potentially meaningful therapeutic benefit. Un-
fortunately, since further research on ONYX-015 was stopped in 2003, these in-
vestigations led down a blind alley and no other chemovirotherapeutic protocol 
addressing pancreatic cancer has yet reached phase III. Currently, trials incorpo-
rating the hyaluronidase expressing adenoviral vector VCN-01 or the naturally 
occurring reovirus Reolysin® are under way (59). 
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Gemcitabine has also been previously combined with GLV-1h68 in vivo. Che-
movirotherapy accelerated tumor shrinkage and inhibited the growth of subcuta-
neous Panc-1 tumors in nude mice (101). However, unlike the combination of 
GLV-1h68 with cisplatin, after which complete remissions were seen in 7 of 8 
tumor-bearing mice, the gemcitabine combination protocol wasn’t able to com-
pletely eradicate the tumor disease. In addition, monotherapy with GLV-1h68 
alone was able to catch up with the therapeutic outcome when only given suffi-
cient time. In this study, chemovirotherapeutic treatment with GLV-1h68 and 
gemcitabine in vitro did not result in any considerable increase of cytotoxicity in 
neither of the administration settings (Figure 26), paralleling the previously ob-
tained results in combination with 5-FU. Reason for the lack of therapeutic benefit 
may be that both chemotherapeutic agents are nucleoside analogues. Given that 
the main mechanism of action of such agents is the interference with cellular DNA 
replication, unintentionally, the replication of the DNA virus GLV-1h168 may have 
been inhibited as well, thereby reducing its oncolytic potency. Factors possibly 
mediating the difference between the in vitro and in vivo results may have been 
the greater delay of chemotherapy in vivo (15 days after single virus injection) 
and its intraperitoneal administration possibly reducing the effective dose of gem-
citabine at the tumor site. 
Chemovirotherapeutic combinations incorporating oxaliplatin have not yet been 
part of (pre-)clinical investigations addressing pancreatic cancer. Nonetheless, 
therapeutic value might be assumed to originate from its capability to induce im-
munogenic cell death, dying tumor cells thereby additionally triggering a long-
term antitumor response (157). Given that such an immunotherapeutic effect is 
also believed to be the main property of OVs, incorporating agents such as oxal-
iplatin into chemovirotherapeutic protocols is of great interest. In vitro, treatment 
of colorectal cancer with a combination of oxaliplatin and Reolysin® has been 
reported to reduce the numbers of viable tumor cells to a greater degree than 
either of the two monotherapies (158). In the same tumor entity, cell line-depend-
ent levels of synergy between oxaliplatin and the Western Reserve strain vaccinia 
virus vvDD (‘double deleted’ virus: thymidine kinase and vaccinia growth factor) 
were found (159). Here, only 1 out of 4 tumor cell lines (AsPc-1) demonstrated a 
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clear increase of cytotoxicity after combination therapy with GLV-1h68 and oxal-
iplatin, compared to the respective monotherapies independently of the admin-
istration sequence (Figure 27). In the other 3 cell lines, therapeutic benefit was 
seen only inconsistently in specific settings. However, main challenge in proving 
benefit of such immunotherapeutic regimens still remains the establishment of 
suitable tumor models and in vitro approaches so far aren’t able to sufficiently 
address this issue. 
Given its only recent development and approval for i) metastatic breast cancer, 
ii) locally advanced or metastatic non-small-cell lung cancer and iii) metastatic 
pancreatic cancer (160), nab-paclitaxel has only once been combined with viral 
agents (161). Solvent-based paclitaxel (Taxol®) on the other hand has been part 
of many chemovirotherapeutic protocols. In vitro, the combination with an adeno-
viral vector was highly synergistic in treating non-small cell lung cancer cells (162) 
and even paclitaxel-resistant cell lines were more strongly killed by the combina-
tion of paclitaxel and Reolysin® (163). Furthermore, in vitro synergism in breast 
cancer cell lines could be translated to in vivo efficacy (164) and near to complete 
tumor eradication was seen in nude mice bearing xenografts of ovarian and pros-
tate cancer (165,166). In an immunocompetent model the combination of an on-
colytic adenovirus with paclitaxel restored its oncolytic potency to similar levels 
as previously seen in athymic mice, possibly due to the chemotherapy-mediated 
inhibition of initial viral clearance by the immune system (167). Combining 
paclitaxel with the ‘double deleted’ vaccinia virus vvDD potently curbed tumor 
growth in colorectal cancer-bearing nude mice and significantly increased animal 
survival (143). Similarly, tumor growth of MIA PaCa-2 xenografts was more 
strongly inhibited by the combination of paclitaxel with the oncolytic adenovirus 
Ad-Delo3-RGD (130). Clinically, only recently a phase II trial has found the com-
bination of paclitaxel, carboplatin and Reolysin® to be safe but failed to prove a 
beneficial effect on progression-free survival for patients with metastatic pancre-
atic adenocarcinoma (168).  
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Compared to the widely used solvent-based paclitaxel, nanoparticle albumin-
bound paclitaxel (Abraxane®) has demonstrated both pharmacokinetic and ther-
apeutic advantages (169). It primarily was designed to compensate for the unfa-
vorable toxicity profile of Cremophor EL, the solvent used to solubilize highly wa-
ter-insoluble paclitaxel. Accordingly, nab-paclitaxel can be administered in higher 
effective doses with less systemic toxicity. Even more, the albumin-bound agent 
was found to accumulate more potently in tumor tissues which was hypothesized 
to be the result of various mechanisms such as an enhanced endothelial 
transcytosis (170) and the prevalence of albumin-binding proteins at the tumor 
site (171). Clinical benefit of nab-paclitaxel was finally proven in a phase III trial 
addressing patients with metastatic breast cancer (172). Compared to solvent-
based paclitaxel, treatment with nab-paclitaxel demonstrated both a more favor-
able toxicity profile and a higher tumor response rate. However, such factors 
might be of more relevance in the in vivo setting and in vitro the outcome after 
nab-paclitaxel or solvent-based paclitaxel treatment may be similar.  
Here, chemovirotherapeutic treatment with GLV-1h68 and nab-paclitaxel led to a 
slightly increased treatment outcome in the majority of cell lines and settings 
tested (Figure 28). However, only in AsPc-1 cells a potent effect was seen (inde-
pendently of the administration order) and in MIA PaCa-2 cells for the first time 
during this investigation antagonism after chemovirotherapy was observed when 
the chemotherapeutic was administered first (nab-PTX -24 hpi). In addition, ther-
apeutic benefit couldn’t be pinned down to a specific administration setting. In 
consideration of the so far collected evidence this led to the conclusion that GLV-
1h68 can be combined with chemotherapeutic agents such as nab-paclitaxel, 
gemcitabine or oxaliplatin in a more flexible time pattern. Clinically, cancer ther-
apy usually depends upon both patient-related factors, such as health-related 
quality of life and morbidity, as well as work-related parameters such as aligning 
strict therapy protocols with unpredictable clinical routine. Being able to unravel 
a therapy protocol without the fear of greatly losing its therapeutic effect therefore 
makes it more feasible in the clinic. 
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For the treatment of metastatic pancreatic cancer however nab-paclitaxel is only 
approved in combination with gemcitabine. Given that the majority of chemoviro-
therapeutic regimens aim at adding the oncolytic and potentially immunothera-
peutic properties of OVs to currently established treatment protocols, a triple-
therapy protocol incorporating GLV-1h68, nab-paclitaxel and gemcitabine was 
devised. The addition of the approved dual chemotherapy nab-paclitaxel + gem-
citabine to an oncolytic adenovirus has only recently been proven to be superior 
to chemotherapy or virotherapy alone in an in vivo model of pancreatic cancer 
(161). A similar protocol combining Reolysin® with carboplatin and paclitaxel, the 
dual chemotherapy being approved for the treatment of advanced head and neck 
cancer, has only recently been tested in the REO 018 phase III trial and was able 
to demonstrate therapeutic benefit by improving patient survival (61). 
“Here, in this work, as a matter of fact, in 2 cell lines of PDA (BxPc-3 and MIA 
PaCa-2) the triple-therapy resulted in a considerable increase of tumor cell killing, 
whereas in the other 2 cell lines (AsPc-1 and Panc-1) the response after triple-
therapy resembled the response after single viro- or dual chemotherapy alone” 
(139) (Figure 31). Importantly, these results were validated by 3 differently oper-
ating cell viability assays. Moreover, in the tumor cell lines which demonstrated 
no increase of cytotoxicity after the triple-therapy, viral titers were shown to be 
drastically reduced under the influence of the dual chemotherapy (Figure 33). 
Accordingly, it has to be assumed that a potent viral replication of GLV-1h68 is 
necessary for a therapeutic benefit of the triple-therapy in vitro.  
4.3 Viral replication is influenced by chemotherapeutic agents 
“Main focus of chemovirotherapeutic regimens lies in harnessing the oncolytic 
and, more importantly, immunotherapeutic potential of the applied viral agents. 
Since both parameters are presumed to depend on a strong viral replication, it 
has to be ascertained that the application of chemotherapeutic agents does not 
interfere with viral replication and spread of infectious progeny virus particles in 
a negative manner. Such interactions depend not only on the chosen agents but 
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also on their dosages and the order of administration of the respective com-
pounds, basic determinants that have to be considered for the design of any suc-
cessful combination therapy.” (139) 
“Thus far, therapeutic benefit after chemovirotherapy both in vitro and in vivo has 
been shown to be linked to an unchanged or even enhanced viral replication in 
most cases.” (139) The latter has mainly been described in adenoviruses or her-
pes viruses although the underlying mechanisms could not always be elucidated. 
“In some cases, chemotherapy-induced DNA damage resulted in a cellular over-
expression of GADD34 or ribonucleotide reductase (RR) which led to an in-
creased replication of herpes virus-based agents if homologous viral gene prod-
ucts had previously been deleted (137,173-175). Similarly, chemotherapy was 
shown to increase the levels of E1A, an early expressed adenoviral gene product 
that not only regulates a multitude of both cellular and viral genes to initiate the 
adenoviral replication cycle but is also known for its chemosensitizing effects 
(167,176). The mitotic inhibitor paclitaxel was found to increase adenoviral as-
sembly and subsequent release from the host cell while leaving DNA synthesis 
unaffected (162).” (139) As another example, increased titers of myxoma virus or 
the vaccinia virus vvDD were observed after combination with rapamycin, which 
correlated with therapeutic benefit both in vitro and in vivo (177,178). “Further-
more, it was shown that chemotherapy-induced senescence promoted replication 
of a measles vaccine virotherapeutic virus and led to increased tumor cell killing 
(179). However, in most cases it remains unclear whether an enhanced viral rep-
lication constitutes the main determinant for therapeutic efficacy.” (139) This 
would suggest that the respective chemo- and virotherapeutics operate inde-
pendently, at which the tumor cells are killed either by the cytotoxic effect of the 
chemotherapy or viral-mediated oncolysis. Consequently, if therapeutic benefit is 
mainly caused by a chemotherapy-induced augmentation of viral replication, in 
other chemovirotherapeutic protocols a similar condition could be recreated by 
administrating higher viral doses. 
“In contrast, it was previously shown that chemotherapeutics such as 5-FU or 
irinotecan induce an unfavorable environment for viral replication (180)” (139), 
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depending on the respective genetic setting of the oncolytic agent (134). “SN-38, 
an active metabolite of clinically used irinotecan, was found to inhibit replication 
of the HSV-1 vector G47Δ, which decreased the therapeutic benefit otherwise 
seen in combination with etoposide where viral replication was not influenced 
(181). Interestingly, therapeutic benefit could be observed despite reduced viral 
titers. Enhanced levels of apoptosis in response to chemovirotherapeutic treat-
ment were found to result in enhanced therapeutic efficacy and therefore out-
weighed detrimental decreases of the effective viral dose (159,182,183). Prodrug 
converting strategies led to a powerful bystander effect, although viral replication 
was inhibited by the converted cytotoxic compound 5-FU (184,185).” (139) How-
ever, the in vitro and in vivo results were not always conclusive. While gemcita-
bine was found to severely impede adenoviral replication in cells of pancreatic 
cancer in vitro, potent expression of early and late viral genes could be detected 
in vivo, leading to the assumption that the corresponding viral gene products were 
the mediator for the enhanced therapeutic effect (132).  
Other data have made aware the importance of monitoring viral replication for a 
sufficient time period. Although diverse chemotherapeutics were found to se-
verely decrease early replication of adenovirus, viral titers were found as high as 
after virotherapy alone when only given sufficient time (186,187). Moreover, dif-
ferent kinds of infectious particles may be affected differently by chemotherapeu-
tic agents. Vaccinia virus for instance forms 3 types of infectious particles which 
fulfill distinct tasks in its strategy to maximize viral spread. While numbers of in-
tracellular mature virus, representing the majority of formed particles that are only 
released during oncolysis, were found to be strongly reduced by the mitotic inhib-
itor paclitaxel, levels of extracellular enveloped virus, which is released early dur-
ing the viral life cycle and is therefore responsible for long-range viral spread, 
remained nearly unchanged (143). 
So far in most chemovirotherapeutic protocols an additive or synergistic cytotoxic 
effect was accompanied by an unaltered viral replication. Combined treatment 
with chemo- and virotherapeutics thereby often led to increases in the proportion 
of apoptotic tumor cells (31,188-191). Furthermore, such interactions were found 
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to depend on the influence of the viral agent on the cell cycle. Addition of the 
HSV-1 agent G47Δ increased the potency of paclitaxel to arrest cells in G2/M-
phase ultimately followed by apoptosis (164). Treatment of lung cancer cells with 
the adenovirus OBP-301 led to an accumulation in S-phase which potentiated 
gemcitabine-mediated cytotoxicity and enhanced therapeutic benefit (192). 
G2/M-phase arrest, which is typically induced by temozolomide treatment and 
renders cells more resistant to the chemotherapeutic agent, was overridden after 
addition of the adenovirus Δ-24-RGD (193).  
However, although complementing mechanisms of the applied chemo- and viro-
therapeutic agents, such as induction of cell death, are very likely, the possibility 
remains that both approaches act independently of each other which would sug-
gest ‘only’ additional cell killing. Nonetheless, such a chemovirotherapeutic pro-
tocol not only would improve initial tumor eradication and therefore more effec-
tively stabilize the tumor disease in the first place but also promote an immuno-
therapeutic effect in the long-term. 
“The here collected evidence demonstrates that the therapeutic benefit of triple-
therapy with GLV-1h68 + nab-paclitaxel and gemcitabine in treating different pan-
creatic cancer cell lines depends on an unaltered viral replication in vitro. These 
findings are of special interest, since, in view of future clinical applications, GLV-
1h68 provides the possibility to non-invasively monitor viral replication as a sur-
rogate marker for an (immuno)therapeutic effect in animal models or human pa-
tients.” (139) However, chemotherapeutics have been shown to affect various 
forms of vaccinia virus differently and the numbers of extracellular enveloped vi-
rus (EEV) might be unchanged under the influence of the dual chemotherapy 
which would ensure a sufficient long-range spread of GLV-1h68, most notably in 
the in vivo setting.  
4.4 Sequence-dependency of chemovirotherapy 
Interactions between the applied agents are likely to depend on their treatment 
order. “Generally, three distinct administration sequences can be differentiated, 
pretreatment with either i) the chemo- (C) or ii) the virotherapeutic (V) agent 
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(C→V / V→C) or iii) their concurrent administration (CV).” (139) In case of pro-
drug converting strategies the rationale for a pretreatment with the OV followed 
by the respective prodrug seems rather obvious. Nonetheless, the exact timing 
of prodrug administration has to be elucidated. In some cases, the greatest ther-
apeutic benefit was seen when the prodrug was administered early, i.e. 1 day 
after the last virotherapeutic treatment (194,195). On the other hand, 5-FU, which 
inhibits the replication of HSV, was found to cause the strongest bystander effect 
when its prodrug 5-FC was given at the peak viral titer 3 days after OV admin-
istration (184). Accordingly, although based on supposedly simple considerations, 
prodrug converting strategies illustrate the complex matter of combining chemo- 
and virotherapeutic agents. “Chemovirotherapeutic strategies are still experi-
mental, rather than based on a profound understanding of the underlying mech-
anisms, and sequence-dependent interactions are not easy to predict. Of special 
interest are synergistic interactions independently from the treatment order but 
mediated via different antitumoral mechanisms. Huang et al. (143) postulated that 
pretreatment with paclitaxel (C→V) induced a cell cycle arrest of colorectal can-
cer cells in the G2/M phase, which rendered them more susceptible to vaccinia 
virus infection. Pretreatment with the virotherapeutic (V→C), was shown to sen-
sitize for an adjacent chemotherapy by the release of cellular danger signals.” 
(139) Therefore, to more accurately predict possible interactions, many more pa-
rameters will have to be considered. 
For starters, “hypothetic considerations of one therapeutic approach sensitizing 
for the other hint at superior treatment outcomes after sequential administration 
of the agents (C→V / V→C) and to a lesser extent, in the concurrent setting (CV) 
as well. Any therapeutic effect based on an augmented viral replication would 
therefore suggest a benefit of administering chemotherapeutics first (174,196).” 
(139) Indeed, the highest titers of reovirus were reached when it was applied 
without further delay than 24 hours after paclitaxel administration (197). However, 
adjusting the timely pattern of a chemovirotherapeutic protocol to a small thera-
peutic window might be a central issue. Besides, “similar increases of adenoviral 
replication have been found to be independent of the treatment order (C→V/ 
V→C) (198).” (139)  
Dissertation Eike Hendrik Binz Ch. 4 Discussion 
102 
 
“Then again, the requirement of a strong viral replication (or rather a high number 
of viral gene products) possibly sensitizing for adjacent chemotherapy suggests 
a therapeutic benefit if tumor cells are pretreated with the virotherapeutic agent 
(V→C) (199). Nevertheless, some of the synergistic interactions associated with 
a potent viral replication have been found to be sequence-independent (166,200). 
In contrast, although gemcitabine negatively influenced the viral life cycle of par-
vovirus H-1PV in the concurrent setting, it was found to prolong survival of tumor-
bearing rats when its administration took place much earlier (i.e., 2 weeks) (C→V) 
(133). Such combination protocols demonstrate the possibility to employ more 
flexible time patterns between chemo- and virotherapy in case of detrimental in-
teractions in the concurrent setting.” (139) 
Other sequence-dependent interactions such as exploiting cell death have been 
proposed as well. In the context of chemovirotherapy, apoptosis primarily repre-
sents the mode of action of chemotherapeutic agents which usually depend on 
the induction of physiologic cell death mechanisms. Viral infection on the other 
hand is a trigger for apoptosis as part of the antiviral host response, inde-
pendently of its actual oncolytic effect. Since in the process of tumorigenesis 
proapoptotic signaling pathways are typically downregulated (rendering chemo-
therapy less effective while facilitating viral infection), OVs (or rather their gene 
products) are believed to sensitize tumor cells for chemotherapy induced apop-
tosis. In line with this consideration, pretreatment with the OV (V→C) or concur-
rent treatment (CV) were shown to result in enhanced tumor cell killing owing 
to an increased induction of apoptosis (128,159,201). However, similarly in-
creased apoptosis was also found in paclitaxel-pretreated cells followed by treat-
ment with an oncolytic adenovirus (C→V) (202). Even more, chemotherapy-in-
duced apoptosis has been shown to facilitate initial viral penetration and promote 
viral spread (C→V) (203).  
The complexity of this matter is further pronounced by the fact that the admin-
istration sequence in some cases might be cell type-dependent. In the human 
PDA cell line Hs766T the combination of myxoma virus with gemcitabine in vitro 
was shown to be beneficial only when gemcitabine was applied first (C→V), 
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whereas in murine Pan02 cells only pretreatment with the OV (V→C) achieved 
therapeutic benefit (204). Similar effects were seen in the immunocompetent 
Pan02 model in vivo, implying that current syngeneic immunocompetent models 
may not be sufficient to fully evaluate sequence dependent effects and translate 
this findings to human patients. 
Nonetheless, investigations identifying underlying mechanisms of sensitization to 
chemo- or virotherapy have to address sequence-dependent effects. “Unfortu-
nately, the experimental settings of investigations addressing sequence-depend-
ent effects are not always conclusive. In one case, both concurrent and delayed 
administration of cisplatin (CV / V→C) resulted in a similar therapeutic benefit; 
however, the increase of cisplatin-induced apoptosis was only investigated in the 
former and therefore might not contribute to the therapeutic success in the se-
quential administration setting (205). Similarly, although pretreatment with either 
agent (C→V / V→C) often results in superior treatment outcomes, the effect of 
the chemotherapeutic agents on viral replication is frequently measured only in 
the concurrent setting. Depending on the respective treatment order, chemother-
apeutics are known to also affect other parameters determining the cellular envi-
ronment for viral replication such as the induction of cell cycle arrest (186) or 
changes in gene expression (137,173-175). Therefore, although chemotherapeu-
tics may directly interfere with the viral life cycle (which is measured in the con-
current setting) it would be shortsighted to extrapolate such results for the se-
quential setting.” (139) 
Here, “the chronological order of the viro- and chemotherapeutic agents (GLV-
1h68 + nab-paclitaxel, gemcitabine” (139) or oxaliplatin) “did not influence the 
therapeutic effect in either of the four tumor cell lines. As a result, it was concluded 
that chemo- and virotherapy could be administered in a more flexible time pattern 
and a triple-therapy protocol was devised in which nab-paclitaxel and gemcita-
bine were added directly after the initial virus infection (at 1 + 1.5 hpi). Moreover, 
analyses of the antitumor effect as well as of the influence of the dual chemother-
apy on viral replication of GLV-1h68 were performed under similar conditions. 
Therapeutic success of the triple-therapy in the concurrent setting was therefore 
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clarified to depend on an effective chemotherapy in addition to an unchanged 
viral replication.” (139) 
4.5 Dose-dependent effects between chemo- and virotherapeutic agents 
determine the therapeutic outcome 
Therapeutic success of combination therapy may also be somewhat dose-de-
pendent, the positive/negative influence of one agent on the other thereby corre-
lating with the administered concentrations. Moreover, “possible synergistic inter-
actions may intensify therapeutic success and allow for dose reductions of the 
applied agents to a less toxic degree (164,206,207). High-dose combination ther-
apy was actually unable to further increase the levels of tumor cell death already 
being induced by low-dose chemovirotherapy (208,209). Furthermore, virus-me-
diated chemosensitization was shown to be powerful enough to render chemo-
therapy-resistant tumor cells sensitive for low-dose chemotherapy (210,211).” 
(139)  
“Since some chemotherapeutic agents are known to directly interfere with the 
viral life cycle, dose-dependent relations in this regard have been in the focus of 
diverse investigations. Although application of high-dose mitomycin C was found 
to severely reduce replication of an oncolytic herpes simplex virus, viral titers 
were found to be unchanged when administered in lower and thereby ‘beneficial’ 
doses (212). Furthermore, low-dose chemotherapy was found to increase viral 
titers to a greater extent than its high-dose application (174,198).” (139) There-
fore, the therapeutic window for optimal augmentation of viral replication which is 
already dependent on the application sequence narrows down even more.  
“The applied dose of an agent in combination therapy is usually determined by 
its cytotoxic effect in monotherapy. However, to demonstrate therapeutic benefit 
of the combination, suitable doses of single agents have to be chosen carefully. 
If doses are too high, single agents will be too ‘successful’ in killing tumor cells 
on their own and the readout of potential combinatorial therapeutic benefits could 
be threatened. Moreover, even if the chemotherapy does not directly interfere 
with the viral life cycle, high concentrations would be immediately cytotoxic and 
therefore prevent effective viral replication by killing tumor cells, which function 
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as hosts for replicating virotherapeutics (132).” (139) This was suspected to be 
the case in pancreatic cancer cell lines where different levels of sensitivity to 
gemcitabine were shown to predict the therapeutic outcome of the chemoviro-
therapeutic protocol (128). “Higher gemcitabine doses in gemcitabine-insensitive 
cell lines were assumed to cause a greater inhibition of viral replication and in 
accordance to also prevent therapeutic benefit.” (139) 
“In line with these considerations, here the chemovirotherapeutic protocols were 
devised by carefully adjusting concentrations of the respective compounds, en-
suring remaining tumor cell masses of ≈ 75 % after 72 hours of chemo- or viro-
therapeutic treatment in monotherapy (designated as a so-called LD25). By doing 
so, the primary aim was to prevent excessive tumor cell killing possibly disguising 
additional effects of the chemovirotherapeutic combination. Nonetheless, reduc-
tions in the viral titers in tumor cell lines that had been non-responsive to the triple 
chemovirotherapy still could be the result of overdosing chemotherapy. On closer 
inspection, AsPc-1 and Panc-1 tumor cells indeed received higher concentrations 
of nab-paclitaxel and/or gemcitabine than the triple-chemovirotherapy-respon-
sive tumor cell lines BxPc-3 and MIA PaCa-2. Therefore, chemotherapeutic 
doses still might have been adjusted in a too high range could potentially have 
negatively influenced viral replication as a result.” (139)  
Further investigations revealed that in BxPc-3 cells even high-dose administra-
tion of nab-paclitaxel didn’t negatively influence viral replication whereas higher 
gemcitabine concentrations actually reduced viral titers in a dose-dependent 
manner (Figure 34 and Figure 36). Moreover, viral GFP expression could be 
somewhat conserved if gemcitabine administration was delayed (Figure 38). 
Hence, 2 separate assumptions can be made on the basis of these data. Either 
would it be beneficial to reduce the concentration of the chemotherapeutic agent 
to a degree at which viral replication remains strong. However, whether less cy-
totoxic doses would likewise result in a beneficial treatment outcome as in the 
responding cell lines would have to be elucidated in vitro. Given the fact that the 
so far collected evidence indicates a rather additive character of the therapeutic 
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agents in independently killing the tumor cells, this conclusion seems rather du-
bious. In contrast, it appears to be more promising to unravel the schedule of the 
treatment protocol and apply GLV-1h68 and the dual chemotherapy separately 
in their effective doses. Thus, detrimental interactions of the therapeutic agents 
and chemotherapy-mediated decreases of the viral titer, especially in the initial 
oncolytic cycles, could be circumvented. Unraveling the therapy protocol would 
also beneficially lessen therapy-induced adverse effects and safeguard overlap-
ping toxicity which to date is frequently used in multimodal chemotherapy proto-
cols. 
In accordance with this consideration the combination of gemcitabine with 2-
weeks-delayed parvovirus H-1PV (C→V) was shown to prolong the survival of 
immunocompetent tumor-bearing rats, although in the concurrent setting the viral 
life cycle was negatively influenced (133). Of even more relevance was the suc-
cessful combination of GLV-1h68 with 15-days-delayed gemcitabine (V→C) 
which significantly improved the response of pancreatic cancer xenografts in 
nude mice (101).  
Of significance may also be the fact that a multitude of chemotherapeutics has 
been shown to exhibit immunotherapeutic properties on their own (213). Contrary 
to the wide-spread belief that chemotherapy in general acts rather immunosup-
pressive, in specific settings humoral and cellular antitumor immune responses 
can be beneficially influenced. This is of especial interest since the field of viro-
therapeutic research currently considers the combination of oncolytic viruses with 
checkpoint inhibitors to have the potential for groundbreaking immunotherapeutic 
success. The combinations of T-VEC with ipilimumab or pembrolizumab, both 
monoclonal antibodes targeting and blocking the immunosuppressive CTLA-4 or 
PD-1 receptor respectively, are currently under evaluation in a phase II and phase 
III trial (NCT01740297, NCT02263508) addressing melanoma patients and will 
be instrumental in assessing this hypothesis. Immunovirotherapeutic success 
with Western Reserve strain derivatives of vaccinia virus was seen in vivo after 
combining them with antibodies against CTLA-4 (214,215) or PD-1 (215,216) 
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which not only significantly decreased tumor burden and improved survival of tu-
mor bearing mice but in some cases also drastically delayed tumor growth after 
rechallenging the mice with the same tumor tissue, indicating the presence of a 
systemic anti-tumor immunity. 
Both chemotherapeutic agents of the here established novel triple-therapy, 
paclitaxel and gemcitabine, have been shown to exhibit immunotherapeutic prop-
erties on their own. Paclitaxel was shown to induce the maturation of dendritic 
cells and increase antigen presentation in vitro (217,218). Gemcitabine, while ex-
hibiting detrimental effects on humoral immune responses, was shown to leave 
antigen-specific cellular immunity unaffected (219). Since chemovirotherapy 
mainly focuses on harnessing the immunotherapeutic potential of an adaptive 
immune response while initially circumventing innate antiviral host responses, 
this condition could enhance both oncolytic and immunotherapeutic potential of 
such a combination. In patients with advanced pancreatic cancer, gemcitabine 
did not severely deplete immune cells (220). Decreases of T lymphocytes and 
NK cells were only transient and the numbers of dendritic and antigen-presenting 
cells were even increased (221).  
The combination of gemcitabine with an immune-activating anti-CD-40 antibody 
was synergistic in vivo and led to an infiltration of CD4+ and CD8+ positive T-
cells to the tumor tissue. Moreover, long-surviving mice resisted rechallenge with 
the same tumor (222). The combination of myxoma virus with gemcitabine in an 
intraperitoneal dissemination model of pancreatic resulted in 100 % long term 
survivors at the end of the study, but only in immunocompetent mice. In the im-
munodeficient model no such effects were seen (204). Gemcitabine was also 
shown to create favorable conditions for OV-induced antitumor immunity by over-
riding reovirus induced recruitment of immunosuppressive MDSCs and acceler-
ating tumor-specific T-cell responses (223). 
However, a recent phase III trial treating metastatic pancreatic cancer with a com-
bination of gemcitabine, capecitabine (prodrug of 5-FU), a telomerase peptide 
vaccine and the proinflammatory cytokine GM-CSF wasn’t able to prove thera-
peutic benefit of this chemoimmunotherapeutic regimen (224). Given that i) nab-
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paclitaxel probably has similar immunotherapeutic properties as solvent-based 
paclitaxel and ii) was shown to increase intratumoral gemcitabine levels whereas 
iii) the vaccinia virus GLV-1h68 has the immunotherapeutic potential of more 
strongly inducing a profound antitumor immune response, the triple-therapy pro-
tocol holds promise for further (pre-)clinical investigations. 
In conclusion, the triple-therapy combining the oncolytic vaccinia virus GLV-1h68 
with the clinically approved dual chemotherapy nab-paclitaxel + gemcitabine has 
demonstrated therapeutic benefit for treating pancreatic adenocarcinoma in vitro 
when viral replication, the key for a potent oncolytic and immunotherapeutic effect, 
wasn’t influenced.  
Based on these and previous findings, unraveling the treatment protocol by ad-
ministering the chemo- and virotherapeutic agents separately has been proposed 
to further augment therapeutic efficacy and circumvent potentially detrimental in-
teractions between the applied agents. “Any approach trying to prove therapeutic 
benefit of such a regimen besides investigating its cytotoxic effect would have to 
focus especially on viral replication and its consequences on antitumor immunity.” 
(139) “However, when employing human pancreatic ductal adenocarcinoma 
(hPDA) cell lines as investigated in this work (AsPc-1, BxPc-3, MIA-PaCa-2, 
Panc-1) such experiments only could be performed in xenograft animal models 
(e.g., in nude or SCID mice). Unfortunately, these immunodeficient mice are lack-
ing important features of the adaptive immunity. As an alternative, usage of hu-
manized mice with a partially or nearly fully reconstituted immune system could 
provide insights on (i) how this triple therapeutic regimen would affect anti-tumor 
immunity, (ii) how immune checkpoint inhibitors could be placed on top, and (iii) 
how means aiming at a depletion of the immunosuppressive phenotypes of hu-
man pancreatic cancer could be made successful; however, proper answers to 
these highly interesting questions only can be provided by future clinical trials. Of 
further interest are investigations on how the triple chemovirotherapy regime with 
GLV-1h68 plus nab-paclitaxel + gemcitabine would affect the dense stroma being 
associated with hPDA. Again, xenograft mouse models are not suitable for such 
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investigations due to the fact that hPDA cells cannot be mixed with human pan-
creatic stromal cells for a remodeling of the specific histological features of hPDA. 
As an alternative, organotypic culture models have emerged as tractable systems 
to recapitulate the complex three-dimensional organization of hPDA (225) and 
could be implemented for such analyses in the future. Such hPDA organoids also 
would be highly instrumental for further investigations on the mechanistic effects 
of the triple chemovirotherapy regime with GLV-1h68 plus nab-PTX + Gem.” (139) 
Full insight in this complex matter will only be provided by treating human patients 
in well documented clinical trials in the long-term. 
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Summary 
Oncolytic virotherapy utilizes naturally occurring or genetically modified viruses 
for targeted cancer treatment. Such oncolytic viruses (OVs) are designed to spe-
cifically infect and replicate in tumor cells ultimately leading to their lysis (so-called 
oncolysis). Additionally, the release of both tumor antigens and immunogenic vi-
ral particles is believed to strongly induce antitumor immunity. However, in line 
with the consideration that multimodal cancer therapy is likely to be more effective 
than monotherapeutic treatment protocols, chemovirotherapy focuses on adding 
the oncolytic and immunotherapeutic potential of OVs to already established 
chemotherapeutic treatment protocols. 
Especially for pancreatic ductal adenocarcinoma (PDA) chemotherapy still fails 
to considerably improve patient survival. Additionally to PDA’s substantial intrin-
sic resistance to chemotherapeutic agents the dense and highly immunosuppres-
sive tumor microenvironment impedes the efficacy of current chemotherapy pro-
tocols. Then again, such conditions have been shown to favor oncolytic virother-
apy. 
This thesis therefore focused on the design of a novel chemovirotherapeutic pro-
tocol to improve the currently poor treatment outcome of pancreatic cancer. For 
this purpose, 4 established and well-characterized tumor cell lines of pancreatic 
adenocarcinoma (AsPc-1, BxPc-3, MIA PaCa-2, Panc-1) were treated in vitro 
with the oncolytic vaccinia virus GLV-1h68 in combination with selected chemo-
therapeutic agents. Moreover, the influence of different administration sequences 
on the therapeutic outcome of chemovirotherapy was analyzed. Cytotoxicity after 
treatment was measured by sulforhodamine B (SRB) assay and confirmed by 
CellTiter Blue (CTB) and MTT assays, respectively. Due to its insertion of green 
fluorescent protein (GFP) GLV-1h68 additionally enabled the non-invasive visu-
alization of viral gene expression and replication. 
In a first step, for each agent doses having only subtherapeutic tumoricidal effects 
had to be determined. Accordingly, all 4 tumor cell lines were treated with as-
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cending doses of the respective chemo- or virotherapeutic agents in monother-
apy. As a result, drug- and dose-dependent antitumor responses were seen indi-
cating resistance against some cytotoxic agents.  
In a next step, the actual chemovirotherapy was performed. Combinations of 
GLV-1h68 with either 5-fluorouracil (5-FU), gemcitabine or oxaliplatin were found 
to result only in a moderate increase of cytotoxicity regardless of their administra-
tion sequence. Only the combination with the mitotic inhibitor nab-paclitaxel 
showed promising signs of potent tumor cell killing. However, given the fact that 
for metastatic pancreatic cancer nab-paclitaxel is only approved in combination 
with gemcitabine a triple-therapy protocol combining GLV-1h68 with the dual 
chemotherapy nab-paclitaxel + gemcitabine was devised. Interestingly, this triple-
therapy resulted in 2 out of 4 tumor cell lines (BxPc-3, MIA PaCa-2) in a strongly 
improved treatment outcome. Notably, in the other tumor cell lines in which no 
enhanced response was seen after the triple-therapy (AsPc-1, Panc-1) viral titers 
were found to be considerably reduced under the influence of the dual chemo-
therapy. Thus, therapeutic success of this therapeutic regimen was linked to an 
unaltered viral replication of GLV-1h68 and - vice versa - failure to a missing sup-
pression of fabricating the progeny GLV-1h68 particles. 
Further investigations indicated that the interference with viral replication specifi-
cally was the result of overdosing gemcitabine. When delaying gemcitabine ad-
ministration viral GFP expression could be somewhat conserved. Similarly, pre-
vious reports had demonstrated the benefit of unraveling a chemovirotherapeutic 
treatment protocol by administering the chemo- and virotherapeutic agents sep-
arately. Thus, the next step of promoting the combination of GLV-1h68 with nab-
paclitaxel and gemcitabine would be to investigate the influence of such 
measures on therapeutic success, at best in an immunocompetent animal model 
while non-invasively monitoring viral replication and therapeutic efficacy. 
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Zusammenfassung 
Onkolytische Virotherapie setzt natürlich vorkommende oder genetisch modifi-
zierte Viren zur spezifischen Krebstherapie ein. Solche onkolytischen Viren (OVs) 
wurden konstruiert, um spezifisch Tumorzellen zu infizieren, in deren Zellinnerem 
zu replizieren und sie letztlich zu lysieren (sogenannte Onkolyse). Zusätzlich ver-
spricht man sich von der gleichzeitigen Freisetzung von Tumorantigenen und im-
munogenen Viruspartikeln die Induktion einer starken tumorgerichteten Immun-
antwort. Der Fokus der Chemovirotherapie liegt – gemäß der Überlegung, dass 
eine multimodale Krebstherapie eine vermeintlich stärkere Wirkung besitzt als 
monotherapeutische Behandlungsschemata – folglich darauf, das onkolytische 
und immuntherapeutische Potential von OVs zu bereits etablierten Chemothera-
pie-Protokollen hinzuzufügen. 
Vor allem im Falle des Pankreaskarzinoms führen aktuelle Chemotherapie-Pro-
tokolle noch immer nicht zu einer wesentlichen Verbesserung des Patientenüber-
lebens. Die therapeutische Wirkung wird dabei nicht nur von einer erheblichen 
intrinsischen Resistenz gegenüber Chemotherapeutika behindert, sondern auch 
durch ein gegenüber zahllosen Krebstherapeutika undurchlässiges und in hohem 
Maße immunsupprimiertes Tumormilieu. Demgegenüber konnte jedoch gezeigt 
werden, dass ein eben solches Umfeld Virotherapie günstig beeinflusst. 
Ziel der hier vorgestellten Promotionsarbeit war daher die Entwicklung eines neu-
artigen Chemovirotherapie-Protokolls zur Verbesserung der Behandlung des 
Pankreaskarzinoms zunächst unter in vitro Bedingungen. In diesem Zuge wurden 
4 etablierte und gut charakterisierte Pankreasadenokarzinom-Zelllinien (AsPc-1, 
BxPc-3, MIA PaCa-2, Panc-1) mit dem Pockenimpfvirus GLV-1h68 und ausge-
wählten Chemotherapeutika behandelt. Zusätzlich wurde der Einfluss von ver-
schiedenen Applikationsschemata auf den Behandlungserfolg nach Chemoviro-
therapie untersucht. Das Therapieansprechen wurde dabei zunächst primär mit-
tels des Sulforhodamine B (SRB) Assays bestimmt und später zusätzlich mithilfe 
der Cell-TiterBlue (CTB) und MTT Assays validiert. GLV-1h68 bot zudem – auf-
grund seiner genetischen Ausstattung mit grün fluoreszierendem Protein (GFP) 
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– die Möglichkeit, die virale Genexpression und damit auch die Effizienz viraler 
Replikation nicht-invasiv zu überwachen.  
Zu Beginn der Arbeit mussten zunächst subtherapeutisch wirksame Dosen jedes 
einzelnen Therapeutikums bestimmt werden. Dafür wurden die 4 Tumorzelllinien 
mit aufsteigenden Konzentrationen des jeweiligen Chemo- oder Virotherapeuti-
kums behandelt. Ein sowohl von der Wahl des Therapeutikums als auch von des-
sen Konzentration abhängiges Therapieansprechen wies dabei auf bereits aus-
gansmäßig vorliegende bzw. erworbene Resistenzen gegenüber manchen Zy-
tostatika hin. 
Schließlich wurde die eigentliche Chemovirotherapie durchgeführt. Die Kombina-
tion aus GLV-1h68 mit 5-Fluorouracil (5-FU), Gemcitabine oder Oxaliplatin resul-
tierte dabei jedoch lediglich in einer geringfügigen Verbesserung des Behand-
lungserfolges, unabhängig von deren zeitlichen Abfolge. Einzig die Kombination 
mit dem Mitosehemmer nab-Paclitaxel versprach ein bedeutsam gesteigertes 
Therapieansprechen. Zur Behandlung des metastasierten Pankreaskarzinoms 
ist nab-Paclitaxel jedoch ausschließlich in Kombination mit Gemcitabine zugelas-
sen. Dies führte letztlich zum Entwurf eines vollkommen neuartigen Triple-The-
rapie Protokolls, in dessen Zuge GLV-1h68 mit der dualen Chemotherapie aus 
nab-Paclitaxel und Gemcitabine kombiniert wurde. Tatsächlich führte dieser An-
satz in 2 der 4 Tumorzelllinien (BxPc-3, MIA PaCa-2) zu einem erhöhten Thera-
pieansprechen. Gleichzeitig waren in den nicht in erhöhtem Maße ansprechen-
den Tumorzelllinien (AsPc-1, Panc-1) die viralen Titer unter Einfluss der dualen 
Chemotherapie deutlich verringert. Damit hing der Behandlungserfolg der Triple-
Therapie ganz offensichtlich direkt mit einer effizienten viralen Replikation zu-
sammen bzw. im Umkehrschluss mit einer fehlenden Hemmung der Bildung von 
viralen Nachkommen des Pockenimpfvirus GLV-1h68. 
Weitere Untersuchungen wiesen darauf hin, dass die Hemmung der viralen Rep-
likation die direkte Folge von diesbezüglich überdosiertem Gemcitabine war. Zu-
dem konnte die virale GFP Expression bei zeitlich verzögerter Gabe von Gemci-
tabine zu einem gewissen Grad erhalten werden. In ähnlicher Weise konnte be-
reits in vorausgegangenen Untersuchungen der Vorteil eines zeitlich “entzerrten” 
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Therapieschemas durch die separate Gabe von Chemo- und Virotherapeutika 
gezeigt werden.  
Basierend auf diesen Erkenntnissen besteht der nächste Schritt zur Weiterent-
wicklung der Kombination aus GLV-1h68 mit nab-Paclitaxel und Gemcitabine in 
einer systematischen Untersuchung der Auswirkung solcher Maßnahmen auf 
den Behandlungserfolg, bestenfalls in einem immunkompetenten Tiermodell un-
ter nicht-invasiver Überwachung der viralen Replikation und therapeutischen 
Wirksamkeit. 
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